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ABSTRACT
A primary area of investigation in pharmacology and medicine is the
study of ligand-receptor interactions. The pharmacological basis of drug
action is often the consequence of non-covalent interactions between small
organic molecules and their high affinity receptors. In addition to their
therapeutic potential these pharmacologically active ligands have recently
been utilized as tools in the dissection of complex signal transduction
pathways. Although such an approach holds unparalleled utility there
currently exists no efficient methodology for the rapid identification of novel
ligand-receptor interactions. We have developed a method which utilizes
yeast interaction trap/two-hybrid technology to rapidly identify proteins
which interact with small organic ligands. This methodology, termed the
Yeast Three-Hybrid System, uses a hybrid ligand as molecular glue to
reconstitute transcription by bringing together two transcriptional modules as
in the Yeast Two-Hybrid System.
The feasibility of the Yeast Three-Hybrid System was demonstrated
using as the hybrid ligand a heterodimer of covalently-linked dexamethasone
and FK506. Yeast expressing fusion proteins of the hormone binding domain
of the rat glucocorticoid receptor fused to the LexA DNA-binding domain,
and of FKBP12 fused to a transcriptional activation domain activated reporter
genes when plated onto medium containing the dexamethasone-FK506
heterodimer. Using this system we were able to screen a number of cDNA
libraries and selectively isolate overlapping clones of FKBP12. These results
demonstrate that the Yeast Three-Hybrid System is a powerful new
technology and can be used to rapidly discover receptors for
pharmacologically active small organic ligands.
Thesis Supervisor: Jun Liu
Title: Assistant Professor of Chemistry and Biology
Table of Contents
List of Illustrations..................................................................................... 7
A cknow ledgm ents................................................................................. 12
Chapter 1
Introduction:
The Study of Complex Biological Systems
B ackground..................................................................................... 14
References for Chapter 1................................................................ 18
Chapter 2
The Yeast Two-Hybrid System:
A Method for Detecting Protein-Protein Interactions
B ackground....................................................................................... 19
Eukaryotic Transcription............................................................... 22
Transcriptional Promoters......................................................... 23
Transcriptional Activators or Enhancers................................ 23
The Foundation of the Yeast Two-Hybrid System:
H istorical O verview ......................................................................... 24
The Contribution of Brent and Ptashne.................................. 24
The Contribution of Ma and Ptashne..................................... 26
The Contribution of Fields and Song....................................... . 27
Components of the Yeast Two-Hybrid System.......................... 28
Roger Brent's Yeast Interaction Trap Cloning System............. 30
Sequence of Events in a Two-Hybrid Screen............................... 34
Recent Applications of the Yeast Two-Hybrid System and Two-
H ybrid Technology............................................................................ 38
Discovery of Novel Mediators of Programmed Cell Death
and Cell Cycle Regulation............................................................... 38
Discovery of Novel Proteins Which Interact with Ligand-
Receptor Complexes and Post-Translationally Modified
P rotein s.............................................................................................. 39
Dissection of Established Protein-Protein Interactions........... 41
Elucidation of Genetic Regulatory Networks........................... . 42
Applications of Two-Hybrid Technology to Drug Discovery
E fforts................................................................................................. 43
References for Chapter 2.................................................................. 46
Chapter 3
The Yeast Three-Hybrid System: A Method for Detecting Ligand-Protein
Interactions
B ackground.......................................................................................... 48
Dissection of T Lymphocyte Signal Transduction Pathways
Using a Pharmacological/Chemical Approach......................... 49
Activation of Signal Transduction Events Through Chemically
Induced Dimerization: The Basis for a Key Component of the
Yeast Three-Hybrid System................................................................ 54
Natural Activation of Signal Transduction Pathways............. 54
Artificial Activation of T Lymphocyte Signal Transduction
Pathways through Chemically Induced Dimerization............. 56
The Yeast Three-Hybrid System: A Method for Detecting
Ligand-Receptor Interactions............................................................ 60
Rational and Components............................................................. 60
Design of the Conserved Portion of the Three-Hybrid
System ................................................................................................ 64
Design of the Three-Hybrid System Test Case.......................... .. 70
Results and D iscussion....................................................................... 73
Construction of the Components for the Initial Three-Hybrid
System Test C ase................................................................................ 73
Synthesis of the dexamethasone-FK506 Hybrid "bait"
L igan d ........................................................................................ 73
Generation of Constructs Which Encode for the Initial
"hook" and "fish" Fusion Proteins..................................... 77
First Generation Three-Hybrid System Test Case..................... 78
Potential Ways to Improve and Fine-Tune the Sensitivity of
the Three-Hybrid System Test Case.............................................. 81
Design of New and Improved "hook" Fusion Proteins.......... 84
Second Generation Three-Hybrid System Test Case.................. 88
Specificity Tests for the Three-Hybrid System Test Case........... 92
Yeast Three-Hybrid Screens for FK506 Interacting Proteins.... 99
First Yeast Three-Hybrid Screen........................................... 100
Second Yeast Three-Hybrid Screen.................................... .. 103
Optimization of pH for Growth of Yeast Strains EJL7 and
EJL 8.............................................................................................. 106
Third Yeast Three-Hybrid Screen........................................ . 106
C on clusion ............................................................................................. 109
References for Chapter 3...................................................................... 111
Chapter 4
Experimental Procedures
M aterials................................................................................................ 113
Materials for Synthetic Organic Chemistry............................... . 113
Materials for Molecular Biology and Yeast Experiments......... 114
M eth od s................................................................................................. 115
Synthetic Chemistry Methods
Synthesis of the dexamethasone-FK506 hybrid "bait"
ligan d ......................................................................................... 115
Molecular Biology and Yeast Methods
Generation of "hook" constructs pEGHBD1-7.................. 122
Generation of "fish" construct pJG4-5-FKBP12................. 127
Procedures for the Construction and Manipulation of
Yeast Strains EJL1-8 for the Three-Hybrid Test Case........ 128
Procedures for the FK506 Interacting Protein Yeast
Three-Hybrid Screens.............................................................. 131
References for Chapter 4..................................................................... 141
Appendix
Efforts Toward the Total Synthesis of Taxusin
B ackground............................................................................................ 142
Results and Discussion...................................................................... 153
C on clusion ............................................................................................. 168
Experimentals and Spectra................................................................. 170
References for Appendix .................................................................... 217
List of Illustrations
Figure Page
2.1 Multi-step protein purification and cloning process. 20
2.2 The Transcriptional Apparatus. 22
2.3 Components of the Yeast Two-Hybrid System. 29
2.4 Roger Brent's pEG202 "bait" plasmid. 31
2.5 Roger Brent's pJG4-5 "fish" plasmid 32
2.6 Sequence of events in a two-hybrid screen. 36
3.1 Modular domains of the immunosuppressant FK506. 52
3.1 FK1012 - Chemical inducer of protein dimerization. 56
3.3 T Cell Receptor mediated signaling pathways: Natural
and Chemically Induced. 58
3.4 Components of the Yeast Three-Hybrid System. 60
3.5 The Hybrid Ligand. 61
3.6 Sequence of events in a three-hybrid screen. 64
3.7 Conserved and random components of the three-
hybrid system. 65
3.8 Modular Domains of the Glucocorticoid Receptor. 67
3.9 Modular domains of the steroid dexamethasone. 68
3.10 Potential dexamethasone molecules for creation of
hybrid "bait" ligands. 69
3.11 Dexamethasone-FK506 Hybrid "Bait" Ligand 72
3.12 Three-hybrid system test case. 73
3.13 Synthesis of the dexamethasone free amine. 74
3.14 Synthesis of the FK506 mixed carbonate activated ester. 75
3.15
3.16
3.17
3.18
3.19
3.20
3.21
3.22
3.23
3.24
3.25
3.26
3.27
3.28
Appendix.1
Coupling and deprotection of the dexamethasone-FK506
hybrid "bait" ligand.
First generation three-hybrid "hook" fusion proteins.
Yeast strains for the first generation three-hybrid
system test case.
Information utilized to design the second generation
"hook" fusion proteins.
Second generation three-hybrid "hook" fusion proteins.
Yeast strains for the second generation three-hybrid
system test case.
Sensitivity of different "hook" fusion proteins.
Potential activation of reporter genes independent of
FK506.
First Specificity Test: Galactose dependence of reporter
gene activation.
Second Specificity Test: FK506 dependence of reporter
gene activation.
Specificity for activation of the lacZ gene.
Yeast three-hybrid screening sequence.
FKBP12 clone isolated from the second three-hybrid
screen for FK506 interacting proteins.
FKBP12 clones isolated from the third three-hybrid
screen for FK506 interacting proteins.
The De Mayo Reaction.
76
78
79
87
88
89
91
94
95
96
97
99
105
108
147
Appendix.2
Appendix.3
Appendix.4
Appendix.5
Appendix.6
Appendix.7
Appendix.8
Appendix.9
Appendix.10
Appendix.11
Appendix.12
Appendix.13
Appendix.14
Appendix.15
Appendix.16
Appendix.17
Appendix.18
Appendix.19
Appendix.20
Appendix.21
Appendix.22
Popular connective transforms of the taxane carbocyclic
skeleton.
Swindell's synthesis of the taxane skeleton.
Blechert's synthesis of the taxane skeleton.
Wender's synthesis of the taxane skeleton.
Winkler's synthesis of the taxane skeleton.
Taxane carbocycle C(3)-C(10) connective transform.
Our retrosynthetic analysis of the taxane skeleton.
First seven steps of our synthesis.
Desired regioselective conversion of diketone 22.
Synthesis of model photosubstrate and photocyclization.
Facial selectivity of Liu's photocyclization.
Synthesis of side chain for first complex photosubstrate.
Synthesis of two enol triflate regioisomers.
Synthesis of first complex photocyclization substrate and
failed photocyclization reaction.
Synthesis of side chain for second complex photo-
substrate.
Synthesis of second complex photocyclization substrate.
Photocyclization of second complex photosubstrate and
subsequent ozonolysis.
C(3)-C(10) fragmentation of undesired ketone isomer.
C(3)-C(10) fragmentation of desired ketone isomer.
Installation of trans ring fusion between the B- Crings.
Improved photosubstrate and photocyclization reaction.
147
148
149
150
151
151
152
153
155
155
157
158
159
160
161
162
163
166
166
168
169
Table
Appendix.1
Appendix.2
Appendix.3
nOE Results on Major Photocyclization Product
nOE Results on Major Ketone Isomer
nOE Results on Minor Ketone Isomer
Page
164
165
165
To Sandra
Acknowledgments
There have been many individuals who have made this thesis possible
and I would like to take this chance to thank a number of them.
First and foremost I would like to thank my thesis advisor Professor
Jun Liu. Jun gave me the opportunity to work on the interface of Chemistry
and Biology and for this I am very grateful. Jun's endless enthusiasm for
science and his support were extremely influential in my graduate career and
I wish him much success in the future. I am sure you will take the Yeast
Three-Hybrid System to amazing new heights in the upcoming years.
Over the past five years I have made many great friendships at MIT.
Dan Allen was my roommate and labmate for two years and one of the best
chemists I have ever known. I hope he finds happiness in Mexico with the
pistachio nuts. Jon Come, Paul Weinreb, and Bryan Blackwell were my best
buddies at MIT and the time I spent with these guys made grad school fun at
times when it wasn't. I will never forget the Slacks or our many trips to the
YDDUM. By the way Paul, I'm still looking for that one thing.
A special thanks to members of the Liu Lab, past and present: Suming,
Fei, Hongsi (My Good/Best Friend), Satomi, Christine, Angelo, Eric, Luo,
Eddy and a special thanks to Chris Armstrong who brought the Yeast Two-
Hybrid System to our lab. Most of all I would like to thank "My Boy" Ben
Turk. I wish Ben the best of luck in all of his future endeavors.
To my friends at the Muddy Charles: Barb, Jimmy, Joe, Mike, Mikey,
and of course Bill. Not only were you good tippers, you were great friends
and I will miss all of you.
To my Dad, Big Eddie, the single most influential individual in my life
and the one who made everything possible. Throughout my 28 years my dad
has taught me many of the most important lessons in life and they have
made all of my successes possible. Thanks for always being there Dad and
teaching me how to do the right thing.
Finally, I would like to thank my wife Sandra. Sandra is the most
loving and caring person I have every met and it is she who makes
everything worth it. Over the past six years her love and support have kept
me going when times were tough and I look forward to sharing the rest of my
life with her. Thank You Sandra for EVERYTHING you have done to make
my life wonderful.
Chapter 1
Introduction:
The Study of Complex Biological Systems
Background
Modern biomedical research has as its focal point the dissection of
complex biological systems and the discovery of the fundamental molecular
components which mediate both normal and abnormal cellular function.
Ultimately, the goal of modern biomedical research is to establish new
information which might be utilized to more effectively prevent, diagnose,
and treat many forms of human disease. Although biological researchers
share a common goal, the methods which they employ to experimentally
accomplish this goal are incredibly varied and diverse. Historically, three
general approaches have been utilized in the experimental dissection process:
biochemical, genetic, and pharmacological.
Biochemical approaches have characteristically involve the
reconstitution of an in vivo biological processes in vitro . This has routinely
been achieved by fractionating the active components of a particular system
from cellular extracts. These approaches can be as simple as the purification
of a single enzyme responsible for a specific biotransformation or as
complicated as the reconstitution of an entire complex biological process by
combining the individually purified components of a large protein machine
in vitro. Two classical examples of such biochemical methods are the
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reconstituion of vesicle mediated protein transport (Rothman, J.E., 1994;
Rothman, J.E. & Orci, L., 1992; Serafini, T. et al., 1991) in the laboratory of Jim
Rothman at Memorial Sloan-Kettering Cancer Center and the reconstitution
of the basal transcriptional process (Pugh, B.F. & Tjian, R., 1990; Dynlachy,
B.D. et al., 1991) in the laboratory of Robert Tjian at the University of
California-Berkeley.
Genetic analysis of complex biological systems is most often performed
in simple eukaryotic organisms, such as the yeast Saccharomyces cerevisiae,
the roundworm Caenorhabditis elegans, and the fruit fly Drosophila
melanogaster, which are much more amenable to genetic analysis than mice
or humans. Amazingly, fundamental biological processes in these simple
organisms have been evolutionarily conserved in higher eukaryotes and
many of the proteins which govern cellular homeostasis in simple
eukaryotes have very similar human homologs. Two classical examples of
such genetic analysis are the dissection of the protein secretory pathway using
Saccharomyces cerevisiae (Novick, P. et al., 1980; Novick, P. et al., 1981;
Scheckman, R., 1992) in the laboratory of Randy Scheckman at the University
of California-Berkeley and the discovery of genes which orchestrate the
programmed cell death process using Caenorhabditis elegans (Ellis, H.M. &
Horvitz, H.R., 1986; Ellis, R.E. et al., 1991; Hengartner, M.O et al., 1992) in the
laboratory of H. Robert Horvitz at the Massachusetts Institute of Technology.
Although genetic insights into complex biological processes have
predominantly come from simple eukaryotic organisms, a significant amount
of information regarding processes which directly mediate human disease has
resulted from the analysis of families which are genetically predisposed to
particular diseases such as familial forms of cancer. A classical example of
medical genetic analysis leading to molecular insights into human disease is
15
the discovery of the importance of the p53 tumor suppressor in human
cancer from Li-Fraumeni syndrome patients (Srivastava, S. et al., 1990;
Malkin, D. et al., 1992).
Pharmacological dissection of complex biological systems has long-
lived in the shadow of the biochemical and genetic approaches yet has been
influential in establishing some of the primary molecular insights into
processes which mediate human disease (Hardman, J.G. et al., 1996).
Historically, much of the emphasis of pharmacological/pharmaceutical
research has focused upon the discovery and characterization of drugs which
bind to, and modulate, a well-defined biological target, discovered through
biochemical methods or genetic analysis. A potential reason for the
underutilization of pharmacological approaches to dissect biological systems
might be the lack of high-affinity ligands available to many academic
researchers. The design of highly active molecular probes often requires a
significant amount of structure-activity data be available on a particular
ligand. For many interesting pharmacologically active agents, with
undetermined mechanisms of action, this information simply is not known,
or is the privileged information of pharmaceutical companies. It has
therefore been quite difficult for many small academic labs to generate viable
molecular probes. The recent development of drug discovery methods which
utilize molecular diversity and combinatorial chemistry to rapidly synthesize
millions of potential pharmacologically active ligands might overcome this
problem. For the researcher who chooses to utilize a pharmacological
approach to dissect biological systems this technology will significantly
increase the number and type of molecular probes at their disposal and might
potentially reduce the need for structure-activity data by generating libraries
which resemble potential molecular probes. This new technology might
16
revolutionize the approach of pharmacological dissection of complex
biological systems and raise this field to new heights in the upcoming years.
There exists two levels of dissection when studying complex
biological systems. The first level involves the discovery of the initial
molecular insight into a particular process. Quite often this insight is the
discovery of a protein which is responsible for a particular biotransformation,
contains a particular mutation which results in a defined phenotype, either
normal or abnormal, or is the target of a pharmacologically active ligand.
Once this specific molecular insight has been obtained it is used to initiate
studies aimed at the second step of the dissection process which seeks to
establish networks of cellular components, most often proteins, which
interact with this initial component and form the basis for specific cellular
functions and processes. Although this second step of the dissection process
can be accomplished by classical biochemical and genetic methods an
emerging technology which has significantly facilitated the study of
interacting protein networks is a yeast genetic technique called the "Yeast
Two-Hybrid System" (Finley, R.L. & Brent, R., 1995). This system has quickly
become the preferred method of biomedical researchers attempting to clone
genes which encode for proteins that interact with known proteins. And two-
hybrid technology holds tremendous potential and future applications in
drug discovery efforts throughout the pharmaceutical and biotechnology
industry (Mendelsohn A.R. & Brent, R., 1994).
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Chapter 2
The Yeast Two-Hybrid System:
A Method for Detecting Protein-Protein Interactions
Background
Many cellular processes are the result of multiprotein complexes
carrying out particular functions through very specific protein-protein
interactions. Examples of protein machines which carry out fundamental
cellular processes include those which are responsible for DNA
replication, transcription, protein translation and cell cycle control.
Additionally, cellular signal transduction pathways which mediate
information transfer from the cell membrane to the nucleus are also the
consequence of interacting protein networks. Modern biological research
concentrates upon the determination of such interacting protein machines
or networks to increase our fundamental understanding of complex
biological systems. Once a particular protein is determined to be
important in a specific cellular process (either through biochemical,
genetic, or pharmacological methods) this process is more precisely
studied through the purification and cloning of proteins which either
directly interact with the protein of interest or are members of a complex
network of proteins involving the protein of interest.
Geneticists have dissected protein-protein interactions and protein
networks using mutations in one gene to identify other genes encoding
interacting proteins. Through the use of multi-copy suppressors and
synthetically lethal mutations geneticists have been able dissect
complicated protein-protein interactions (Guarente, L., 1993). Although
these genetic approaches are very powerful the most utilized approaches
for discovering novel protein-protein interactions have involved classical
biochemical methods and standard gene cloning techniques.
Purification of Interacting Protein
Digestion and Peptide Sequencing
Cloning of the cDNA Encoding the Protein
Figure 2.1 Multi-step protein purification and cloning process.
The purification of proteins which interact with known proteins,
and the subsequent cloning of the genes which encode these proteins is a
complicated multi-step process (Figure 2.1). The initial step involves the
biochemical purification of proteins which interact with a known protein.
This has routinely been accomplished through either immunoaffinity
procedures using polyclonal or monoclonal antibodies to the known
protein or by expressing the known protein in a tagged form (GST, FLAG,
HA, or His6) and purifying interacting proteins by affinity
chromatography. Once purified proteins are obtained in sufficient
quantities they are subjected to tryptic digestion and peptide sequencing to
acquire amino acid sequence information. From this amino acid sequence
information degenerate oligonucleotides are designed which are used to
clone the gene which encodes for the interacting protein. Although this
has been the preferred method to identify protein-protein interactions it is
obvious that this method is quite labor intensive and often requires years
of work to clone genes for proteins which interact with known proteins.
Several years ago a methodology was developed which revolutionized the
way which scientists approach the discovery of novel protein-protein
interactions. This method utilizes the reconstitution of transcription at
reporter genes, in yeast, to directly clone cDNAs encoding proteins which
interact with a previously identified protein.
Eukaryotic Transcription
Eukaryotic transcription is the process by which the genetic
information stored within genomic DNA is converted to a form which is
capable of being translated into specific proteins. From a DNA template
RNA is transcribed to afford messenger RNA (mRNA). This RNA
intermediate is subsequently processed and the information contained
within its sequence used to direct protein synthesis on the ribosome. The
process by which DNA is copied into mRNA is orchestrated by a large
protein complex composed of transcription factors and the enzyme RNA
Polymerase II (Figure 2.2). These complexes are of two major types:
transcriptional promoters and transcriptional enhancers.
Complete
Initiation
Complex
Figure 2.2 The Transcriptional Apparatus. Transciption factors are
represented by their letter designations and RNA Polymerase II is
designated by pol (Buratowski S., 1994).
Transcriptional Promoters
Transcriptional promoters are responsible for the assembly of the
transcription initiation complex at specific sites along the genomic DNA
for all genes (Buratowski, S., 1994). Upstream of all genes which are to be
transcribed is a site known as the promoter region which contains a very
specific DNA sequence known as the TATA box. This DNA sequence is
responsible for binding to a specific transcription factor, the TBP or TATA
Binding Protein. Immediately after the TBP binds to the TATA box other
transcription factors begin to assemble on the DNA in what has been
determined to be a very well defined sequence of events (Buratowski, S. et
al., 1989, Conway & Conway, 1993). Together these transcription factors
form a complex molecular scaffolding which recruits RNA Polymerase II
to the transcriptional start site. This complex has been called the basal
transcriptional machinery and has been determined to be the only
complex needed to activate transcription in vitro. The in vivo
transcriptional process is much more elaborate and requires the assistance
of a second group of transcription factors termed transcriptional activators
or enhancers to efficiently activate transcription.
Transcriptional Activators or Enhancers
Whereas the members of the basal transcriptional machinery bind
to the promoter region of a particular gene within one hundred bases
immediately upstream of the transcriptional start site, transcriptional
activators may bind to DNA sequences which are several thousand bases
away from the transcriptional promoter complex (Tjian, R. & Maniatis, T.,
1994). Even from such distant points activators serve to increase the
efficiency of the transcriptional process, presumably by stabilizing the basal
transcriptional machinery. It is well established that these transcription
factors are modular proteins and contain several functionally separable
domains. All transcriptional activators contain two fundamental
modular protein domains. The first domain is a DNA recognition
domain which allows the transcriptional activator to bind specific DNA
sequences. The second domain is a transcriptional activation domain
which contains stretches of acidic amino acids that make contacts with the
basal transcriptional machinery and stabilize it. This stabilization greatly
improves the efficiency of the transcriptional apparatus and significantly
enhances transcription. It is this modular nature of transcriptional
activators which forms the foundation on which the Yeast Two-Hybrid
System was founded. Historically, there were two primary experimental
inquiries which established the modular nature of transcription factors
and an intellectual extension of these inquiries which described their
potential utility in cloning genes for proteins which interact with known
proteins.
The Foundation of the Yeast Two-Hybrid System: Historical Overview
The Contribution of Brent and Ptashne
The initial experiments which began to lay the foundation for the
establishment of the Yeast Two-Hybrid System were conducted by Roger
Brent and Mark Ptashne from the Department of Biochemistry and
Molecular Biology at Harvard University (Brent, R. & Ptashne, M., 1985).
Brent and Ptashne, building upon previous work conducted in E. coli,
attempted to show that transcription factors possessed two separable
domains, a DNA binding domain and a transcriptional activation domain.
At the time there were two major theories regarding how transcriptional
activators might activate transcription. The first theory was that the
binding of a transcriptional activator to a particular sequence of DNA
induced a conformational change in the structure of the DNA which was
propagated down the double helix toward the promoter region stabilizing
RNA Polymerase II. A second theory suggested that transcriptional
activators bound to DNA at specific positions and regions of the
transcriptional activator, which were distinct from those necessary for
DNA binding, contacted the RNA Polymerase II and activated
transcription.
Initial experiments which began to favor the second mechanism
were conducted in Escherichia coli on the lambda repressor protein.
Mutants of the lambda repressor were isolated which were able to bind to
DNA with the same affinity as the wild-type protein but were unable to
activate transcription (Guarente, L. & Ptashne, M., 1981). Interestingly, all
of these mutations seemed to cluster on the surface of the protein which
began to argue for the second mechanism of transcriptional activation.
Brent and Ptashne generated a chimeric transcription factor to
prove that the second mechanism of transcriptional activation was the
correct mechanism. They constructed a plasmid which expressed a hybrid
transcription factor that contained the DNA binding domain of the E. coli
repressor LexA fused to a region of the yeast transcriptional activator Gal4
which contained no DNA binding activity. Brent and Ptashne then
showed that this chimeric transcription factor, when expressed in yeast,
could activate the transcription of an exogenously added reporter plasmid
which contained bacterial LexA DNA binding sites in the promoter region.
These studies not only strongly argued for the second mechanism of
transcriptional activation but also showed that transcriptional modules
from different organisms were highly interchangeable and could be
combined to afford functional transcriptional activators.
The Contribution of Ma and Ptashne
A second experimental inquiry which continued to establish the
foundation on which the Yeast Two-Hybrid System was built was the
work of Jun Ma and Mark Ptashne (Ma, J. & Ptashne, M., 1988). Whereas
Brent and Ptashne showed that transcriptional modules from different
transcription factors could be combined on the same protein to create a
functional transcriptional activator, Ma and Ptashne set out to explore the
possibility of reconstituting transcription using transcriptional modules
which were contained on totally different proteins. The yeast Gal4
transcriptional activator binds to an inhibitory protein called Gal80 which
represses Gal4 mediated transcription. It is the carboxy terminal thirty
amino acids of Gal4 which are primarily responsible for this interaction.
Ma and Ptashne generated a chimeric Gal4 protein which contained a
major deletion to afford a protein which contained only the Gal4 DNA
binding domain fused directly to the last thirty amino acids of the Gal4
protein. This protein possessed no ability to activate transcription at the
Gal4 promoter since it lacked a transcriptional activation domain. They
also generated a construct which expressed Gal80 fused to the
transcriptional activator, B42 (Ma, J. & Ptashne, M., 1987; Ruden, D.M. et
al., 1991), at a position which did not abrogate binding of Gal80 to Gal4.
When these two proteins were co-expressed in a strain of yeast, which
lacked the endogenous Gal4 and Gal80 proteins, reconstitution of Gal4
inducible genes was observed. This directly confirmed that the
reconstitution of transcription did not require the transcriptional modules
to be present on the same protein but transcription could be activated as a
result of protein-protein interactions provided one protein contained a
DNA binding domain and the other a transcriptional activation domain.
This type of transcriptional activation, though not incredibly common, is
seen in a number of natural systems. The most well studied of these
systems is the herpes simplex virus which produces a protein, VP16, that
possesses a transcriptional activation domain and is able to bind to the
human Oct-1 protein which contains a DNA binding domain. The
complexation of these two proteins is absolutely required for viral
replication within the human host.
The Contribution of Fields and Song
The major intellectual extension of the information generated by
the members of the Ptashne lab which led to the establishment of the
Yeast Two-Hybrid System was made by Stanley Fields and Ok-kyo Song of
the State University of New York at Stony Brook (Fields, S. & Song, O.,
1989). Fields and Song took two yeast proteins which were known to
interact, SNF1 and SNF4, and fused them to the DNA binding domain
and transcriptional activation domain of the Gal4 protein respectively.
When yeast genetically engineered to contain the lacZ gene downstream
of the endogenous Gal4 promoter were transformed with plasmids
encoding the two Gal4 fusion proteins the lacZ gene was activated,
signifying transcriptional reconstitution at this gene. Fields and Song
envisioned a yeast genetic system in which genes were cloned for proteins
which interacted with known proteins. They reasoned that if a known
protein was fused to the Gal4 DNA binding domain, and a library of
proteins were expressed as fusions to the Gal4 transcriptional activation
domain, yeast which contained fruitful protein-protein interactions could
be identified by the activation of specific reporter genes and interacting
clones could be isolated. Their Nature paper set into place the intellectual
framework for the Yeast Two-Hybrid System.
Components of the Yeast Two-Hybrid System
Since the seminal work of Fields and Song a number of laboratories
have developed their own versions of the Yeast Two-Hybrid System to
clone interacting proteins (Durfee, T. et al., 1993; Zervos, A.S. et al., 1993;
Vojtek, A.B. et al., 1993). All of these systems contain three essential
elements (Figure 2.3).
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Figure 2.3 Components of the Yeast Two-Hybrid System.
First, all utilize yeast vectors to express a known protein fused to a
specific DNA binding domain. Second, all utilize yeast vectors to express a
library of proteins encoded by a cDNA library fused to a transcriptional
activator. Third, all utilize reporter genes which contain binding sites for
the specific DNA binding domain in their promoter regions allowing for
the selection of yeast that harbor cDNAs that encode for proteins that
interact with the known protein. The terminology which has emerged for
the components of the Yeast Two-Hybrid System labels the protein which
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contains the DNA binding domain the "bait" and the protein which
contains the transcriptional activation domain the "prey" or "fish". The
specifics of which DNA binding domain or transcriptional activation
domain are utilized varies from system to system and there appears to be
very little difference between the systems with regard to sensitivity.
Most of the systems utilize two different reporter genes to ensure
specificity and control for false positives when conducting a two-hybrid
screen. The first reporter gene encodes a particular enzyme which is
required for the biosynthesis of an essential amino acid. The yeast used in
the screen are auxotrophic for this particular amino acid and only a
fruitful protein-protein interaction, and the subsequent reconstitution of
transcription at this particular reporter gene, will allow for the yeast to
grow in the absence of this amino acid. The second reporter gene, the lacZ
gene, encodes the enzyme P-galactosidase which converts the
chromogenic substrate X-Gal (5-bromo-4-chloro-3-indolyl-4-D-galacto-
pyranoside) into a species which turns yeast expressing this enzyme blue.
By looking for activation of both reporter genes when conducting a two-
hybrid screen many false positives are eliminated.
Roger Brent's Yeast Interaction Trap Cloning System
The particular version of the Yeast Two-Hybrid System which we
have utilized in our studies was developed in the laboratory of Dr. Roger
Brent at the Massachusetts General Hospital (Finley, R.L. & Brent, R.,
1995). Brent has termed this version the Yeast Interaction Trap Cloning
System. This system utilizes amino acids 1-201 of the E. coli LexA protein
as the specific DNA binding domain. The "bait" plasmid used to generate
LexA DNA binding domain constructs, pEG202, is shown in Figure 2.4.
This plasmid contains the strong alcohol dehydrogenase promoter
(ADHpro) to express "bait" proteins as LexA DNA binding domain
fusions. This plasmid also contains the HIS3 selectable marker, the 2p.M
origin of replication for yeast, the pBR ori origin of replication for E.coli,
and an ampicillin resistance gene (ampr).
The "fish" plasmid used to generate transcriptional activation
domain-cDNA library fusions, pJG4-5, is shown in Figure 2.5. This
plasmid utilizes the GALl inducible promoter to express activation
domain-library encoded "fish" fusion proteins. The transcriptional
activation domain, acid blob B42, is flanked by the SV40 nuclear
localization sequence (PPKKKRKVA) to ensure that "fish" fusion proteins
enter the nucleus, and the hemagluttinin epitope tag (HA) for western blot
studies. This plasmid also contains the TRP1 selectable marker, the 2gM
origin of replication for yeast, the pUC ori origin of replication for E.coli,
and the ampicillin resistance gene (ampr). Since the "fish" protein is
under the control of the GALl promoter it is only expressed when the
yeast which harbor this plasmid are grown in the presence of galactose and
not glucose.
The Brent System utilizes a number of exogenously added reporter
plasmids which contain the lacZ gene downstream of LexA operators.
These plasmids vary in the number of LexA operators which are
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Figure 2.5 Roger Brent's pJG4-5 "fish" plasmid.
contained within the promoter region and therefore differ in sensitivity.
Each LexA operator contains two LexA binding sites each of which binds to
LexA fusion proteins as dimers. Plasmid pSH18-34 (Golemis, E. & Brent,
R., 1992) possesses the most sensitive promoter which contains 4 LexA
operators upstream of the lacZ gene. This promoter can therefore
potentially bind to eight LexA dimers. It has been determined
experimentally, using proteins with known binding affinities expressed as
the "bait" and "fish" fusion proteins, that this reporter gene is most
reliable when comparing the relative binding affinities of different
protein-protein interactions. Protein-protein interactions which possess a
Kd < 19M will turn yeast containing the pSH18-34 reporter plasmid dark
blue when grown on X-Gal (Estojak, J. et al., 1995).
A number of different yeast strains are utilized in the Brent
Interaction Trap Cloning System. These yeast strains differ primarily in
the number of LexA operators which are contained upstream of the
chromosomally located LEU2 gene. These yeast have all been genetically
engineered so that the normal LEU2 upstream activating sequence (UAS)
has been replaced by cassettes which contain variable numbers of LexA
operators. Since the natural promoter has been removed these yeast can
not express an enzyme which is essential for the biosynthesis of leucine
under normal conditions. These yeast are auxotrophic for leucine and this
amino acid must be included in the growth medium for the yeast to
survive. The yeast become leucine prototrophs when the LEU2 gene
becomes activated as the result of a fruitful protein-protein interaction and
are able to grow on media which lack leucine. The most common strain
used in two-hybrid screening is the EGY48(MAT ca, his3, trpl, ura3,
6LexAop-LEU2) strain. This strain contains 6 LexA operators upstream of
the LEU2 gene and is the most sensitive screening strain. EGY48 is also
auxotrophic for a number of other nutrients which allows for the yeast to
be transformed with multiple plasmids carrying different selectable
markers. Three selectable markers, HIS3, TRP1, and URA3, are utilized
for maintenance of the pEG202 "bait" plasmid, the pJG4-5 "fish" plasmid,
and the pSH18-34 reporter plasmid respectively.
Sequence of Events in a Two-Hybrid Screen
The initial step in preparing for a yeast two-hybrid screen is to
generate a "bait" plasmid which encodes the protein of interest for which
interactors are sought, fused to the LexA DNA binding domain. Using the
Brent System this is achieved by subcloning the gene encoding the protein
of interest into the multiple cloning region of the pEG202 plasmid. Once
this has been accomplished two tests must be performed to determine
whether this particular "bait" fusion protein is suitable for use in the two-
hybrid screening system/interaction trap cloning system. The first test is
to demonstrate that the "bait" fusion protein enters the nucleus and is able
to bind the LexA operators when expressed in yeast. The second test is to
confirm the inability of this particular "bait" fusion protein to activate
transcription at the specific reporter genes on its own. If the "bait" does
not enter the nucleus a variation of the pEG202 plasmid might be utilized
which encodes a strong nuclear localization sequence as part of the "bait"
fusion protein. If the "bait" activates a low basal level of transcription at
the LEU2 or lacZ genes by itself less sensitive reporter genes might be
utilized which contain fewer LexA operators upstream of these reporter
genes. Once yeast which harbor the pEG202-Protein of Interest have
passed both of these tests it is acceptable to initiate a two-hybrid screen.
The first step in a two-hybrid screen (Figure 2.6) is to create a
screening strain of yeast by transforming yeast which harbor pEG202-
Protein of Interest and reporter plasmid pSH18-34 (or less sensitive
reporters) with pJG4-5-cDNA library. To ensure a successful two-hybrid
screen a library derived from a cell-type or tissue in which the protein of
interest is known to function should be used. Once this screening strain
has been generated by high efficiency transformation the actual selection
process can be initiated.
The initial phase of a two-hybrid selection process is to plate several
million yeast cells from the screening strain onto plates which lack leucine
and to isolate leucine prototrophs which arise between Days two and five.
The use of LEU2 gene activation as the initial selectable marker allows for
the screening of millions of yeast cells, most containing different cDNA
inserts, and the rapid reduction of this large number of cells to a much
smaller number that potentially contain viable interactors encoded by the
pJG4-5-cDNA library plasmid.
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pEG202 Protein of Interest I
pSH18-34
High Efficiency pJG4-5 cDNA Library
Transformation
Collect Primary Transformants
Yeast strain containing:
pEG202 Protein of Interest
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pJG4-5 cDNA Library
Initiate Two-Hybrid Screen
for Interacting Proteins
Replate onto Two-Hybrid Leucine Prototroph Selection Plates
SC (His-,Ura-,Trp-, Leu') 2% Galactose
Collect Leu + Prototrophs
Test Leu + Prototrophs for Activation of the lacZ gene on:
SC ( His-,Ura-,Trp ) 2% Galactose X-Gal
Collect Leu+, lacZ+ Yeast Colonies
Prove Specificity for Protein of Interest
Retrieve pJG4-5-cDNA plasmids and retransform
into a strain which expresses an unrelated protein
from pEG202.
Sequence cDNA inserts from strains which are Leu', lacZ
Figure 2.6 Sequence of events in a two-hybrid screen.
Yeast which are Leu + prototrophs are then tested for their ability to
activate the second reporter gene, lacZ. This eliminates a number of false-
positives which grow on leucine deficient media due to mutations which
establish leucine prototrophy or activation tagged proteins expressed by
pJG4-5-cDNA which have affinity for the region of DNA upstream of the
LEU2 gene independent of the "bait" fusion protein. Yeast colonies
determined to be both Leu + and lacZ + are subjected to one final specificity
test to further reduce any false-positives before being fully characterized.
A final specificity test is conducted to determine that the proteins
expressed by the pJG4-5-cDNA "fish" plasmid specifically interact with the
protein of interest in the "bait". This is accomplished by isolating the
pJG4-5-cDNA plasmids from Leu + , lacZ + yeast and using these plasmids
to transform strains of yeast which harbor unrelated "bait" fusion proteins
along with the pSH18-34 reporter plasmid. The pJG4-5-cDNA plasmids
from yeast which exhibit no reporter gene activation in the presence of
unrelated "bait" fusion proteins are presumed to encode proteins which
specifically interact with the protein of interest. These plasmids are
retrieved and the cDNA inserts are sequenced by either manual or
automated sequencing techniques to determine the potential protein
interactors.
Since these clones were isolated through a genetic technique it must
be confirmed biochemically that the proteins encoded by these clones
interact with the protein of interest. Once a biochemical interaction has
been established it is also important to prove that these interactions are
biologically relevant by generating functional data most often through cell
culture studies. Both biochemical and cell culture studies are necessary to
prove that the interactions determined through the two-hybrid screen are
biologically relevant interactions.
Recent Applications of the Yeast Two-Hybrid System and Two-Hybrid
Technology
In just over three and one-half years since the first reported uses of
the Yeast Two-Hybrid System to discover novel protein-protein
interactions this system has quickly become the preferred method of
modern biologists seeking to characterize protein interactions involved in
biological processes. This powerful methodology has shed considerable
light on a number of complex cellular processes which were very much
mysteries only a few years ago. A number of proteins have been
discovered which are central to the control of cellular homeostasis and
pharmacological modulation of these proteins might have important
implications in the maintenance of human health.
Discovery of Novel Mediators of Programmed Cell Death and Cell Cycle
Regulation
Protein complexes which initiate cell death pathways mediated by
the TNF(Q and Fas/APO1 (CD95) receptors have recently been elucidated by
the Yeast Two-Hybrid System (Rothe, M. et al., 1995; Chinnaiyan, A.M. et
al., 1995; Hsu, H. et al., 1995; Stanger, B.Z. et al., 1995). The process of cell
death is essential in the maintenance of human health and many disease
states are the result of either increased or decreased amounts of
programmed cell death. Selective pharmacological modulation of cell
death pathways through these recently discovered proteins might have
profound effects on the treatment of patients with a number of disease
including cancer, autoimmune disease, and Alzheimer's Disease (Barr, P.J.
& Tomei, D., 1994; Thompson C.B., 1995). The Yeast Two-hybrid System
has also been used to identify a number of novel cell cycle regulatory
proteins determined to play key roles in cell cycle control (Harper, J.W. et
al., 1993; Gyuris, J. et al., 1993). These proteins play an important role in
the suppression of neoplasia and the information derived through two-
hybrid screening will undoubtedly be useful in further elucidating
important cell cycle events and improving our knowledge of this
important cellular activity.
Although the cloning of genes which encode proteins that interact
with a known protein has been the primary use of the Yeast-Two Hybrid
System, modifications and applications of two-hybrid technology have
been utilized in a number of diverse studies.
Discovery of Novel Proteins Which Interact with Ligand-Receptor
Complexes and Post-Translationally Modified Proteins
A modification of the two-hybrid system has been used to screen for
proteins which interact with a particular ligand-receptor complex. In these
screens a "bait" fusion protein bound to a specific small organic ligand,
considered to be the biologically "active" form of the protein, created a
novel protein interface which could interact with potential binding
proteins expressed by the "fish" plasmid. This type of two-hybrid screen
was used to isolate the protein target bound by the immunosuppressant
rapamycin-FKBP12 complex (Chiu, M.I. et al., 1994) and the identification
of novel transcriptional activators which bound to the steroid hormone
receptors in the presence of steroid hormone ligand (Onate, S.A. et al.,
1995; Lee, J.W. et al., 1995; Hong, H. et al., 1996).
One limitation of the Yeast-Two Hybrid System is the detection of
protein-protein interactions which require a post-translational
modification, such as phosphorylation, for the interaction to occur. This
problem is encountered when attempting to identify novel SH2 domains
which interact with receptors that contain a consensus SH2 domain
binding site (Pawson, T. & Gish, G.D., 1992) and must be phosphorylated
on tyrosine for protein-protein interactions to occur. This problem has
recently been circumvented by researchers at Hoffman LaRoche who
developed a method entitled the "Yeast Tribrid System-Genetic Detection
of trans-phosphorylated ITAM-SH2-Interactions" (Osborne, M.A. et al.,
1995). These researchers co-expressed the gamma subunit of the high-
affinity IgE receptor subunit which contains an immunoreceptor tyrosine-
based activation motif (ITAM) fused to a DNA binding domain and the
protein tyrosine kinases Syk or Lck which are known to phosphorylate the
ITAM motif. They were able to isolate a number of novel SH2 domains
which bound tightly to the ITAM and were absolutely dependent on the
co-expression of the Syk or Lck tyrosine kinase.
Dissection of Established Protein-Protein Interactions
Yeast two-hybrid technology has also been utilized to study a
number of protein-protein interactions in vivo in both yeast and
mammalian cells. Use of two-hybrid technology to study the structure-
function requirements of known protein-protein interactions has a
number of advantages over classical biochemical method since all proteins
are expressed in vivo and their ability to interact with one another is easily
determined by quantifying reporter gene activation. Such studies reduce
the need for time consuming protein purification steps and a large
number of amino acid mutations, either specifically or randomly
generated, within a particular protein might be studied in a relatively
short amount of time. This method has been utilized to establish a very
detailed profile of the residues and domains necessary for a number of
interacting proteins. Protein-protein interactions dissected include the cell
death regulatory Bcl2-Bax interaction (Hanada, M. et al., 1995) and the p85-
p110 interactions of phosphatidylinositol-3'-kinase (Holt, K.H. et al., 1994)
in yeast and the helix-loop-helix (Finkel, T. et al., 1993; Hoang, A.T. et al.,
1995) and leucine zipper ( Dang, C.V. et al., 1991) protein interactions in
mammalian cells. Additionally, two-hybrid technology has been used to
study mutations which are found in a key cell cycle inhibitory protein, p16,
found in familial melanoma cancer patients (Reymond, A. & Brent, R.,
1995).
Elucidation of Genetic Regulatory Networks
Another application of two-hybrid technology is the determination
of genetic regulatory networks. With the incredible rate of speed which
genome sequencing projects are uncovering genes which encode for novel
proteins there is a tremendous need for methods which might aid in the
elucidation of the functions of some of these newly identified proteins. A
number of labs are utilizing interaction mating techniques which allow
for the potential mapping of protein-protein interactions of an entire
genome (Bendixen, C. et al., 1994; Finley, R.L. & Brent, R., 1994).
Interaction mating involves the transformation of haploid yeast with
opposite mating types, MAT a and MAT a, one with a particular "bait"
and the other with a particular "fish". When these yeast are combined,
and mated, the resulting diploid strain of yeast contains both the "bait"
and "fish" and positive interactors can be established through activation of
reporter genes. Fields and colleagues began to lay the groundwork for the
examination of genome-wide protein regulatory networks by randomly
identifying binary interactions of proteins encoded by the bacteriophage T7
genome (Bartel, P.L. et al., 1996). Through this interaction mating method
they identified a number of protein-protein interactions which were
known to exist and a number which were expected to exist through genetic
and biochemical studies. Most importantly, they identified a number of
novel protein-protein interactions. The success of this interaction mating
technique with a simple genome strongly suggests that similar
methodology might be utilized in the future to identify novel protein-
protein interactions in more complex genomes.
Applications of Two-Hybrid Technology to Drug Discovery Efforts
Two-hybrid technology also has potential applications which are
directly applicable to pharmaceutical/biotechnology drug discovery efforts
(Mendelsohn, A.R. & Brent, R., 1994). A number of labs have utilized
two-hybrid technology to identify randomly generated peptides from
peptide libraries which possess binding affinity for a particular protein of
interest. These systems were set up in a similar fashion to a two-hybrid
screen except the "fish" protein, normally expressed as a fusion protein
encoded by a cDNA library, contained a randomly generated peptide. The
initial report described a method in which peptides that interacted with
the Retinoblastoma (Rb) protein were isolated from a library of peptides
(Yang, M.Y. et al., 1995). These peptides were expressed as linear sequences
of 16 amino acids fused to a transcriptional activator. Interactors isolated
yielded peptides which contained an amino acid sequence motif which
was found in natural interacting proteins of the Rb tumor suppressor such
as SV40 large T antigen and D-type cyclins.
A second method screened conformationally restrained libraries of
peptides to determine those which interacted with the cell cycle dependent
kinase CDK2 (Colas, P. et al., 1996). This was accomplished by displaying
libraries of 20 amino acids in the active site loop of the E. coli thiorodoxin
protein which was fused to a transcriptional activator. Conformationally
restrained peptides are utilized in immunoglobulin and T cell receptor
complimentarity determining regions and are known to characteristically
bind very tightly to potential binding targets. The peptides isolated were
determined to bind to CDK2 with nM binding affinities and were able to
inhibit kinase activity. Additionally, the sequences of these
conformationally restrained peptides did not resemble natural interactors
of CDK2 and would enhance the molecular diversity in the discovery of
pharmacologically active ligands.
Another application of two-hybrid technology to drug discovery
efforts, though not yet reported on in the literature, would be the
identification of small molecules which were able to inhibit specific
protein-protein interactions which led to a particular disease state (Fields,
S. & Sternglanz, R., 1994). By creating a yeast strain which expressed these
interacting proteins as the "bait" and "fish" potential drugs which
disrupted this interaction could be identified by screening for ligands
which inhibited reporter gene activation. This type of assay might also be
conducted in mammalian cells using the mammalian two-hybrid system
which has been used to dissect protein-protein interactions of known
interactors.
Although two-hybrid technology has a number of interesting
applications to drug discovery efforts a major limitation is the inability of
this technology to determine interactions between a protein of interest and
a non-genetically encoded species such as a small organic ligand. Small
organic ligands have historically been the therapeutic agents of choice and
will continue to be the largest class of medicinally important drugs in the
future. These ligands offer considerable advantages over genetically
encoded drugs such as peptides and the ability to utilize two-hybrid
technology, or a modification of it, to determine non-genetically encoded
ligands which interact with a known protein would have important
implications in future drug discover efforts.
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Chapter 3
The Yeast Three-Hybrid System:
A Method for Detecting Ligand-Receptor Interactions
Background
A fundamental area of inquiry in pharmacology and medicine is
the determination of ligand-receptor interactions. The pharmacological
basis of drug action, at the cellullar level, is quite often the consequence of
non-covalent interactions between therapeutically relevant small organic
molecules (M.W. <1 kDa) and high-affinity binding proteins within a
specific cell-type (Hardman, J.G. et al., 1996). These small organic ligands
may function as agonists or anatagonists of key regulatory events which
orchestrate both normal and abnormal cellular functions. For years the
pharmaceutical industry's approach to discovering such ligands has been
one of the random screening of thousands of small molecules in specific
in vitro and in vivo assays to determine a potent lead compound for their
drug discovery efforts. This lead compound might be a natural product or
a small organic molecule which does not appear in nature but was
synthesized through a medicinal chemistry effort. Quite often these
ligands exert very well-defined effects with regard to cellular function but
their mechanism of action at the molecular level (ligand-protein
interaction level) is completely unknown. Identification of the cellular
receptors for such pharmacologically active agents holds unparalleled
utility in the drug discovery process and tremendous potential in the
expansion of scientific frontiers on both the basic and applied levels of
research.
At the basic level, the identification of the receptor for a
pharmacological agent would afford considerable insight into the
molecular circuitry which mediates certain cell-type specific processes.
Much of this circuitry remains quite elusive and the elucidation of
proteins involved in particular cellular processes would initiate
numerous research efforts improving our molecular understanding of the
events which orchestrate cellular function. Any of the information
derived from such studies might be directly applied to drug discovery
efforts by defining novel targets for pharmacological intervention, either
directly or through subsequent studies to determine interacting proteins,
in a variety of disease states. A classical example of how the
determination of the receptor for a pharmacologically active ligand has
resulted in an explosion of scientific inquiry is apparent from the
discovery of the receptor for the immunosuppressant FK506.
Dissection of T Lymphocyte Signal Transduction Pathways Using a
Pharmacological/Chemical Approach
The natural product FK506 was initially isolated in 1985 by
Fujisawa Pharmaceuticals Company. After screening this natural product
in a variety of cellular assays it was determined to be a highly potent
immunosuppressant with potential clinical utility in the prevention of
allograft rejection following organ transplantation. At the time of its
discovery the field of clinical translation was in the state of astonishing
advances. Several years earlier the drug cyclosporine A (CsA) was
approved by the FDA for use in allograft rejection, revolutionizing the
way clinicians treated transplant recipients and saving thousands of lives
(Starzl, T.E. et al., 1989). Although CsA had found widespread use in a
clinical setting, and FK506 was being hailed as the next miracle drug (and
future billion dollar molecule) very little was known about the
mechanism of action of either of these drugs at the molecular level. In
fact, very little was known about the intracellular signal transduction
pathways which mediated T Lymphocyte activation following T cell
receptor (TCR) engagement by peptide-Major Histocompatibility
Complexes (MHC) on the surface of Antigen Presenting Cells (APCs). This
mysterious gap which connected the cell surface to the nucleus through a
sea of cytosolic proteins was simply known as the "black box" of signal
transduction and the scientific community longed for the further
elucidation of the specific proteins which played a role in this important
signal transduction pathway.
It was established that both CsA and FK506 were effective at
inhibiting T lymphocyte function at a point proximal to TCR activation
and early in the G1 phase of the cell cycle (Schreiber, S.L., 1991). These two
drugs were able to effectively inhibit the secretion of the cytokine
interluekin-2 (IL-2), an immediate to early gene product of T Lymphocyte
activation, and a protein responsible for the expansion and proliferation of
immune cells. In an effort to more clearly define the mechanism of action
of FK506 researchers at Yale University, in the laboratory of organic
chemist Stuart Schreiber, used this powerful drug as a molecular probe to
gain an increased understanding of T Lymphocyte signal transduction
pathways and the particular proteins which were responsible for T cell
activation and proliferation.
Utilizing their skills in synthetic organic chemistry, Schreiber and
coworkers synthesized an FK506 affinity matrix. With the FK506 affinity
matrix they painstakingly purified proteins which bound to this
pharmacologically active ligand. After over a year of labor intensive
research Schreiber and coworkers were able to purify a small quantity of a
12 kDa protein which bound to FK506 that they called FKBP12 (Harding,
M.W. et al. 1989). From this purified protein they obtained peptide
sequence information and used this information to clone the FKBP12 gene
(Standaert, R.F., et al. 1990). The entire process took Schreiber and his
colleagues approximately three years but this discovery would set the stage
for an intense scientific effort which would significantly improve our
understanding of T Lymphocyte function.
The FKBP12 protein was determined to possess an intrinsic
enzymatic activity, peptidyl-prolyl isomerase (PPIase), which was thought
to play a role in protein folding. Interestingly, the molecular target of CsA,
cyclophilin, was also determined to be a PPIase. Both FK506 and CsA were
found to effectively inhibit this enzymatic activity and it was initially
rationalized that that these drugs disrupted T cell function by simply
preventing specific proteins involved in T cell signaling pathways from
folding correctly. This was not the case as Schreiber and coworkers
synthesized an FK506 analog 506BD, for FK506 binding domain, which
contained the domain of FK506 which was required for binding to FKBP12
but lacked specific functionality on the opposite side of this rather large
organic molecule (Bierer et al., 1990). Although it effectively inhibited
PPIase activity, this molecule possessed absolutely no immunosuppressive
activity. This dissociation between inhibition of PPIase activity and
immunosuppressive potency led Schreiber and colleagues to concluded
that FK506 was a modular ligand which contained two separable domains.
One domain was responsible for binding to FKBP12, the binding domain,
and a second domain was responsible for conferring immunosuppressive
activity, the effector domain (Figure 3.1). Both domains were needed for
immunosuppressive activity and these drugs were in fact prodrugs which
required receptor binding to become pharmacologically active.
Figure 3.1 Modular domains of the immunosuppressant FK506.
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In order to determine the precise mechanism of action of FK506
Schreiber and Liu identified proteins which interacted with the FK506-
FKBP12 complex utilizing biochemical affinity chromatography methods
(Liu et al., 1991). They determined that a protein complex which included
the protein phosphatase calcineurin, also known as PP2B, specifically
bound to this immunophillin-drug complex with high-affinity.
Additionally, enzymatic activity of this phosphatase was potently
inhibited by the FK506-FKBP12 complex. This discovery established
calcineurin as a key regulatory protein in the T cell activation pathway and
began to illuminate what was previously only a "black box" of T
lymphocyte signal transduction. This improved understanding of a
fundamental biological process was all made possible by the initial
discovery of the binding protein for the pharmacologically active FK506
ligand.
From this single example it is quite apparent that a
pharmacological/chemical approach to the study of complex biological
systems holds tremendous potential. It is also apparent that the initial
discovery of a receptor for a small organic ligand and subsequent gene
cloning is tedious, labor intensive work. Presently, there are no efficient
methodologies which allow for the rapid identification of the protein
target for a non-genetically encoded small organic molecule. Although
the Yeast Two-Hybrid System is useful in the discovery of proteins which
interact with a known protein it is limited in that the components studied
using this technology must be genetically encoded, proteins or peptides.
There is thus an unmet need for an efficient way to identify binding
proteins for biologically active, non-genetically encoded small organic
molecules whether these molecules be natural products or molecules
derived through combinatorial or medicinal chemistry efforts. We set out
to combine the disciplines of synthetic organic chemistry and yeast
genetics in an attempt to harness the power of the Yeast Two-Hybrid
System and develop a novel methodology which would allow for the
rapid cloning of genes which encoded receptors for pharmacologically
active small organic ligands. The inspiration for this method came out of
the recent collaborative work of Stuart Schreiber from the Department of
Chemistry at Harvard University and Gerald Crabtree from Stanford
University School of Medicine. Schreiber and Crabtree utilized their
combined knowledge of chemistry and biology to develop a novel method
to artificially activate specific signal transduction pathways leading to gene
induction in vivo using small organic ligands as signaling initiators.
Activation of Signal Transduction Events through Chemically Induced
Dimerization: The Basis for a Key Component of the Yeast Three-Hybrid
System
Natural Activation of Signal Transduction Pathways
There exists a number of ways which receptors transmit molecular
information from the cell surface to the nucleus in order to activate gene
transcription (Seed, B., 1994). Three principle mechanisms are known to
exist which initiate signal transduction pathways from the cell membrane:
allosteric conformational change of a receptor as a result of ligand binding,
receptor dimerization, and receptor multimerization.
Allosteric conformational changes are perhaps the most well
studied in the activation of heterotrimeric G-proteins by seven-membrane
spanning receptors such as the P-adrenergic receptors. Upon binding to
their endogenous ligands these receptors undergo conformational changes
at portions of the protein which are distant from the ligand binding site
resulting in the dissociation of a heterotrimeric G-protein complex which
is associated with the cytosolic tail of these receptors. This dissociation
causes the release of the Got subunit from the Goy inhibitory subunits
initiating receptor mediated signaling events.
Receptor dimerization is also a well studied initiating step of
specific signal transduction events being most prevalent among growth
factor receptors. These receptors are normally type I membrane receptors
with a significant cytosolic tail which possesses enzymatic activity such as
kinase activity. Upon binding to endogenous ligand, such as human
Growth Hormone (hGH), these receptors dimerize and the dimerized
cytosolic tails become enzymatically activated resulting in the initiation of
specific signal transduction events.
A third type of initiating mode is receptor multimerization. This is
most often seen in the immune system where receptor clustering leads to
the initiation of specific signal transduction pathways. This clustering is
the result of TCR engagement of MHC molecules on antigen presenting
cells (APCs).
The ability to selectively activate certain signaling pathways would
allow researchers to perform a number of genetic experiments not
accessible by standard genetic technologies and might hold widespread
potential applications for human health through gene therapy.
Artificial Activation of T Lymphocyte Signal Transduction Pathways
through Chemically Induced Dimerization
Schreiber and Crabtree had the idea of inducing receptor
dimerization/multimerization in the absence of hormone or peptide-
MHC to initiate specific signal transduction pathways and divert signaling
molecules activated downstream of this initiation step to activate specific
reporter genes. To bring about receptor dimerization/multimerization
they planned to utilize a small organic ligand which was a homodimer of
the immunosuppressant FK506 called FK1012 (Figure 3.2).
Figure 3.2 FK1012 - Chemical inducer of protein dimerization.
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Since the FK506 molecule possessed two totally separable domains, which
served two different functions, the FK506 molecules could be coupled
together through their effector domains and the ability of the ligand to
associate with its high-affinity binding protein, FKBP12, would not be
compromised. Such a modification would however totally abolish
immunosuppressive activity since the FK1012-FKBP12 complex would not
be able to interact with the protein phosphatase calcineurin through the
effector domain. Using an FK506 homodimer would allow for the
artificial dimerization of chimeric proteins which contained FKBP12
expressed as a fusion to another protein. Expressing a number of FKBP12
proteins in tandem might allow for the multimerization of the chimeric
proteins. If the chimeric proteins contained the cytosolic tail of a receptor
signaling protein the artificial dimerization/multimerization of this
protein might lead to artificial activation of a particular signal
transduction pathway. To prove the feasibility of such a system, in vivo,
Schreiber and Crabtree decided utilize one of the most well studied
receptor mediated signaling pathways, the TCR mediated signaling
pathway.
The TCR is a receptor complex composed of eight membrane
proteins (a03ySF2ý2) (Figure 3.3). One particular protein in this complex,
the zeta protein, is considered to be one of the most important
components of the TCR. Upon multimerization this protein becomes
phosphorylated by members of the Src family of protein tyrosine kinases
(Lck and Fyn) and activates a number of downstream signaling molecules.
Signaling molecules which are activated distal to the TCR include the
transcription factors NF-ATc and NF-ATn (Nuclear Factor of Activated T
cell cytosolic/nuclear) (Crabtree, G.R., 1989; Schreiber, S.L. & Crabtree, G.R.,
1992).
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These transcription factors heterodimerize and bind to a consensus NF-AT
promoter site upstream of the IL-2 gene enhancing transcriptional
activation of this important gene required for normal T cell function.
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Schreiber, Crabtree and coworkers generated a construct which expressed a
chimeric protein containing a consensus myristylation sequence (ensuring
that the protein was post-translationally modified and anchored to the
plasma membrane), the cytoslic domain of the TCR zeta chain, and three
FKBP12s fused in tandem to one another (Figure 3.3). Jurkat cells were
transiently transfected with constructs encoding this chimeric protein
along with reporter plasmid which contained an NF-AT responsive
promoter upstream of the gene encoding secreted alkaline phosphatase
(SEAP). When the transfected cells were grown in the presence of FK1012,
activation of the reporter gene was observed at levels which were
comparable to those seen when T cells were stimulated through normal
TCR pathways using well-established methods (Spencer et al., 1993). These
experiments were the first to prove the feasibility of dimerizing/
multimerizing signaling molecules in vivo through the use of Chemically
Induced Dimerization or CID.
The Yeast Three-Hybrid System : A Method for the Detection of Ligand-
Receptor Interactions
Rational and Components
We set out to explore the possibility of modulating gene expression
at the nuclear level using the chemically induced dimerization of two
transcriptional modules, one containing a specific DNA binding domain
and the other a transcriptional activation domain, to activate transcription
at particular reporter genes. This type of chemically induced dimerization,
if successful, would form the fundamental basis for a novel methodology
which we hoped to develop that could be used to rapidly clone genes
which encoded for the receptors of pharmacologically active small organic
ligands.
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Figure 3.4 Components of the Yeast Three-Hybrid System.
This methodology would be an extension of the powerful Yeast Two-
Hybrid System and would be entitled the Yeast Three-Hybrid System: A
Method for Detecting Ligand-Receptor Interactions. The components of
this new system would include three hybrid molecules: two protein
hybrids and one small molecule ligand hybrid (Figure 3.4).
The small molecule ligand hybrid would be composed of two small
organic ligands connected by a covalent linker (Figure 3.5). One of these
ligands, represented by the triangle, would be a ligand with a previously
identified high-affinity receptor. The second ligand, represented by the
semi-circle, would be an orphan ligand. An orphan ligand is a ligand
which has a well-defined biological function but no known receptor or
molecular mechanism of action.
Ligand with a known
high-affinity receptor
Orphan Ligand
Ligand with a defined
biological function but
unknown mechanism
of action.
Figure 3.5 The Hybrid Ligand.
These two molecules would be linked together at positions on their
molecular architecture which would not abrogate binding to their known
or potential receptors. For the orphan ligand this position would have to
be established through detailed structure-activity studies. A number of
analogs of the orphan ligand would need to be constructed and tested in
cell culture assays to determine which position on the molecule could be
modified to afford a ligand with reasonable biological activity.
The hybrid proteins which were to be used are quite similar to those
used in the Yeast Two-Hybrid System. Protein Hybrid #1 would contain a
specific DNA binding domain fused to a known protein and Protein
Hybrid #2 would contain a transcriptional activation domain fused to
either a library of proteins encoded by a cDNA library, used for screening
purposes, or a known protein, used after the receptor for an orphan ligand
had been discovered. There exists only one difference between the
chimeric proteins which would be used in the three-hybrid system vs. the
two-hybrid system. This difference is that Protein Hybrid #1 would
contain a DNA binding domain fused to a known protein for which
interacting proteins would not be directly screened. This chimeric protein
would contain the high-affinity receptor for the triangle ligand of the
hybrid ligand molecule (Figure 3.3) and this high-affinity ligand-receptor
complex would serve to localize the hybrid ligand to the nucleus and
present the orphan ligand to potential interacting proteins encoded by the
library.
The Yeast Three-Hybrid System contains three hybrid molecules so
the terminology used to identify each of the components (Figure 3.6)
would have to be slightly different than for the Yeast Two-Hybrid System
(Figure 2.4). In the Three-Hybrid System Protein Hybrid #1 which
contained the DNA binding domain fused to the high-affinity ligand for
the triangle ligand would be called the "hook", the small organic hybrid
ligand would be called the "bait", and Protein Hybrid #2 which contained
the transcriptional activator fused to the proteins expressed by the cDNA
library would be called the "fish". When conducting a three-hybrid screen
a potential sequence of events which would lead to the cloning of genes
which encoded novel receptors for pharmacologically active orphan
ligands is shown in Figure 3.6.
The initial step would be for the exogenously added, non-genetically
encoded, hybrid "bait" ligand to cross the yeast cell membrane and cell
wall, travel through the cytosol, and find its high-affinity receptor in the
nucleus to "Bait the Hook". The second step would be for potential
receptors for the orphan ligand, expressed as transcriptional activation
domain fusions, to enter the nucleus and bind to the "baited hook" to
"Catch the Fish". The "bait" would initiate the chemically induced
heterodimerization of the two transcriptional modules, acting as a
molecular glue, and reconstituting transcription at particular reporter
genes. The reporter genes which were activated would be exactly the same
as those used in the two-hybrid system and would allow for the selective
isolation of yeast colonies which harbored "fish" plasmids that encoded
for potential high-affinity receptors for the orphan ligand.
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Figure 3.6 Sequence of events in a three-hybrid screen.
Design of the Conserved Portion of the Three-Hybrid System
When we initially set out to design the components of the Yeast
Three-Hybrid System it was obvious that the most important choice
would be the design of the conserved portion of the three-hybrid system
(Figure 3.7).
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This was the portion of the system which would remain constant for all
three-hybrid screens or potential applications of three-hybrid technology.
It was preferred that this ligand-receptor interaction be a well-studied
high-affinity interaction and that both the ligand and receptor satisfy very
strict criteria.
It was import that the ligand be commercially available and
reasonably priced so that all researchers would have access to large
quantities of this ligand. It was also necessary that a large amount of
detailed structure-activity data be readily available with regards to the
binding of this ligand to its high-affinity receptor. This would be very
important in the determination of where on the molecular architecture
this ligand could be synthetically modified to afford analogs which
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Figure 3.7 Conserved and random components of the three-hybrid system.
retained high-affinity for the receptor. It would also be convenient if the
synthetic chemistry utilized to modify the ligand be somewhat
straightfoward so that researchers in laboratories which did not possess a
significant amount of synthetic expertise could gain access to three-hybrid
technology. Finally, it was important that this ligand did not possess an
endogenous high-affinity receptor in yeast. The existence of such a
receptor might dramatically decrease the sensitivity of the method and
might require that very high concentrations of hybrid "bait" ligand be used
when conducting a yeast three-hybrid screen. This might be unrealistic in
a number of three-hybrid screens since quite often the orphan ligand will
be a natural product which is only available in very small quantities.
With regards to the high-affinity receptor, it would be necessary that it
possess a conserved ligand binding module which could be fused to
unrelated proteins yet maintain high binding affinity for its ligand. It was
also important that this receptor be cloned, and the clone be readily
available so that "hook" constructs could be easily generated.
After significant consideration the decision was made to utilize the
steroid hormone-steroid hormone receptor interaction as the conserved
portion of the Yeast Three-Hybrid System. The steroid hormone-steroid
hormone receptor interaction is one of the most well-studied ligand-
receptor interactions known. The glucocorticoid receptor is a transcription
factor, present only in mammalian cells, which possesses three modular
domains (Giguere et al., 1986.) (Figure 3.8).
The amino terminal portion of this protein contains a large
transcriptional activation domain, the central portion a DNA binding
domain, and the carboxy terminal portion a ligand binding domain which
binds to many steroid hormones with low nM binding affinity. In the
absence of steroid hormone the glucocorticoid receptor is sequestered in
the cytosol of the cell by a large protein inhibitory complex containing the
heat shock proteins HSP70 and HSP90 which bind to the hormone binding
domain (Pratt, 1990). Upon binding of steroid the glucocorticoid receptor
is released from this inhibitory protein complex, translocates to the
nucleus, and activates glucocorticoid responsive genes (Picard et al., 1988).
The most potent activator of glucocorticoid inducible genes is the synthetic
steroid agonist dexamethasone. This drug, routinely prescribed in a
clinical setting for its immunosuppressive and anti-inflammatory
properties (Cohen, 1989), binds to the glucocorticoid receptor with a Kd of
approximately 5 nM (Rusconi & Yamamoto, 1987).
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Figure 3.8 Modular Domains of the Glucocorticoid Receptor.
DNA Binding Domain
Dexamethasone satisfied all of the criteria we were looking for in a
ligand. It was commercially available, reasonably price ($40/1gram), and
possessed two separable domains, one which was responsible for receptor
binding and one which could be synthetically modified to afford analogs
which maintained high-affinity binding to the glucocorticoid receptor
hormone binding domain (Figure 3.9 A).
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Figure 3.9 A. Modular domains of the steroid dexamethasone.
B. Dexamethasone-Biotin affinity reagent.
This was well established since the glucocorticoid receptor was initially
purified using a dexamethasone-biotin affinity reagent which possessed a
O
Kd of 25-30 nM for the glucocorticoid receptor (Govindan & Manz, 1980;
Manz et al., 1983) (Figure 3.9 B). Additionally, a large amount of Structure-
Activity Relationship (SAR) data was available (Lefebvre et al., 1989)
which indicated that as long as the linker off the C20 position contained a
linker of eight or more carbons the ligand bound to the hormone binding
domain with comparable affinity to the dexamethasone-biotin conjugate.
Dexamethasone could be easily modified in three to four synthetic steps to
afford molecules which possessed linkers with either nucleophilic or
electrophilic ends for effective coupling to orphan ligands through a
simple amide bond forming reaction (Figure 3.10).
The hormone binding domain (HBD) of the glucocorticoid receptor
(GR) has been utilized as a tool in a number of experiments to create
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Figure 3.10 Potential dexamethasone molecules for creation of hybrid
"bait" ligands.
conditionally active proteins under hormone control (Mattioni et al.,
1994). Given the nature of the HBD to bind a large protein inhibitory
complex in the absence of steroid ligand and release this steric bulk in the
presence of ligand a number of researchers have generated fusion proteins
between constitutively active proteins such as kinases and the HBD
(Jackson et al., 1993; Samuels, M.L., et al., 1993). In the absence of ligand
these proteins cannot function normally and induce phosphorylation
either because they are sequestered to a portion of the cell where substrates
are not available or the steric hindrance of the inhibitory protein complex
will not allow the kinase domain to come in contact with potential
substrates. This inhibitory effect is effectively released in the presence of
ligand and the kinase becomes constitutively active once again, able to
phosphorylate all substrates. These experiments clearly indicate that the
HBD module is transferable from protein to protein and still maintains
high-affinity for the steroid ligand making the dexamethasone-
glucocorticoid receptor interaction the perfect interaction for the
conserved portion of the Yeast Three-Hybrid System.
Design of the Three-Hybrid System Test Case
With the conserved portion of the Yeast Three-Hybrid System
established the next decision was to choose an orphan ligand to prove the
efficacy of this potential new method. Although Schreiber and Crabtree
had established that CID was possible in mammalian cells (Spencer et al.,
1993; Pruschy et al., 1994) when dimerizing cytosolically localized proteins,
the ability to chemically induce dimerization of nuclear proteins in either
mammalian cells or any signaling molecules in yeast cells had never been
established. The orphan ligand used in the three-hybrid system test case
could not be a true orphan ligand but instead needed to be a ligand which
was previously an orphan but whose receptor had recently been
discovered. The choice of such an "orphan ligand" would allow us to
initially establish the ability of a heterodimeric ligand to induce the
heterodimerization of two transcriptional modules, in yeast, and activate
reporter genes. Once this was established, the next step would be to
conduct the first ever Yeast Three-Hybrid Screen to rapidly identify
proteins known to interact with this "orphan ligand" and establish the
utility of the Yeast Three-Hybrid System as a powerful new method to
rapidly clone genes which encode for proteins which bind to
pharmacologically active ligands.
It was decided to utilize the immunosuppressant FK506 as the
"orphan ligand" in the three-hybrid system test case. As previously
elaborated on, the immunosuppressant FK506 is an organic ligand which
contains two separable domains, one which binds FKBP12 with high-
affinity and the other which is responsible for inhibition of the protein
phosphatase calcineurin. It was decided to synthetically modify FK506
through its effector domain, utilizing the published procedures in the
synthesis of FK1012, and couple it to the steroid hormone dexamethasone
through a linker connected to C20 to afford a dexamethasone-FK506 hybrid
ligand which would be used as the "bait" in the three-hybrid system test
case. (Figure 3.11).
Initial experimental efforts concentrated upon the synthesis of the
dexamethasone-FK506 hybrid "bait" ligand along with the generation of a
yeast strain which could be used to prove the efficacy of the three-hybrid
system. This strain of yeast would express a "hook" protein composed of a
DNA binding domain fused to the HBD of the glucocorticoid receptor and
a "fish" protein composed of a transcriptional activation domain fused to
FKBP12. When this strain of yeast was grown on the dexamethasone-
FK506 hybrid "bait" ligand activation of reporter genes utilized in yeast
two-hybrid system screening should be observed (Figure 3.12).
Results and Discussion
Construction of the Components for the Initial Three-Hybrid System Test
Case
Synthesis of the dexamethasone-FK506 hybrid "bait" ligand
Retrosynthetically, the dexamethasone-FK506 hybrid "bait" ligand
could be disconnected at either one of the amide linkages along the
organic tether which connected the two molecules. This would afford
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two molecules which could easily be coupled to one another through an
amide bond forming reaction. We chose to disconnect the hybrid "bait"
ligand at the amide bond closest to the FK506 molecule to afford a
dexamethasone molecule which contained a polymethylene linker
emanating from the C20 position, ending in a primary amine, and an
FK506 activated ester. The dexamethasone primary amine (1) was
constructed in three steps following published procedures detailed in the
synthesis of the dexamethasone-biotin affinity reagent (Manz et al., 1983)
(Figure 3.13).
Initially, dexamethasone was oxidized in the presence of periodic
acid to cleave the a-hydroxy ketone at C21 and afford a dexamethasone
carboxylic acid which was readily converted to the N-hydroxysuccinimide
activated ester. This ester could eventually be coupled to a mixed
acid/amine if the hybrid "bait" ligand needed to possess an electrophilic
linker to react with a nucleophilic orphan ligand or with a diamine linker
which would be used to react with an electrophilic orphan ligand. In our
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Figure 3.13 Synthesis of the dexamethasone free amine.
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case the dexamethasone activated ester was reacted with excess 1,10
diaminodecane to afford the dexamethasone primary amine (1).
The FK506 mixed carbonate activated ester (2) was synthesized
according to the procedures of Schreiber and coworkers in the synthesis of
FK1012 (Pruschy et al., 1994) (Figure 3.14). Initially, the free hydroxyl
groups of FK506 were protected as the tert-butyldimethylsilyl (TBS) ethers.
The allyl group contained in the effector domain was then cleaved after
conversion to the diol by osmium tetroxide and subsequent treatment
within sodium periodate to afford aldehyde functionality at this position.
The aldehyde was reduced selectively to the alcohol using the sterically
congested reducing agent lithium tris[(3-ethyl-3-pentyl) oxy]aluminum-
hydride. Finally, the alcohol was converted to the mixed carbonate N-
hydroxysuccinimide activated ester (2) by the addition of N,N'
disuccinimidylcarbonate.
Dexamethasone and FK506 were coupled by formation of the amide
bond between dexamethasone primary amine (1) and the FK506 activated
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Figure 3.14 Synthesis of the FK506 mixed carbonate activated ester.
ester (2) and the protecting groups were removed by treatment with HF to
afford the dexamethasone-FK506 hybrid "bait" ligand (Figure 3.15). (The
use of the 1,10 diaminodecane linker proved to be crucial since attempts at
coupling these molecules were unsuccessful when shorter linkers were
used.)
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Figure 3.15 Coupling and deprotection of the dexamethasone-FK506
hybrid "bait" ligand.
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Generation of Constructs Which Encode for the Initial "hook" and "fish"
Fusion Proteins
We decided to use the two-hybrid system developed in the
laboratory of Dr. Roger Brent at the Massachusetts General Hospital
(Finley, R.L. & Brent, R., 1995). As previously described (Chapter 2) this
system utilizes the bacterial LexA DNA binding protein. The "hook"
constructs which needed to be generated would express protein fusions
between the LexA DNA binding domain and the rat Glucocorticoid
Receptor (rGR) hormone binding domain (HBD). A similar fusion was
generated by Dr. Keith Yamamoto and coworkers at the University of
California-San Francisco in some of their early work on the functional
dissection of the modular domains of the glucocorticoid receptor
(Godowski et al., 1988). Dr. Yamamoto and his colleagues precisely
mapped the transcriptional activation regions of the glucocorticoid
receptor by fusing portions of the rGR to the LexA DNA binding domain
(amino acids 1-87) and observing transcriptional activation of reporter
genes in mammalian cells transiently transfected with a number of LexA
fusion constructs. Several of the functional constructs contained a region
of the HBD from amino acids 524-795 expressed as LexA fusion proteins.
These constructs were able to bind to dexamethasone with high-affinity
and it was decided to utilize this portion of the hormone binding domain
in our initial "hook" fusion proteins. Additionally, Dr. Yamamoto and
coworkers discovered a specific point mutation, C656G, within the
hormone binding domain of the rGR which reduced the Kd of
dexamethasone for the HBD ten-fold from 5 nM to 0.5 nM (Chakraborti et
al., 1991). It was decided to also utilize this mutation in our initial "hook"
fusion proteins.
Plasmids containing full length rGR, WT and C656G, were obtained
from Dr. Yamamoto and used to generate "hook" constructs encoding for
"hook" fusion proteins from amino acids 524-795 of the rGR to the first
201 amino acids of the LexA DNA binding domain (Figure 3.16).
Additionally, a "fish" construct was generated which encoded for a "fish"
fusion protein containing full length human FKBP12 fused to the B42
transcriptional activator (Ma & Ptashne, 1987; Ruden, D.M. et al., 1991).
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Figure 3.16 First generation three-hybrid "hook" fusion proteins.
First Generation Three-Hybrid System Test Case
To determine whether the dexamethasone-FK506 hybrid "bait"
ligand was able to chemically induce the heterodimerization of the "hook"
and "fish" fusion proteins in vivo, activating the LEU2 and lacZ genes
utilized in the Brent Interaction Trap, two strains of yeast were prepared by
transforming EGY48 with a "hook" plasmid which encoded the LexA
pEGHBD 
2nEGHBD2
DNA binding domain fused to either WT or C656G rGR HBD amino acids
524-795 along with a "fish" plasmid which encoded for FKBP12 fused to
the transcriptional activator B42, and the reporter plasmid pSH18-34
(Figure 3.17)
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Figure 3.17 Yeast strains for the first generation three-hybrid system test
case.
These two strains, named EJL1 and EJL2, were plated onto yeast dropout
plates which contained Synthetic Complete medium lacking histidine,
uridine, and tryptophan (SC (His-,Ura-, Trp-)) and were supplemented
with 2% Galactose, X-Gal, pH 7.0, and various concentrations of the
dexamethasone-FK506 hybrid "bait" ligand (0.5 gM, 1iM, and 10 gM).
These yeast were incubated at 30 OC. Activation of the lacZ gene, as
indicated by appearance of blue yeast colonies, was observed for only strain
EJL2 at the 10 gM and 1 gM concentrations of hybrid "bait" ligand.
Activation was initially observed at three days and four days for the 10 gM
and 1 jM concentrations respectively. Activation of the lacZ gene was
only induced to moderate levels at 10 gM and very low levels at 1 gM.
Next the ability of EJL1 and EJL2 to grow in the absence of leucine
was investigated. Since the EGY48 strain of yeast is auxotrophic for
leucine the only way to induce leucine prototrophy would be the
successful heterodimerization of the "hook" and "fish" fusion proteins
resulting in activation of the LEU2 gene. Yeast strains EJL1 and EJL2 were
plated onto SC (His-,Ura-,Trp-,Leu-) 2% Galactose, 1 gM dexamethasone-
FK506, X-Gal, pH 7.0 and incubated at 30 OC. After six days at 30 OC leucine
prototrophy was observed for only EJL2 which grew slowly into isolated
colonies that turned only light blue in color. The results of these initial
experiments indicated that although the chemically induced
heterodimerization of the two transcription modules contained in the
"hook" and "fish" fusion proteins was occurring, it was not doing so to a
significant degree. In order to attempt a three-hybrid screen to isolate
FK506 interacting proteins it would be necessary to significantly enhance
the sensitivity of this test case system. In a standard two-hybrid screen
colonies which exhibit leucine prototrophy, and harbor potential
interactors, initially appear after two days at 30 oC and the strongest
interactors are isolated from day 2 through day 5. After day 5 a large
number of insignificant colonies arise which are predominantly
background and it becomes very difficult to sort through these colonies
and isolate potential interactors. At this point it was necessary to
investigate ways to improve the sensitivity of the three-hybrid system test
case to enhance reporter gene activation and reduce the amount of time
needed for the control strains to grow in the absence of leucine.
Potential Ways to Improve and Fine-Tune the Sensitivity of the Three-
Hybrid System Test Case
Having the luxury of using a well-defined high-affinity ligand-
receptor interaction as the three-hybrid system test case we could begin to
refine the sensitivity of the three-hybrid system. Any refinements which
were made would not only be important for the success of the three-hybrid
test case but would also significantly influence future three-hybrid screens.
There were three major areas which we believed needed to be investigated
in order to improve the sensitivity of the three-hybrid system to afford
maximum sensitivity. The first two involved optimizing the effective
intracellular concentration of hybrid "bait" ligand within the yeast cells
and the third involved the optimization of the specific rGR hormone
binding domain fused to the LexA DNA binding domain.
One of the major obstacles which must be overcome when utilizing
small organic ligands for experiments in yeast is the relative
impermeability of yeast toward a number of these ligands. For this reason
experiments conducted in yeast must use concentrations of small organic
ligands which are at least ten-fold greater than those used for similar
experiments in mammalian cells. In order to overcome this problem of
yeast permeability researchers have taken both genetic and
pharmacological approaches. Genetically, the use of gene knockout
technology through homologous recombination (Alani, E. et al., 1987) has
been utilized to disrupt certain genes which tend to make yeast cells more
permeable to small ligands (Shah, N. & Klausner, R.D., 1993). The most
widely studied knockout which confers increased drug sensitivity is the
deletion of the ERG6 gene (Winsor, B. et al., 1987) which encodes a yeast
methyl transferase. By disrupting this gene the biosynthesis of ergosterol,
one of the only steroids in yeast and major component of the cell
membrane is inhibited, and yeast become much more permeable to small
organic ligands. Yeast with the ERG6 gene deletion are viable and only
exhibit differences in mating and transformation efficiency. This might
however pose a problem when attempting to screen a library for proteins
which interact with a particular ligand since, as previously mentioned in
Chapter 2, screening is preceded by a high efficiency transformation.
Pharmacologically, the polybasic cyclic nonapeptide of polymyxin B,
derived from enzymatic reaction of polymyxin B sulfate, has been
determined to increase the permeability of yeast (Vaara, M. & Vaara, T.,
1983; Boguslawski, G., 1985) to a number of small organic ligands along
with the drug econazole, which is known to inhibit the biosynthesis of
ergosterol. Taking a pharmacological approach toward increasing the
permeability of yeast to hybrid "bait" ligands would seem to be the most
viable option for the Yeast Three-Hybrid System.
A second problem with using yeast for experiments with small
organic molecules is that Saccharomyces cerevisia possess a large number
ABC transporter (for ATP-binding cassette) proteins (Higgins, C.F., 1992)
which enhance the efflux of small organic ligands from inside yeast cells
leading to a multidrug resistant phenotype. These proteins are similar to
the mammalian P-glycoprotein or Mdrl proteins which are found in a
number of tumor cells. Saccharomyces cerevisia genes which are
members of this family include STS1, PDR5, and LEM1 (Meyers, S. et al.,
1992; Bissinger, P.H. and Kuchler, K., 1994; Kralli, A. et al., 1995) which
have been determined to mediate dexamethasone resistance in yeast. The
presence of such transporter proteins might pose a major problem to the
sensitivity of the Yeast-Three Hybrid System though it has not been
determined if these transporter are capable of accommodating large
organic ligands such as potential hybrid "bait" ligands which might
potentially be used in a three-hybrid screen. Once again there are two
potential approaches to reducing this problem of ligand efflux, genetic and
pharmacological. By utilizing gene knockout technology to remove ABC
transporters researchers have dramatically increased sensitivity of yeast to
small organic ligands including dexamethasone. Pharmacologically, a
number of drugs which inhibit ABC transporters are being developed
which inhibit mammalian MDR proteins and it is quite probable that a
number of these will inhibit the highly conserved yeast homologs. It
would seem that either of these approaches would be compatible with the
three-hybrid system. The genetic approach, though slightly more
involved, might simplify future three-hybrid screens since a three-hybrid
strain of yeast might be constructed which has these genes deleted and
could be used for all three-hybrid screens. This would avoid the constant
use of potentially expensive or toxic pharmacological inhibitors of MDR
proteins.
A third area which might be investigated to improve the sensitivity
of the three-hybrid system test case would be the optimization of the
"hook" protein used. Keeping all of the variables constant except for the
"hook" fusion protein would give us the opportunity to fully optimize
this variable and once optimized the most sensitive "hook" fusion protein
could be utilized for all future three-hybrid screens and applications of
three-hybrid technology.
It was decided to initially attempt to improve the sensitivity of the
three-hybrid system test case by exploring the third option and generate
potential new and improved "hook" proteins.
Design of New and Improved "hook" Fusion Proteins
The decision to initially use the rGR hormone binding domain
from amino acids 524-795 was influenced by the fact that this portion of
the hormone binding domain was fused to the LexA DNA binding
domain in previous experiments and effectively placed the chimeric
protein under hormonal control. However, for these experiments the
overall affinity of the hormone binding domain for the steroid ligand was
not nearly as critical as in the Yeast Three-Hybrid System. In an effort to
determine if different HBD fusions might significantly improve
sensitivity a thorough search of the literature was conducted. This search
uncovered two important papers published by Yamamoto and coworkers
which reported on very detailed dissections of the modular domains of
the rGR. Several observations by these researchers provided us with a
number of important facts which would allow the potential improvement
of the sensitivity of the three-hybrid test case by generating modified
"hook" fusion proteins.
The first paper reported on the functional dissection of the
hormone and DNA binding activities of the rGR (Rusconi & Yamamoto,
1987). Several chimeric proteins containing portions of the HBD fused to
the protein P-galactosidase were expressed, purified, and dexamethasone
affinity measurements were determined for these fusions. The results of
these studies brought into question the choice of the "hook" fusion
proteins used in the initial three-hybrid test case. The two fusions which
were of most relevance to our experiments were fusions between P-
galactosidase and amino acids 497-795 and amino acids 547-795 of the rGR.
The fusion from amino acids 497-795 was determined to have a Kd for
dexamethasone in the low nM range, which was almost equivalent to that
for full length receptor. However, the fusion between P-galactosidase and
amino acids 547-795 possessed a Kd in the low gM range, a difference of a
thousand fold when compared to either wild-type receptor or the 0-
galactosidase-rGR 497-795 fusion protein. The "hook" protein encoded by
the original "hook" constructs possessed fusions between LexA and amino
acids 524-795 of the rGR. This length of the HBD was almost exactly in the
middle of the two characterized P-galactosidase fusion proteins. Without
calculating a Kd using the exact fusion proteins used in our initial three-
hybrid test case it would be impossible to determine just how tightly
dexamethasone or the hybrid "bait" ligand bound to the initial "hook"
fusion protein. Our "hook" protein might bind as tightly as low nM or as
weakly as low gM. It was decided to simply create new "hook" constructs
which contained the extended HBD from amino acids 497-795. These
"hook" fusion proteins would have the potential to greatly improve the
sensitivity of the three-hybrid test case.
A second very important piece of information was revealed in a
paper which genetically dissected the rGR in yeast (Garabedian &
Yamamoto, 1992). These studies documented a rather strange phenomena
which occurred only in yeast cells when conducting experiments utilizing
HBD fusions and the steroid hormone dexamethasone. Yamamoto and
coworkers determined that dexamethasone binding to HBD fusions in cell
extracts obtained from yeast differed by 1000-fold when compared to the
same fusions obtained from extracts prepared in mammalian cells: Kd of 8
nM from mammalian cells vs. Kd > 5 gM from yeast cells. They concluded
that dexamethasone binding to the HBD was defined by the cell-type in
which the HBD fusion was expressed due to nonreceptor factors which
played important roles in ligand binding. In these studies a very
interesting mutation in the HBD was discovered which was classified as a
gain-of-function mutation. This point mutation at amino acid 620 of the
rGR contained a Phe to Ser mutation. The F620S mutation significantly
increased the response seen in their assay for all ligands used but was
most striking when dexamethasone was utilized. When HBD fusions
containing the F620S mutation were prepared in yeast they displayed
significantly tighter binding to dexamethasone than the wild-type HBD. It
was rationalized that this F620S mutation altered the interaction of the
HBD with a yeast nonreceptor factor increasing the availability to bind
dexamethasone.
Utilizing all of the structure-activity data available through the
studies of Yamamoto and coworkers (Figure 3.18) a number of new and
potentially improved "hook" fusion proteins were designed with the hope
that these new fusions would significantly increase the sensitivity of the
three-hybrid system test case. Six new constructs were generated which
encoded "hook" fusion proteins in which the length of the HBD was
extended and contained both the C656G "Affinity Mutation" and F620S
"Availability Mutation" alone and in combination with one another in
C656G,F620S double mutant versions of the HBD (Figure 3.19). It was
believed that the constructs which contained both the "affinity" and
"availability" mutations would be the most interesting, significantly
increasing the sensitivity of the three-hybrid system test case.
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P-Galactosidase-HBD Amino Acids 547-795 Kd Low tM
Figure 3.18 Information utilized to design the second generation
"hook" fusion proteins.
Second Generation Three-Hybrid System Test Case
To determine whether the new "hook" fusion proteins would
increase the sensitivity of the second generation three-hybrid system test
case six new strains of yeast were prepared. EGY48 was transformed with
each of the new "hook" plasmids along with the "fish" plasmid which
encoded for FKBP12 fused to the transcriptional activator B42, and the
reporter plasmid pSH18-34 (Figure 3.20)
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Figure 3.19 Second generation three-hybrid "hook" fusion proteins.
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Figure 3.20 Yeast strains for second generation three-hybrid system
test case.
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Yeast strains EJL3-8 were initially plated onto SC (His-, Ura-, Trp-)
2% Galactose, 1 gM dexamethasone-FK506, X-Gal, pH 7.0 and incubated at
30 OC. Additionally, a strain of yeast, EJLPC, which contain a positive
control for the activation of the lacZ and LEU2 reporter genes was also
plated. This strain was transformed with the plasmid pSH17-4, which
expresses a chimeric protein between the LexA DNA binding domain,
amino acids 1-87, and the transcriptional activation domain of the Gal4
protein, pJG4-5-FKBP12, and pSH18-34. After 12-18 hours at 30 oC
activation of the lacZ gene, as indicated by blue color, was clearly observed
in the EJLPC strain with almost complete activation seen by 24 hours.
Yeast strains EJL7 and EJL8 began to exhibit lacZ reporter gene activation at
36 hours with near maximum activation seen at 48 hours. Activation of
yeast strains EJL7 and EJL8 was comparable to positive control strain
EJLPC. Strains EJL4-6 displayed lacZ reporter gene activation which was
very similar to EJL2 with blue color being observed initially at four days.
Strain EJL3 showed no activation of lacZ reporter gene and was similar to
EJL1. The results of reporter gene activation for all of the three-hybrid
system test case yeast strains are summarized in Figure 3.21.
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Figure 3.21 Sensitivity of different "hook" fusion proteins.
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With the "hook" fusion protein optimized for activation of lacZ
gene yeast strains EJL2-8 were plated onto SC (His-, Ura-, Trp-, Leu-) 2%
Galactose, 1 gM dexamethasone-FK506, X-Gal, pH 7.0 and incubated at 30
OC to investigate activation of the LEU2 gene. Effective activation of the
LEU2 gene paralleled what was observed for the lacZ gene with isolated
colonies seen at 24 hours for EJLPC and at 36 hours for the EJL7 and EJL8
which contained the optimized "hook" fusion proteins. For strains EJL4,
5, and 6 pinpoint colonies were observed at approximately 5 days and
healthy colonies were obvious at 7 days. This was exactly what was
observed for yeast strain EJL2 in the initial three-hybrid test case.
Through modification of the "hook" fusion protein, we were able to
effectively optimized the yeast three-hybrid system test case. Next we
conducted experiments to determine the specificity of this system.
Specificity Tests for the Three-Hybrid Test Case
The results of the second generation three-hybrid test case indicated
that the chemically induced dimerization of the "hook" and the "fish"
fusion proteins was efficacious. Additionally, the level of activation
indicated that either of the C656G, F620S double mutant "hook" fusion
proteins could be used to screen a library for FK506 interacting proteins.
However, before screening for FK506 interacting proteins it was necessary
to ensure that the reporter gene activation observed in the three-hybrid
system test case was specific and was not some type of artifact. A number
of control experiments needed to be performed to prove the FK506
dependence of the three-hybrid test case.
One potential concern which we had was the fact that although the
major transcriptional activation domain of the rGR resides within the
amino terminal portion of the protein a very small transcriptional
activation domain was determined to be contained within the HBD from
amino acids 545 to 575 (Hollenberg, S.M. & Evans, R.M., 1988) (Figure 3.8).
There was some concern that the activation of the lacZ and LEU2 genes
observed in the three-hybrid system test case could be the result of this
transcriptional activator. In the absence of ligand this transcriptional
activator in the HBD would be in an "Inactive" form. However, upon
binding to the dexamethasone-FK506 hybrid "bait" ligand the
transcriptional activator in the HBD could be converted to an "Active"
form which might have the potential to activate the reporter genes in an
FK506 independent manner (Figure 3.22). If this were to be the case the
results obtained in the three-hybrid system test case, where activation of
the reporter genes correlated with the overall affinity/availability for the
dexamethasone-FK506 hybrid "bait" ligand would still be consistent.
There were two potential ways that the specificity of the three-hybrid
system test case for FK506 could be tested.
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Figure 3.22 Potential activation of reporter genes independent of FK506.
The first involved a specificity test used in standard two-hybrid
screening. Since the "fish" fusion protein was expressed from the
galactose inducible GALl promoter yeast grown in the presence of glucose,
instead of galactose, would not express the "fish" fusion protein.
Therefore, if yeast strains EJL2-8 were grown on glucose the only fusion
protein which would be expressed would be the "hook" fusion protein
and activation of the lacZ and LEU2 genes in the presence of the
dexamethasone-FK506 hybrid "bait" ligand should not be observed if the
interaction was an FK506 dependent interaction (Figure 3.23).
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Figure 3.23 First Specificity Test: Galactose dependence of reporter gene
activation.
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A second specificity test involves the growth of yeast strains EJL2-8
on an excess of free FK506 in addition to the dexamethasone-FK506 hybrid
"bait" ligand. If reporter gene activation was dependent on FK506
activation of the lacZ and LEU2 genes should be abolished due to
competition for the "fish" fusion protein by the excess free FK506 (Figure
3.24).
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Yeas strains EJLPC and EJL2-8 were patched onto a SC (His-,Ura-
,Trp-), 2% Glucose master plate and were replica plated to three different
plates to determine the specificity of the three-hybrid system test case:
1. SC (His-, Ura-, Trp-), 2% Galactose, 1i M
dexamethasone-FK506, X-Gal, pH 7.0.
2. SC (His-, Ura-, Trp-), 2% Galactose, 1gM
dexamethasone-FK506, 10 pM FK506, X-Gal, pH 7.0.
3. SC (His-, Ura-, Trp-), 2% Glucose, 1pM
dexamethasone-FK506, X-Gal, pH 7.0.
These plates were incubated at 30 oC for three days and plates 1 and 2 were
photographed (Figure 3.25).
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Figure 3.24 Second Specificity Test: FK506 dependence of reporter gene
activation.
Figure 3.25 Specificity for activation of the lacZ gene. Eight yeast strains
(1-8), corresponding to EJLPC, EJL3, EJL2, EJL4-8, were replica plated onto
SC (His-, Ura-, Trp-) 2% Galactose, X-Gal, 1gM dexamethasone-FK506 (Left
plate) and SC (His-, Ura-, Trp-) 2% Galactose, X-Gal, 1tM dexamethasone-
FK506, 10 gM FK506 (Right plate). These plates were incubated at 30 OC
for three days before being photographed.
These plates clearly show that activation of the lacZ gene is FK506
dependent due to 100% competition for reporter gene activation in the
presence of a ten-fold excess of free FK506. (Glucose plates are not shown
but exhibited no lacZ gene activation) Therefore, it can be concluded that
the chemically induced dimerization is specific and that pEGHBD6 or
pEGHBD7 could be used as viable "hook" fusion proteins in three-hybrid
screens for FK506 interacting proteins.
For completeness, specificity of LEU2 gene activation was also
determined by replica plating yeast strains EJLPC and EJL2-8 on the
following yeast plates:
1. SC (His-, Ura-, Trp-, Leu-), 2% Galactose, 1iM
dexamethasone-FK506, pH 6.5.
2. SC (His-, Ura-, Trp-, Leu-), 2% Galactose, 1gM
dexamethasone-FK506, 10 pM FK506, pH 6.5.
3. SC (His-, Ura-, Trp-, Leu-), 2% Glucose, 1gM
dexamethasone-FK506, pH 6.5.
These plates were incubated at 30 oC and FK506 dependence was confirmed
for activation of the LEU2 gene also. No growth was observed for strains
EJL2-8 on plates 2 and 3 even at seven days.
The results of these experiments confirmed that the chemically
induced dimerization of the "hook" and "fish" fusion proteins was both a
viable and specific process. They also identified HBD fusions which
contained both the C656G and F620S mutations to be the most sensitive
"hook" fusion proteins and the "hook" fusion proteins of choice in future
yeast three-hybrid screens and applications of three-hybrid technology.
The next step in establishing the Yeast Three-Hybrid System as a powerful
new method for the detection of novel ligand-receptor interactions would
involve the screening of a cDNA library and isolation of specific yeast
colonies which harbored clones encoding known FK506 interacting
proteins.
Yeast Three-Hybrid Screens for FK506 Interacting Proteins
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Figure 3.26 Yeast three-hybrid screening sequence.
First Yeast Three-Hybrid Screen
We decided to screen a HeLa cDNA library to isolate genes which
encoded for known FK506 binding proteins and validate the Yeast Three-
Hybrid System as a powerful new method to directly clone receptors for
pharmacologically active, non-genetically encoded, small organic ligands.
The general strategy for this initial three-hybrid screen is outlined in
Figure 3.26. This strategy could potentially be used in all future yeast
three-hybrid screens by simply changing the orphan ligand used to
generate the hybrid "bait" ligand and possibly changing the source of the
cDNA library to one which was derived from a particular cell in which the
orphan ligand possessed potent biological activity.
A three-hybrid screening strain of yeast was prepared by initially
generating an EGY48 strain which harbored "hook" plasmid pEGHBD6
(Figure 3.19) and reporter plasmid pSH18-34. This strain was transformed
with a HeLa cDNA library subcloned into pJG4-5 and the primary
transformants were isolated and stored at -80 oC. Unlike a yeast two-
hybrid screen, where a new strain of yeast must be prepared for every
different screen conducted, the same screening strain of yeast can be
utilized in a number of different three-hybrid screens provided that the
orphan ligand possesses biological activity in the cell or tissue type from
which the cDNA library was constructed. This is possible because the
three-hybrid screening strain contains an optimized "hook" fusion protein
which is conserved from screen to screen compared to the two-hybrid
system "bait" fusion protein which is variable from screen to screen. In
the Yeast Three-Hybrid System the variability of each screen is contained
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within the endogenously added hybrid "bait" ligand which contains the
orphan ligand.
Yeast cells (9.0 x 106 cells) were plated onto SC ( His-, Ura-, Trp-, Leu-
), 2% Galactose, 1gM dexamethasone-FK506 plates and incubated at 30 oC.
Leu+ colonies were isolated from days 3-11 and the procedure to identify
colonies which harbored clones which potentially encoded for FK506
interacting proteins was followed from Figure 3.26. No colonies were
isolated which met all of the criteria outlined in this procedure for
specifically isolating FKBP interacting clones. The only colony of interest
was one which displayed a dexamethasone-FK506 dependent growth
pattern on media which lacked leucine but whose growth could not be
effectively competed by a ten-fold excess of the FK506 ligand. More than
likely this colony harbored a cDNA which encoded for one of several
proteins which are known to interact with the HBD of the glucocorticoid
receptor in the presence of steroid ligand (Onate, S.A. et al., 1995).
Surprisingly, when yeast strains EJL7 and EJL8 were plated onto the
same selection plates used in this initial yeast three-hybrid screen it took
these strains approximately 7-8 days to grow in the absence of leucine.
This length of time was considerably longer than had previously been
observed in the three-hybrid test case for these exact strains of yeast. At
this point the major experimental stumbling block, which would
ultimately insure the success of the three-hybrid screen, was overcome by
simply comparing the composition of the plates utilized in the current
three-hybrid screen to those used in the three-hybrid test case.
101
In the three-hybrid test case the plates, in addition to lacking
leucine, contained the chromogenic substrate X-Gal so that activation of
both the lacZ and LEU2 reporter genes could be tested on the same plates.
These plates were buffered to pH 7.0 using potassium phosphate buffer
since this is the optimum pH for 3-galactosidase activity. However, when
conducting a screen it is suggested that a double selection protocol, as that
used in the three-hybrid system test case, not be used since yeast do not
grow well at pH 7.0. Therefore, a two step selection procedure is normally
used with the initial selection for Leu + prototrophs followed by retesting
these colonies for activation of the lacZ gene either on separate plates or by
filter binding assay. For this reason this initial Yeast Three-Hybrid Screen
was conducted on plates which were not buffered to pH 7.0. Upon testing
the pH of the liquid stock solutions used to pour the three-hybrid
screening plates it was determined to be quite acidic with a pH between 4.5
and 5.0. It was reasoned that the dexamethasone-FK506 hybrid "bait"
ligand was not stable at pH 4.5-5.0, 30 OC for a significant amount of time
and for this reason a large amount of the hybrid "bait" ligand decomposed
over time resulting in the inefficient activation of reporter genes in the
EJL7 and EJL8 strains of yeast and failure of the initial three-hybrid screen
to uncover any colonies which displayed an FK506 dependent growth
pattern.
To determine whether the pH of the selection plates was
responsible for the sluggish growth which was observed for the EJL7 and
EJL8 strains of yeast and the failure of the initial three-hybrid screen new
plates were poured which were adjusted to pH 7 with potassium
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phosphate buffer. Yeast strains EJL7 and EJL8 were plated onto these SC
(His-, Ura-, Trp-, Leu-), 2% Galactose, 1gM dexamethasone-FK506, pH 7.0
plates and were incubated at 30 oC. At pH 7.0 growth in the absence of
leucine was initially observed as pinpoint colonies at 36 hours and
significant growth was observed at 72 hours. This proved that growth of
yeast strains EJL7 and EJL8 was severely compromised at pH 4.5-5.0 more
than likely as a result of dexamethasone-FK506 hybrid "bait" ligand
decomposition. With this information a second three-hybrid screen could
be conducted which would potentially stand a much better chance of
success than the initial three-hybrid screen.
Second Yeast Three-Hybrid Screen
A second screen of the HeLa library for FK506 interacting proteins
using yeast plates which were buffered to pH 7.0 with potassium
phosphate was conducted.
Yeast cells (1.2 x 107 cells) were plated onto SC ( His-, Ura-, Trp-, Leu-
), 2% Galactose, 1gM dexamethasone-FK506, pH 7.0 and the plates were
incubated at 30 OC. A total of 70 Leu + colonies were isolated from days 4-11
and the procedure from Figure 3.26 was followed to determine which of
these colonies harbored clones which potentially encoded for FK506
interacting proteins. Of the initial 70 colonies almost all exhibited growth
independent of the dexamethasone-FK506 hybrid "bait" ligand. Of the
small number which displayed "bait" dependent growth only a single
colony displayed growth in the absence of leucine which could be
competed 100% by a ten-fold excess of the FK506 ligand. The pJG4-5-cDNA
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containing plasmid was retrieved from this yeast colony and subjected to
restriction digestion with EcoRI and XhoI to determine the size of the
cDNA insert. The cDNA insert was approximately 1.5 kb in length. This
length was approximately 100 bases larger than the insert predicted for the
cDNA derived from the entire FKBP12 open reading frame (ORF) and 3'
untranslated region (UTR). Restriction mapping of this insert with EcoRI,
XhoI and either ApalI, NdeI, HpaI or AvaII all confirmed that the cDNA
insert contained the entire ORF and 3' UTR of FKBP12 along with
approximately 100 bases in the 5' UTR. The cDNA insert was manually
sequenced and determined to contain 90 nucleotides from the 5' UTR of
the FKBP12 gene. This insert coded for an in-frame fusion protein
between the transcriptional activation domain cassette and human
FKBP12 plus an additional 30 amino acids on the amino terminus of the
protein (Figure 3.27).
The results of this three-hybrid screen confirmed that the Yeast
Three-Hybrid System could in fact be utilized to selectively isolate yeast
colonies which harbored cDNAs encoding for FK506 interacting proteins.
We did however only isolate a single FKBP12 clone. In order to further
improve the efficiency of the three-hybrid screen for FK506 interacting
proteins we decided to determine the optimum pH for growth of the EJL7
and EJL8 strains of yeast so that a third three-hybrid screen could be
conducted with the hope of increasing the number and diversity of
FKBP12 clones which were isolated.
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Clone 1
GAA TTC GGC ACG AGG CGG GGC AGA GCC AGA GCC GTG
E F G T R R G R A R A V
GAA CCG CCG CCA GGT CGC TGT TGG TCC ACG CCG CCC
E P P P G R C W S T P P
GTC GCG CCG CCC GCC CGC TCA GCG TCC GCC GCC GCC
V A P P A R S A S A A A
ATG GGA GTG CAG GTG GAA ACC ATC TCC CCA GGA GAC GGG
M G V Q V E T I S P G D G
CGC ACC TTC CCC AAG CGC GGC CAG ACC TGC GTG GTG CAC
R T F P K R G Q T C V V H
TAC ACC GGG ATG CTT GAA GAT GGA AAG AAA TTT GAT TCC
Y T G M L E D G K K F D S
TCC CGG GAC AGA AAC AAG CCC TTT AAG TTT ATG CTA GGC
S R D R N K P F K F M L G
AAG CAG GAG GTG ATC CGA GGC TGG GAA GAA GGG GTT GCC
K Q E V I R G W E E G V A
CAG ATG AGT GTG GGT CAG AGA GCC AAA CTG ACT ATA TCT
Q M S V G Q R A K L T I S
CCA GAT TAT GCC TAT GGT GCC ACT GGG CAC CCA GGC ATC
P D Y A Y G A T G H P G I
ATC CCA CCA CAT GCC ACT CTC GTC TTC GAT GTG GAG CTT
I P P H A T L V F D V E L
CTA AAA CTG GAA TGA
L K L E *
Figure 3.27 FKBP12 clone isolated from the second three-hybrid screen for
FK506 interacting proteins. Bold nucleotide and amino acid sequence
indicates the FKBP12 ORF. Plain nucleotide and amino acid sequence
indicates nucleotides and amino acids derived from the FKBP12 5' UTR.
Underlined nucleotide and amino acid sequence indicates nucleotides and
amino acids at the fusion point between the transcriptional activation
cassette and the FKBP12 protein isolated through the screen.
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Optimization of pH for Growth of yeast strains EJL7 and EJL8
In order to determine the optimum pH for growth of the EJL7 and
EJL8 strains of yeast on leucine deficient medium, plates were poured
which were buffered at several pHs. Yeast strains EJLPC, EJL7, and EJL8
were plated onto SC (His-, Ura-, Trp-, Leu-), 2% Galactose, 1gM
dexamethasone-FK506 plates buffered at pH 7.0, pH 6.5 and pH 5.9 with
potassium phosphate buffer. These yeast were plated and incubated at 30
oC. Optimum growth was observed at pH 6.5 where pinpoint colonies
were observed at 24 hours and grew at a rate which was almost equivalent
to the positive control EJLPC. With the pH optimized for most efficient
growth on leucine deficient medium a third yeast three-hybrid screen for
FK506 interacting proteins could be conducted.
Third Yeast Three-Hybrid Screen
With the second three-hybrid screen showing encouraging results a
new screen was conducted with the hope of isolating a greater number of
FK506 interacting clones. For this screen the "hook" fusion protein
encoded by pEGHBD7 was used. This "hook" fusion protein induced
slightly greater activation of the lacZ and LEU2 genes in the three-hybrid
system test case than the "hook" fusion protein encoded by pEGHBD6 used
in the first two yeast three-hybrid screens for FK506 interacting proteins.
A second three-hybrid screening strain of yeast was prepared by
initially generating an EGY48 strain which harbored "hook" plasmid
pEGHBD7 and reporter plasmid pSH18-34. This strain of yeast was
transformed with a Jurkat (Human T-Cell) cDNA library subcloned into
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pJG4-5 to afford primary transformants which were stored at -80 OC.
Yeast cells (1.62 x 106 cells) were plated onto SC (His-, Ura-, Trp-,
Leu-), 2% Galactose, 1•M dexamethasone-FK506 plates, pH 6.5 and
incubated at 30 OC. A total of 101 Leu + colonies were isolated from days 4-
10 and the procedure to identify FK506 interacting clones was followed
from Figure 3.26. Of the initial colonies, 92 displayed "bait" independent
growth, and 3 displayed 100% FK506 competition for growth in the absence
of leucine. The pJG4-5-cDNA containing plasmid was retrieved from
these yeast colonies and subjected to restriction digestion with EcoRI and
Xhol to determine the size of the cDNA insert. Two contained cDNA
inserts which were approximately 1.3 kb and the other approximately 1.2
kb. The cDNA inserts of these plasmids were sequenced by both manual
and automated sequencing. Sequencing results showed that two different
FKBP12 clones were isolated, one in duplicate. These two overlapping
clones encoded for in-frame fusion protein between the transcriptional
activation domain cassette and human FKBP12, one with an additional 24
amino acids on the amino terminus of the protein and the second with a 5
amino acid deletion into the amino terminus of the FKBP12 protein
(Figure 3.28).
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Clone 1
GAA TTC GGC ACG AGG CGG GAA CCG
E F G T R R E P
ACG CCG CCC GTC GCG CCG CCC GCC
T P P V A P P A
Clone 2
ATG GGA GTG CAG GTG GAA ACC
M G V Q V E T
CGC ACC TTC CCC AAG CGC GGC
R T F P K R G
CCG CCA GGT CGC TGT TGG TCC
P P G R C W S
CGC TCA GCG TCC GCC GCC GCC
R S A S
ATC TCC
I S
CAG ACC
Q T
A A A
CCA GGA GAC GGG
P G D G
TGC GTG GTG CAC
C V V H
TAC ACC GGG ATG CTT GAA GAT GGA AAG AAA TTT GAT TCC
Y T G M L E D G K K F D S
TCC CGG GAC AGA AAC AAG CCC TTT AAG TTT ATG CTA GGC
S R D R N K P F K F M L G
AAG CAG GAG
K Q E
GTG ATC
V I
CAG ATG AGT GTG GGT
Q M S V G
CGA GGC
R G
CAG AGA
Q R
TGG GAA
W E
GCC AAA
A K
GAA GGG GTT GCC
E G V A
CTG ACT ATA TCT
L T I S
CCA GAT TAT GCC TAT GGT GCC ACT GGG CAC CCA GGC ATC
P D Y A Y G A T G H P G I
ATC CCA CCA CAT GCC ACT CTC GTC TTC GAT GTG GAG CTT
I P P H A T L V F D V E L
CTA AAA CTG GAA TGA
L K L E *
Figure 3.28 FKBP12 clones isolated from the third three-hybrid screen for
FK506 interacting proteins. Bold nucleotide and amino acid sequence
indicates the FKBP12 ORF. Plain nucleotide and amino acid sequence
indicates nucleotides and amino acids derived from the FKBP12 5' UTR.
Underlined nucleotide and amino acid sequence indicates nucleotides and
amino acids at the fusion point between the transcriptional activation
cassette and the FKBP12 protein isolated through the screen.
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Conclusion
The studies conducted in this chapter have proven that the Yeast
Three-Hybrid System is a viable new method for the determination and
cloning of receptors for pharmacologically active, non-genetically encoded,
small organic ligands and have set the foundation for the future use of
this powerful new technology by both biologists and chemists seeking to
dissect complex biological systems through a pharmacological approach.
The use of FK506 as the "orphan ligand" in the Yeast Three-Hybrid
screen allows for the direct comparison of this powerful new methodology
to classical methods for determining novel ligand-receptor interactions.
Classical methods would require several months to several years of labor
intensive work to purify a novel receptor and clone the gene which
encoded this receptor. Although the scientific information ultimately
derived from the discovery of such a receptor would be quite significant it
would still invovlve an expensive, labor intensive, and time consuming
process. Using the Yeast Three-Hybrid System we were able to clone the
FKBP12 gene in just three weeks from the time the Yeast Three-Hybrid
System was optimized. Additionally, the yeast three-hybrid screen for
FK506 interacting proteins was performed by a single individual, involved
very little expense, and the techniques used for yeast manipulation, to
determine positive colonies, and plasmid isolation for sequencing were
incredibly simple.
We believe that the speed and simplicity of the Yeast Three-Hybrid
System will significantly facilitate the discovery of novel receptors for
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interesting pharmacologically active ligands and enrich our
understanding of many complex biologically systems. Additionally, the
Yeast Three-Hybrid System possesses a number of applications to drug
discovery efforts. In addition to providing novel targets for specific
therapeutic intervention, creative applications of three-hybrid technology,
in both yeast and mammalian cells, might be used to develop high-
throughput assays to rapidly identify novel ligands which bind to, and
potentially modulate the activity of, any important protein involved in a
particular disease state. The potential of Three-Hybrid Technology appears
to be limitless and only time will tell just how powerful this method can
really become.
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Chapter 4
Experimental Procedures
Materials
Materials for Synthetic Organic Chemistry
Dexamethasone was purchase from Research Biochemicals Inc.
FK506 was a gift from Fujisawa Pharmaceuticals Company. All other
reagents and solvents were commercial grade and purchased from
Aldrich, EM Science, or Mallincrodt Chemical and were used without
further purification except for tetrahydrofuran and methylene chloride
which were distilled under nitrogen or argon from sodium benzophenone
ketyl and calcium hydride respectively. Analytical thin-layer
chromatography (TLC) was performed on EM Science pre-coated glass-
backed silica gel 60 F-254 0.25 mm plates with staining using an ethanolic
solution of 3% p-anisaldehyde containing 0.5% concentrated sulfuric acid.
Preparative chromatography was performed on ANALTECH pre-coated
glass-backed silica gel GF-254 1.0 mm plates. Flash chromatography was
performed using 230-400 mesh Merck silica gel.
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Materials for Molecular Biology and Yeast Experiments
Rat glucocorticoid receptor encoding plasmids 6RGR-WT and
6RGR-C656G were obtained from Dr. Keith Yamamoto (University of
California at San Francisco). FKBP12 encoding plasmid pGEX-FKBP12 was
obtained from Suming Kong (M.I.T. Liu Lab). Yeast two-hybrid system
plasmids pEG202, pJG4-5, pSH18-34, and pSH17-4 along with yeast strain
EGY48 were obtained from Dr. Roger Brent (Harvard Medical
School/Massachusetts General Hospital). Library encoding pJG4-5
plasmids containing the HeLa and Jurkat cDNA libraries were obtained
from Dr. Roger Brent and Dr. Brian Seed (Harvard Medical School)
respectively. KC8 bacteria were obtained from Dr. Chris Kaiser
(Massachusetts Institute of Technology). PCR primers and pJG4-5
universal sequencing primer were purchased from Biosynthesis, Inc. PCR
Amplification Kit was purchased from Perkin Elmer. Restriction
enzymes, reaction buffers, Bovine Serum Albumin, DNA Ligase Buffer
and T4 DNA Ligase were purchased from New England Biolabs. NuSieve
GTG Low melt agarose was purchased from FMC Bioproducts. Amino
acids, salts, D(+)Galactose, Ampicillin, Sodium Dodecyl Sulfate, Salmon
Sperm DNA, and Polyethylene Glycol (MW 3350) were purchased from
Sigma. X-gal was purchased from Boehringer Mannheim. Qiagen kits
were purchased from the Qiagen Company. Sequenase Version 2.0 DNA
Sequencing Kit and all sequencing buffers were purchased from U.S.
Biochemical. [35S] ATP was purchased from Amersham Life Science (10
mCi/mL). Ultra Pure Sequagel Sequencing System solutions were
purchased from National Diagnostics.
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Methods
Synthetic Chemistry Methods
Synthesis of the dexamethasone-FK506 hybrid "bait" ligand
Dexamethasone 17P-N-(10-Amino) decylcarboxamide primary amine
The dexamethasone 17P-N-(10-Amino) decylcarboxamide primary
amine was synthesized according to previously published procedures
(Manz et al., 1983).
Dexamethasone 170-carboxylic acid (9-Fluoro-16a-methyl-110,17-
dihydroxy-3-oxo-1,4-androstadiene-17f-carboxylic acid). Dexamethasone
(0.277 g, 0.71 mmol) was placed in a 250 mL roundbottom flask and to this
flask was added ethanol (50 mL), HIO4 ( 0.025 M, 30 mL), H2SO4 (2.5 M, 0.95
mL) and H20 (18.75 mL). The reaction was allowed to stir at room
temperature for 18 hours. The ethanol was removed in vacuo, and a
white precipitate fell out of solution. This precipitate was extracted with
ethyl acetate, dried by filtration through MgSO 4, and concentrated in
vacuo to afford quantitative yield of the product as a white powder. The
product was carried on without further purification.
Dexamethasone 17P-N-Hydroxysuccinimidyl carboxyester (N-
Hydroxy-succinimidyl 9-Fluoro-16a-methyl-113,17-dihydroxy-3-oxo-1,4-
androstadiene-17p-carboxylic acid). Dexamethasone 170-carboxylic acid
(0.207 g, 0.55 mmol) was added to a 50 mL roundbottom flask along with
dicyclohexylcarbodiimide (0.112 g, 0.55 mmol) and N-hydroxysuccinimide
(0.063 g, 0.55 mmol). The flask was pumped under vacuum and filled
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with argon. Anhydrous tetrahydrofuran (10 mL) was added to the reaction
vessel and the reaction was allowed to proceed at room temperature.
After two hours a precipitate formed and the reaction was continued for
an additional 14 hours. The dicyclohexylurea was removed by filtration
and the organic phase was concentrated in vacuo to afford crude product
as a white powder. The product was purified by flash chromatography
(SiO 2 4% methanol/chloroform) to afford 0.205 g of product (73%).
Dexamethasone 170-N-(10-Amino) decylcarboxamide ( N- (10-
Amino) decyl 9-Fluoro-16a-methyl-113,17-dihydroxy-3-oxo-1,4-andro-
stadiene-17P-carboxamide). Dexamethasone 17P-N-Hydroxysuccinimidyl
carboxyester (0.090 g, 0.190 mmol) was dissolved in tetrahydrofuran (3 mL)
and to this solution was added 1,10-diaminodecane (0.97 g, 0.562 mmol,
2.95 equiv.). The reaction was allowed to stir at room temperature for 12
hours before being concentrated in vacuo. The product was purified by
preparative thin-layer chromatography (SiO 2 10% methanol/chloroform
1% triethylamine) to afford 0.090 g of a white solid (89%).
Synthesis of the 24,32-Bis(tert-butyldimethylsilyloxy)-FK506 N-Hydroxy-
succinimidyl Mixed Carbonate Activated Ester
The 24,32-Bis(tert-butyldimethylsilyloxy)-FK506 N-Hydroxysuccin-
imidyl Mixed Carbonate Activated Ester was synthesized according to
previously published procedures (Pruschey et al, 1994).
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24,32-Bis(tert-butyldimethylsilyloxy)-FK506. FK506 (0.118 g, 0.147
mmol) was added to a 10 mL roundbottom flask which was pumped
under vacuum, and filled with argon. Anhydrous methylene chloride (3.8
mL) was added and the reaction vessel was cooled in an ice bath for 15
minutes. To this reaction vessel was added 2,6 Lutidine (0.176 g, 1.65
mmol, 192 gL, 11.2 equiv.) and tert-Butyldimethylsilyltrifluoromethane-
sulfonate (0.216 g, 0.819 mmol, 188 gL, 5.5 equiv.). The reaction was
allowed to proceed for one hour before being quenched with saturated
sodium bicarbonate and extracted with diethyl ether. The organic phase
was dried by filtration through MgSO 4, concentrated in vacuo, and the
product was purified by flash chromatography (SiO 2 33% ether/hexanes) to
afford 0.150 g of 24,34-Bis(tert-butyldimethylsilyloxy)-FK506 (98%).
24,32-Bis(tert-butyldimethylsilyloxy)-FK506 Aldehyde. 24,34-Bis
(tert-butyldimethylsilyloxy)-FK506 (0.147 g, 0.141 mmol) was dissolved in
tetrahydrofuran (4.2 mL) and water (0.260 mL). To this solution was added
0.157 M aqueous OsO4 (181 gL, 0.0285 mmol, 0.2 equiv.) and N-methyl-
morpholine N-oxide ( 0.083 g, 0.709 mmol, 5 equiv.). The reaction was
allowed to stir at room temperature for three hours. The reaction was
diluted with 0.840 mL of a 50% aqueous methanol solution and sodium
periodate (0.285 g, 1.33 mmol, 10 equiv.) was added. After 15 minutes a
white precipitate formed and the reaction was allowed to proceed for an
additional two hours. The reaction mixture was diluted with diethyl ether
and the white precipitate formed a paste. The organic phase was decanted
and saturated sodium bicarbonate was added. The aqueous phase was
extracted with diethyl ether and the organic phases were washed with
copious amounts of saturated sodium bicarbonate, brine, and water. The
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diethyl ether was dried by filtration through MgSO 4 and concentrated in
vacuo to afford crude product. The product was purified by flash
chromatography (SiO 2, 50% ether/hexanes) in several batches. (Caution:
This reaction seems to be very, very sensitive. The organic phase must be
extensively washed so as to avoid product decomposition).
24,32-Bis(tert-butyldimethylsilyloxy)-FK506 Alcohol. 24,34-Bis
(tert-butyldimethylsilyloxy)-FK506 Aldehyde (0.031 g, 0.0297 mmol) was
placed in a 5 mL roundbottom flask which was pumped under vacuum
and filled with argon. Anhydrous tetrahydrofuran (1 mL) was added to
the flask and the reaction mixture, which possessed a grey/black tint was
cooled to -78 OC for 15 minutes. To this reaction vessel was added lithium
tris [(3-ethyl-3-pentyl)oxy] aluminum hydride (0.5 M in tetrahydrofuran,
100 gL, 0.05 mmol, 1.67 equiv.). The reaction was allowed to proceed for
one hour before being quenched with saturated ammonium chloride and
extracted with diethyl ether. The ether layered was dried by filtration
through MgSO4 and concentrated in vacuo. The product was purified by
flash chromatography (SiO 2 50% ether/hexanes) to afford 0.018 g of
product as a clear colorless oil (58%).
24,32-Bis(tert-butyldimethylsilyloxy)-FK506 N-Hydroxysuccinimidyl
Mixed Carbonate. 24,34-Bis(tert-butyldimethylsilyloxy)-FK506 Alcohol
(0.018 g, 0.017 mmol) was placed in a 5 mL roundbottom flask and
dissolved in acetonitrile (1 mL). To this flask was added 2,6 Lutidine (0.018
g, 0.170 mmol, 20 gL, 10 equiv.) and N-N'- disuccinimidyl carbonate (0.022
g, 0.085 mmol, 5 equiv.) The reaction was allowed to stir at room
temperature for 18 hours before being concentrated in vacuo and purified
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by flash chromatography (SiO 2 66% ether/hexanes) to afford 0.014 g of
product as a clear colorless oil (70%).
Synthesis of Dexamethasone 173-N-(10-Amino) decylcarboxamide-FK506.
(dexamethasone-FK506 hybrid "bait" ligand)
Dexamethasone 17P-N-(10-Amino) decylcarboxamide-24,32-Bis(tert-
butyldimethylsilyloxy)-FK506. 24,32-Bis(tert-butyldimethylsilyloxy)-FK506
N-Hydroxysuccinimidyl Mixed Carbonate (0.008 g, 0.0067 mmol) and
Dexamethasone 17P-N-(10-Amino) decylcarboxamide (0.020 g, 0.037 mmol,
5.5 equiv.) were placed in a 5 mL roundbottom flask and dissolved in
anhydrous tetrahydrofuran (1 mL) and excess triethylamine. The reaction
was allowed to proceed at room temperature for three hours. At this time
the reaction was quenched with saturated sodium bicarbonate and the
aqueous phase was extracted with ethyl acetate. The organic layer was
dried by filtration through MgSO4 and concentrated in vacuo. The
product was carried on to the next step without further purification.
Dexamethasone 17P-N-(10-Amino) decylcarboxamide-FK506.
Dexamethasone 173-N-(10-Amino) decylcarboxamide-24,32-Bis(tert-
butyldimethylsilyloxy)-FK506 (approximately 0.010 g, 0.0062 mmol) was
dissolved in acetonitrile (1 mL) and placed in a 15 mL polypropylene
Falcon tube. To this solution was added 49% hydrofluoric acid (100 gL)
and the reaction was allowed to proceed at room temperature for 24 hours.
The reaction was quenched with saturated sodium bicarbonate and the
aqueous phase was extracted with ethyl acetate. The organic phase was
dried by filtration through MgSO4 and concentrated in vacuo. The
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product was purified by preparative thin-layer chromatography (SiO 2 5%
methanol/methylene chloride) to afford 0.0037 g of product (40% for two
steps). 1H NMR (500 MHz, CDCl3) 8 7.19 (d, 1H, J=9.8 Hz), 6.56 (t, 1H), 6.33
(d, 1H, J=9.8 Hz), 6.11 (s, 1H), 5.38 and 5.17 (rotamers, br s, 1H), 5.24 (1
rotamer, br d, J=8.6 Hz), 5.03 (m, 1H), 4.42 (br d, 1H, J=11 Hz), 4.38 ( br d, 1H,
J=5.4 Hz), 3.73 (d, 1H, J=7.7 Hz), 3.61 (d, 1H, J=8.1 Hz), 3.45, 3.43, 3.40, 3.39,
3.31, 3.30 (rotamers of 3 methoxyls s, 9H) 2.84 and 2.68 (rotamers, d, 1H,
J=14.2 Hz). PDMS (m/z) Calculated for C75H 116N 30 1 8 F 1365.8. Found
1365.9 (M+H)+ , 1389.9 (M+Na)+.
,in
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Molecular Biology Methods
Yeast Three-Hybrid System "hook" and "fish" plasmid construction
Generation of "hook" constructs pEGHBD 1-7
PCR Primers
Primer Sequence rGR Position
1 5'-GCATCAATrGGCAGGAGTCTCACAAGACACT-3' 5'-a.a. 524
2 5'-GCATCAATTGTATCGGAAATGTCTTCAGGCT-3' 5'-a.a. 497
3 5'-GCATCTCGAGTCATTTTTGATGAAACAG-3' 3'-a.a. 795
4 5'-TCATGGATGTCTCTCATGGCA-3'
Bold Designates Restriction Site: Primer 1&2 MfeI and Primer 3 XhoI
Underline Designates Mutation: Codon 620 F to S Mutation.
Polymerase Chain Reaction (PCR) Amplification of Hormone Binding
Domain Inserts for pEGHBD 1-3
Miniprep DNA (0.5-1 gg) from either 6RGR-WT or 6RGR-C656G
was resuspended in a total volume of 100 gL containing Taq DNA
Polymerase (2.5 Units)/Vent DNA Polymerase (0.2 Units), (2 mM) each of
dGTP, dATP, dTTP, dCTP, (2 mM) MgC12, 20 pmols of forward primer,
either Primer 1 or Primer 2, and reverse primer, Primer 3, and 10X
reaction buffer (10 gL). 20 amplification cycles consisting of denaturation
at 94 oC for 1 min., annealing at 55 OC for 1 min., and extension at 72 oC
for 2 min. were performed.
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Polymerase Chain Reaction (PCR) Amplification of Hormone Binding
Domain Inserts for pEGHBD 4-7 (Generation of F620S Mutation)
Step 1
Miniprep DNA (0.5-1 tg) from either 6RGR-WT or 6RGR-C656G
was resuspended in a total volume of 100 jtL containing Taq DNA
Polymerase (2.5 Units)/Vent DNA Polymerase (0.2 Units), (2 mM) each of
dGTP, dATP, dTTP, dCTP, (2 mM) MgCl2, 10 pmols of forward mutagenic
primer, Primer 4, and reverse primer, Primer 3, and o10X reaction buffer (10
jL). 20 amplification cycles consisting of denaturation at 94 OC for 1 min.,
annealing at 55 oC for 1 min., and extension at 72 OC for 2 min. were
performed.
Step 2
The 1PCR reaction mixtures were split into two 50 gL portions. One-
half the original quantity of dGTP, dATP, dTTP, dCTP, MgCl2, and 10x
reaction buffer (10 gL), and 20 pmols of forward primer, either Primer 1 or
Primer 2, were added and the volume was adjusted to 100 gL. 20
amplification cycles consisting of denaturation at 94 OC for 1 min.,
annealing at 55 oC for 1 min., and extension at 72 OC for 2 min. were
performed.
After PCR amplification the reaction mixtures were adjusted to a
final volume of 120 RL by the addition of 20 gL of TE (10 mM Tris-HC1, pH
8.0, 0.1 mM EDTA). To each mixture was added 100 gL of
phenol/chloroform followed by a 20 second vortex. The mixture was
spun at 4 °C in a micrufuge for three minutes and the aqueous phase was
reextracted with an additional 100 tL of phenol/chloroform. To each
aqueous phase was added 75 gL of ammonium acetate and 350 jL of
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absolute ethanol. The samples were placed at -20 OC for one hour and
spun at 4 oC in a microfuge for twenty minutes. The supernatant was
removed and the amplified PCR product was resuspended in 10 gL of TE
(10 mM Tris-HC1, pH 8.0, 0.1 mM EDTA).
Restriction Digestion of Hormone Binding Domain PCR Products
PCR amplified DNA (5 gQL), from each of the aforementioned PCR
reactions, was resuspended in a total volume of 20 gL containing 10X
reaction Buffer 4 (2 gL), 10X BSA (2 gL), MfeI (5 Units), and XhoI (10 units).
The DNA was digested in a water bath at 37 oC for one hour.
Restriction Digestion of pEG202
pEG202 plasmid DNA (0.5-1 gg) was resuspended in a total volume
of 20 p.L containing 10X reaction Buffer 4 (2 gL), 10X BSA (2 gL), EcoRI (10
Units), and XhoI (10 Units). The DNA was digested in a water bath at 37 oC
for one hour.
Standard Procedure for In-Gel Ligations
Digested PCR products and pEG202 were loaded onto a 1.5%
Nusieve-low-melt agarose gel poured with TAE (40 mM Tris-acetate, 1
mM EDTA) and electrophoresed in a cold room at 80V. The digested DNA
bands were excised under long-wavelength UV light using a hand held
lamp. Each gel slice was transferred directly to a sterile 1.5 mL
microcentrifuge tube. The gel was melted in a 65 oC heat block for 10
minutes and immediately transferred to a 37 OC water bath and incubated
for 5 minutes. In sterile 1.5 mL microcentrifuge tubes PCR amplified and
digested hormone binding domain inserts were combined with digested
124
pEG202 (in 9:1 and 1:9 ratios) in a total volume of 10 gL of melted agarose.
These tubes were placed back in the 65 OC heating block for 5 minutes
followed by transfer to the 37 oC water bath for 5 minutes. To each of these
tubes was added 10 gL of a 2X Ligation Solution containing 2X DNA Ligase
Buffer (100 mM Tris-HC1, pH 7.8, 20 mM MgCl 2, 20 mM DTT, 2 mM ATP,
and 50 tg/mL BSA) and T4 DNA Ligase (400 Units). The tubes were
immediately placed on ice, transferred to a 16 oC heating block in a cold
room and incubated overnight. The samples were diluted with 10 gtL of
TE (10 mM Tris-HC1, pH 8.0, 0.1 mM EDTA), incubated at 65 OC for 10
minutes and 37 oC for 5 minutes. The ligated plasmid mixture was used to
transform E. coli strain DH5u
Standard Procedure for Bacterial Heat Shock Transformation
Competent E. coli DH5cx (50 giL) were transformed by the addition of
DNA from the In-Gel Ligation mixture (5-10 gL) and incubated on ice for
20 minutes. The transformation mixture was heat shocked at 37 oC for 3-5
minutes and allowed to recover from heat shock by incubation for 1 hour
at 37 OC in 500 gL of sterile Luria-Bertani Broth (LB). Bacteria were
pelleted, resuspended in 200 - 300 gL of LB and plated onto LB/ampicillin
(amp) plates (50-100 gg/mL). Plates were incubated at 37 oC for 12 hours to
allow transformed bacteria to grow.
Standard Procedure for Bacterial Minipreps
Single colonies from LB/amp plates were used to inoculate 2 mL of
liquid LB/amp (50-100 gg / mL) which was allowed to grow at 37 oC for 8-
12 hours. The E. coli solutions were transferred to a 1.5 mL
microcentrifuge tube and pelleted by centrifugation for 15 seconds. The
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supernatant was removed and 150 gL of SET (20% Sucrose, 50 mM Tris-
HCI, pH 8.0,50 mM EDTA) and 5 gL of RNAse A (10 mg/mL) was added to
each tube followed by vigorous vortexing and incubation at room
temperature for 10 minutes. Alkali Lysis Solution (0.2M NaOH, 1% SDS)
(350 gQL) was added, and the tubes were inverted until the solution cleared
and were placed on ice for 5 minutes. To each solution was added 250 gL
of cold 3M sodium acetate (pH 4.8) followed by incubation on ice for 10
minutes. Tubes were centrifuged at 4 oC for 10 minutes and the
supernatant was transferred to a new 1.5 mL microcentrifuge tube which
was filled with room temperature isopropanol, mixed, and centrifuged for
5 minutes at room temperature. The precipitated DNA was washed with
70% ethanol, dried, and resuspended in 100 gL of TE (10 mM Tris-HC1, pH
8.0, 0.1 mM EDTA).
Confirmation of Hormone Binding Domain Containing Constructs
Plasmids harboring the hormone binding domain inserts were
confirmed by restriction digestion of miniprep DNA with Scal and XhoI
followed by 1.5% agarose gel electrophoresis in TBE (45 mM Tris-borate, 1
mM EDTA) with ethidium bromide visualization. Vector alone afforded
three fragments at approximately 5.75, 2.40, and 1.65 kb. Vector plus
hormone binding domain insert afforded four fragments at approximately
5.75, 2.40, 1.98 or 1.90 (depending on the length of the hormone binding
domain insert) and 0.54 kb.
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Generation of "fish" construct pIG4-5-FKBP12
PCR Primers
Primer Sequence FKBP12 Position
5 5'-GCATGAATrCATGGGAGTGCAGGTGGAAAC-3' 5'-a.a. Met o
6 5'-GCATGAATTrCTCATTCCAGTITTTAGAAGC-3' 3'-a.a. 107
Bold Designates Restriction Site: Primer 5 & 6 EcoRI
Miniprep DNA (0.5-1 kg) from pGEX-FKBP12 was resuspended in a
total volume of 100 gL containing Taq DNA Polymerase (2.5 Units)/Vent
DNA Polymerase (0.2 Units), (2 mM) each of dGTP, dATP, dTTP, dCTP, (2
mM) MgCl2, 20 pmols of forward primer, Primer 5, and reverse primer,
Primer 6, and 10X reaction buffer (10 gL). 20 amplification cycles consisting
of denaturation at 94 OC for 1 min., annealing at 55 OC for 1 min., and
extension at 72 OC for 2 min. were performed.
The PCR product was isolated, digested with EcoRI and ligated into
pJG4-5 cut with EcoRI following the Standard Procedure for In-Gel
Ligation. The resulting ligated pJG4-5 plasmid was transformed into E.
coli DH5a(x according to the Standard Bacterial Heat Shock Transformation
Procedure and pJG4-5-FKBP12 plasmid DNA was isolated according to the
Standard Bacterial Miniprep Procedure. Presence and orientation of the
FKBP12 insert was confirmed by restriction digestion with ApaLI and XhoI
followed by 1.5% agarose gel electrophoresis in TBE (45 mM Tris-borate, 1
mM EDTA) with ethidium bromide visualization. Desired constructs
afford a 0.35 kb fragment.
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Procedures for the Construction and Manipulation of Yeast Strains EJL1-8
for the Three-Hybrid System Test Case
Standard Procedure for Normal Lithium Acetate Yeast Transformations
Yeast strain EGY48 (MAT ac, trpl, ura3, his3, lexAop-LEU2) was
cultured overnight in rich complex medium (1% yeast extract, 2%
peptone, 1% glucose) at 30 oC. This yeast culture was used to seed a 10 mL
culture in rich medium (OD600 < 0.2) which was allowed to expand for at
least two doublings (OD600 approximately 0.8) before being harvested.
Yeast cells were pelleted in a 15 mL Falcon tube at 2,500 rpm in a Beckman
GS-6R table top centrifuge for 5 minutes. The yeast pellet was washed
with cold ddH 20, 1 mL of TE (10 mM Tris-HC1, pH 7.5, 0.1 mM EDTA)/100
mM lithium acetate, pH 7.5, and resuspended in 500 gL of TE (10 mM Tris-
HC1, pH 7.5, 0.1 mM EDTA)/100 mM lithium acetate, pH 7.5. Yeast were
aliquoted in 50 gL portions to 1.5 mL microcentrifuge tubes for each
individual transformation. To each tube was added 5 gL (0.5-1.0 gg) of
miniprep DNA, 5 p•L of 10 mg/mL sheared salmon sperm carrier DNA
and 300 gL of a 40% PEG (Polyethylene Glycol)/TE (10 mM Tris-HC1, pH
7.5, 0.1 mM EDTA)/100 mM lithium acetate, pH 7.5, solution prepared
fresh. The transformation mixture was allowed to rotate at room
temperature for 30 minute before being heat shocked in a 42 oC water bath
for 15 minutes. The yeast were pelleted in a microfuge, washed with 500
gL of TE (10 mM Tris-HC1, pH 7.5, 0.1 mM EDTA)/ 100 mM lithium
acetate, pH 7.5, resuspended in 200 gL of TE (10 mM Tris-HC1, pH 7.5, 0.1
mM EDTA) and plated onto the appropriate selection plates. Plates were
allowed to incubate at 30 oC for 2-3 days for transformants to grow. Single,
double, and triple transformations were performed with pEG202, pSH18-
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34, pJG4-5, and pSH17-4 plasmids using 5 gL of miniprep DNA for each
plasmid used. All strains used in these studies were stored as frozen
stocks by growing overnight at 30 oC and diluting with an equivalent
volume of a sterile 30% glycerol solution (15% final concentration of
glycerol).
This procedure was followed exactly for yeast which already
harbored plasmids except the yeast were cultured in Synthetic Complete
medium containing 2% glucose and lacking nutrients for the particular
selectable marker complemented by the previously transformed plasmid.
Standard Procedure for Pouring Yeast Plates
Composition of Synthetic Complete(SC) Dropout Plate and Media(500 mL)
250 mL 2XS
250 mL 4% Agar
25 mL 40% Glucose or Galactose
25 mL Amino Acid Stock Solution
5.0 mL 0.2% Adenine
5.0 mL 0.2% Uridine
4.5 mL 1% Leucine
1.5 mL 1% Lysine
1.0 mL 1% Arginine
1.0 mL 1% Histidine
1.0 mL 1% Tryptophan
20X Amino Acid Stock Solution
(700 mL ddH20)
0.28 g Methionine
0.42 g Tyrosine
0.42 g Isoleucine
0.70 g Phenylalanine
1.40 g Glutamic Acid
1.40 g Aspartic Acid
2.10 g Valine
2.80 g Threonine
5.60 g Serine
X-gal (20 mg/mL solution in DMF) used at a 1:250 Dilution
10X Potassium Phosphate Buffers 0.7 M pH 7.0, 6.5, and 5.9.
pH 7.0 Used for X-gal assays and Screen #2
pH 6.5 Used for Screen #3
All potassium phosphate buffer was added to a final concentration of
0.07M (Stock Solution 0.7 M).
dexamethasone-FK506 was stored at -20 oC in ethanol at 5 or 10 mM.
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Plates were poured by initially heating the 4% Agar and 2X S
solutions in a microwave on medium power for seven to eight minutes.
The agar and S were combined and allowed to cool to less than 65 oC
(warm to touch) before a solution containing either glucose or galactose
and amino acids (minus those used as selectable markers) was added to the
agar/S solution. The appropriate amounts of X-gal, dexamethasone-
FK506, FK506, or phosphate buffer were added at this point, the solution
was mixed by either swirling or pipetting, and plates were poured which
contained between 18 and 22 mLs of solution. Plates were allowed to gel
overnight and dry for one day at room temperature before being stored in
a cold room at 4 oC. (dexamethasone-FK506 plates are stable at 4 OC for 1-2
months, X-gal plates lose maximum sensitivity within one month of
storage at 4 OC). Drugs and nutrients were also added to pre-poured plates
by dissolving in 300 gL of ddH20, spreading on the plates with a sterile
spreader, and allowing the plates to dry at 37 oC for approximately 2 hours.
Standard Procedure for Replica Plating
A master plate for replica plating was prepared by streaking
appropriate yeast strains onto a SC (His-, Ura-, Trp-), 2% Glucose plate with
a sterile toothpick. This plate was incubated at 30 oC for 2 days to allow
yeast to grow in heavy patches. These yeast were transferred during the
replica plating procedure by touching the yeast from the master plate to a
piece of standard black velvet placed over an inverted 400 mL beaker and
secured by an elastic band. Appropriate plates were then touched to this
velvet and allowed to incubate at 30 oC.
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Procedures for the FK506 Interacting Protein Yeast Three-Hybrid Screens
Standard Procedure for High Efficiency Lithium Acetate Transformations
(Library Transformations)
1. Inoculate a 10 mL culture of SC (His-, Ura-), 2% Glucose with EGY48
containing "hook" plasmid pEGHBD 6 or 7 and reporter plasmid pSH18-34
and allow to grow overnight at 30 oC.
2. Dilute overnight culture in 100 mL of SC (His-, Ura-), 2% Glucose to an
OD 600 of < 0.5 and culture at 30 OC until OD 600 is approximately 2.00
(Usually 3-4 Hours).
3. Pellet yeast cells at room temperature in a Beckman GS-6R table top
centrifuge at 2,500 rpm for 10 minutes.
4. Remove media with a pipette and resuspend the pellet with gentle
swirling in 50 mL of sterile ddH 20.
5. Pellet the yeast cells as in Step 3.
6. Remove the ddH20 with a pipette, resuspend the yeast cells with gentle
pipetting in 100 mM lithium acetate, pH 7.5 (2 mL), and transfer to two 1.5
mL microcentrifuge tubes.
7. Pellet the yeast cells in a microfuge at 16,000 rpm for 15 seconds and
remove the lithium acetate.
8. Resuspend the yeast cells in a final volume of 1.00 mL of 100 m M
lithium acetate (Usually requires the addition of 800 gL of 100 mM lithium
acetate to 200 gL of yeast cells).
9. Transfer 50 gL of the yeast solution to 18-1.5 mL microcentrifuge tubes,
pellet the cells at 16,000 rpm for 15 seconds and gently remove the
supernatant.
10. To each tube add the following reagents in this specific order:
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240 gL of 50% Polyethylene Glycol (PEG)
36 gL of 1.0 M lithium acetate
5 gL of Sheared Salmon Sperm DNA (10 mg/mL) (Salmon Sperm
DNA was sheared and was stored at -20 OC in 100-200 mL aliquots. For best
transformation efficiency the sheared salmon sperm DNA was boiled for
three minutes and placed immediately on ice prior to each use.)
70 gL of sterile ddH20 plus pJG4-5 containing the cDNA library
It is very important to add the reagents in this particular order making
sure not to disturb the yeast pellet upon addition of the 50% PEG solution.
Contact of the yeast pellet with 1.0 M lithium acetate will drastically reduce
transformation efficiency. Additionally, stock solutions of 50% PEG and
1.0 M lithium acetate should be kept tightly sealed since slight changes in
final PEG or lithium acetate concentrations will reduce transformation
efficiency.
11. Vortex the microcentrifuge tubes until all the yeast is homogeneously
resuspended. If after extensive vortexing some clumps remain resuspend
using gentle pipetting.
12. Incubate the transformation mixtures at 30 OC on a rotator for exactly
30 minutes.
13. Heat shock the transformation mixtures in a 42 OC water bath for
exactly 18 minutes.
14. Pellet the yeast cells in a microcentrifuge at 16,000 rpm for 15 seconds,
remove the supernatant and gently resuspend in 2.0 mL of sterile ddH20.
( The yeast are somewhat fragile at this point. It is preferred that only a
few tubes be resuspended at a time in a portion of the 2.0 mL of ddH20 and
all the solutions be combined when the tubes are resuspended. This will
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significantly reduce the stress on the fragile yeast cells and improve
transformation efficiency.)
15. To determine the primary transformation efficiency calculate the
number of cells in 1 tL aliquot of this plating solution using 1:100,000 and
1:1,000,000 dilutions of the 1 gL aliquot. Plate these dilutions onto SC
( His-, Ura-, Trp-), 2% Glucose plates and incubate at 30 oC for three days.
16. Plate the remaining transformed yeast in 160 gL aliquots onto SC (His-,
Ura-, Trp-), 2% Glucose plates and incubate at 30 OC for three days.
17. Remove the plates from the 30 oC warm room, count the dilution
plates to determine the number of primary transformants, and chill the
remaining plates for 2 hours in a cold room.
18. Using a sterile microscope slide scrape transformed yeast off the
selection plates and combine in 25 mL of ddH20, in a 50 mL Falcon tube.
19. Pellet the cells in a table top centrifuge at 2,500 rpm for 10 minutes,
wash 2X with 25 mL of sterile ddH20 and resuspend the cells in an
equivalent volume of a sterile 30% glycerol solution (About 4.0 mL).
20. Aliquot to 1.5 mL microcentrifuge tubes, freeze in dry ice/ethanol, and
transfer to a -80 OC freezer. These frozen strains can now be used as
standard three-hybrid screening strains for future three-hybrid screens.
21. Determine the number of yeast cells per gL of stock solution. Thaw
one tube of frozen stock and remove a 1 gL aliquot. Dilute this aliquot
1:10,000 and 1:100,000 to determine the number of cells in lpL of the stock
after plating onto SC (His-, Ura-, Trp-), 2% Glucose plates and incubate at
30 OC for three days.
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Preparation of Three-Hybrid Screening Strain Containing a HeLa cDNA
Library
EGY48 transformed with pEGHBD 6 and pSH18-34 was transformed
with 108 gg of a HeLa cDNA library subcloned into pJG4-5 following the
standard high efficiency lithium acetate transformation procedure. A total
of 22.3 x 106 primary transformants were obtained ( 2.06 x 105 / gg DNA).
These transformants were collected and stored at -80 oC. The frozen stocks
contained 3.0 x 105 cells / AL.
Preparation of Three-Hybrid Screening Strain Containing a Jurkat
(Human T Cell) cDNA Library
EGY48 transformed with pEGHBD 7 and pSH18-34 was transformed
with 60 gg of a Jurkat cDNA library subcloned into pJG4-5 following the
standard high efficiency lithium acetate transformation procedure. A total
of 11.3 x 106 primary transformants were obtained ( 1.88 x 105 /gg DNA).
These transformants were collected and stored at -80 OC. The frozen stocks
contained 1.6 x 105 cells/tL.
Standard Procedure for Conducting a Yeast Three-Hybrid Screen
1. Thaw frozen three-hybrid screening strain, containing pEGHBD 6 or 7,
pSH18-34, and pJG4-5-cDNA library, on ice.
2. Dilute the desired number of yeast cells for the particular screen 1:1000
in SC (His-, Ura-, Trp-), 2% Galactose and culture for four hours at 30 oC.
(This is necessary to begin induction of the "fish" fusion protein which is
under the GALl promoter.)
3. Pellet the cells at 2,500 rpm in a Beckman GS-6R table top centrifuge for
10 minutes at room temperature.
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4. Wash the cells with 5 mLs of ddH20.
5. Resuspend the cells in ddH20 so that the final concentration of cells is
between 3.3 x 106 and 5.0 x 106 cells / mL.
6. Plate 150 gL of cells onto SC (His-, Ura-, Trp-, Leu-), 2% Galactose, 1pM
dexamethasone-FK506 plates. (For three-hybrid screening it is preferred
that these plates be buffered to pH 6.5 or lower.)
7. Incubate plates at 30 OC for ten to twelve days.
8. Each day circle colonies which appear with a different color ink.
9. Collect colonies when they have reached approximately 1 mm in
diameter and streak onto: SC (His-, Ura-, Trp-, Leu-), 2% Galactose, 1 AM
dexamethasone-FK506 (2 plates: One for a master plate, one to compare to
the FK506 competition plate) and SC (His-, Ura-, Trp-, Leu-) 2% Galactose,
1 AM dexamethasone-FK506, 10 AM FK506.
10. Incubate plates at 30 oC for four to five days.
11. Streak colonies from master plate onto SC (His-, Ura-, Trp-, Leu-), 2%
Galactose with no drug.
11. Retrieve and sequence pJG4-5-cDNA from colonies which do not grow
on SC (His-, Ura-, Trp-, Leu-), 2% Galactose and do not grow on SC (His-,
Ura-, Trp-, Leu-), 2% Galactose, 1 AM dexamethasone-FK506, 10 AM FK506.
(Note: After colonies grow on master plate they should be transferred to
SC (His-, Ura-, Trp-), 2% Glucose plates so that reporter gene products are
diminished before conducting competition comparisons).
Initial Three-Hybrid Screen for FK506 Interacting Proteins
Frozen three-hybrid screening strain containing the HeLa cDNA
library (9.0 x 106 cells) was screened on SC (His-, Ura-, Trp-, Leu-), 2%
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Galactose, 1 gM dexamethasone-FK506, pH 4.5-5.0 plates following the
standard procedure.
Second Three-Hybrid Screen for FK506 Interacting Proteins
Frozen three-hybrid screening strain containing the HeLa cDNA
library (1.2 x 107 cells) was screened on SC (His-, Ura-, Trp-, Leu-), 2%
Galactose, 1 gM dexamethasone-FK506, pH 7.0 plates following the
standard procedure.
Third Three-Hybrid Screen for FK506 Interacting Proteins
Frozen three-hybrid screening strain containing the Jurkat cDNA
library (1.62 x 106 cells) was screened on SC (His-, Ura-, Trp-, Leu-), 2%
Galactose, 1 gM dexamethasone-FK506, pH 6.54 plates following the
standard procedure.
Standard Procedures for pJG4-5 Plasmid Retrieval
Yeast positively selected for in the screen harbored three different
plasmids: pEGHBD 6 or 7, pSH18-34, and pJG4-5-cDNA. Two methods
were utilized to selectively retrieve the pJG4-5-cDNA plasmid. Both
involved the initial isolation of total plasmid DNA by yeast miniprep.
One method isolated the pJG4-5-cDNA plasmid by bacterial
transformation followed by restriction digestion of minipreps. The second
utilized E. coli KC8 (pyrF, leub600, trpC, and hisB463) which contained the
bacterial trpC-9830 mutation which could be complemented by the TRP1
gene on the pJG4-5-cDNA plasmid.
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Standard Procedure for Yeast Minipreps
1. Inoculate a 2.0 mL culture of SC (His-, Ura-, Trp-), 2% Glucose with
yeast and allow to grow overnight at 30 oC.
2. Pellet 1.5 mL of culture in a 1.5 mL microcentrifuge tube and resuspend
in 50 gL of STES (0.5M NaC1, 0.2 M Tris-HC1, pH 7.6, 0.01 M EDTA, 1%
Sodium Dodecyl Sulfate (SDS)).
3. Fill tubes to the liquid surface with 0.4 mm acid washed glass beads
(Sigma) and vortex 2 times for 1 minute each.
4. Add 60 p•L of phenol/chloroform and vortex 2 times for 1 minute each.
5. Add 20 gL of TE (10 mM Tris-HC1, pH 8.0, 0.1 mM EDTA) and spin at
16,000 rpm in a microfuge for 10 minutes.
6. Carefully transfer the supernatant to a new 1.5 mL microcentrifuge tube
and add 1/10 the volume of 3.0 M sodium acetate, 2 volumes of 100%
ethanol, and place at -20 oC for 1 hour.
7. Pellet the plasmid DNA for 30 minutes at 4 OC, wash the pellet with
70% ethanol, dry, and resuspend in 40 gL of TE (pH 8.0).
Standard Procedure for pJG4-5-cDNA Isolation by Bacterial Miniprep
Total plasmid DNA obtained from the yeast miniprep, containing
pEGHBD 6 or 7, pSH18-34, and pJG4-5-cDNA, was used to transform
competent E. coli DH5a according to the standard procedure. Minipreps
were performed on positive transformants according to the standard
procedure and miniprep DNA was digested with EcoRI and XhoI to
identify the pJG4-5-cDNA plasmid. Digestion of pJG4-5 excised the cDNA
insert which could easily be distinguished from the restriction pattern
afforded by digestion of pEGHBD 6 or 7 and pSH18-34. DH5a which
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harbored pJG4-5-cDNA were used to purify large quantities of pJG4-5-
cDNA by Qiagen procedures for sequencing.
Standard Procedure for pJG4-5-cDNA Isolation Using E. coli KC8
Electrocompetent E. coli KC8 (50 gL) were treated with total plasmid
DNA obtained from yeast miniprep (2.5 gL) on ice. The E. coli/DNA
mixture was transferred to a chilled 0.2 cm electrode gap, 50 Gene Pulser/E.
coli Pulser Cuvette and electroporated at 2.5 kV in a BioRad Gene Pulser.
E. coli KC8 were resuspended in LB (1 mL) and allowed to recover at 37 OC
for one hour before being plated onto LB/amp (50 gg/mL) and incubated
for 12 hours at 37 OC. Positive transformants were picked with a sterile
loop, streaked onto M9/amp + trp- medium, and incubated at 37 oC for 12
hours to select for transformants which harbored the pJG4-5-cDNA
plasmid. pJG4-5-cDNA was retrieved by KC8 bacterial miniprep following
the standard procedure and this plasmid DNA was used to transform E.
coli DH5x the standard transformation procedure. This DH5X strain was
used to purify large quantities of pJG4-5-cDNA by Qiagen procedures for
sequencing.
Standard Procedure for Manual DNA Sequencing of the pJG4-5-cDNA
Insert
Qiagen Purification of pJG4-5-cDNA Plasmids containing interacting
clones
Bacterial colonies determined to harbor the pJG4-5 plasmid
containing interacting clones were grown for 12 hours in 25 mL of
LB/amp (100 gg/mL) at 30 OC. Plasmid DNA was purified utilizing a
Qiagen kit according to the manufacturers directions. Purified DNA was
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resuspended in 50 gL of TE (10 mM Tris-HC1, pH 8.0, 0.1 mM EDTA).
Concentration of DNA was measured on a UV spectrophotometer at 260
nm (Double-stranded DNA OD260 1=50 ptg/mL). Approximately 150 gg of
purified DNA was obtained from each qiagen purification.
Preparation of Qiagen DNA for Sequencing Reactions
Qiagen purified double-stranded template DNA (3 gg) was dissolved
in ddH20 to a final volume of 50 gL. The DNA was treated with 1 M
NaOH (12.5 gL) and incubated for 5 minutes at room temperature. DNA
was precipitated by the addition of 5 M ammonium acetate (pH 7.5) (25 gL)
and 350 gL ethanol and placed at -80 oC for 15 minutes. DNA was pelleted
for 10 minutes at 4 OC, washed with 70% ethanol, dried, and resuspended
in 7 gL of ddH20.
Standard Procedure for DNA Sequencing Reactions
Single-stranded Qiagen DNA (7 gL) was combined with sequencing
reaction buffer (2 gL) and pJG4-5 universal sequencing primer, 5'-
CTGAGTGGAGATGCCTCC-3', (1 gL of a 0.5 pM stock solution, 0.5 pmol).
The primer was allowed to anneal for 30 minutes at 37 OC. To each 10 gL
reaction was added Dithiothreitol (DTT) 0.1 M (1 gL), Labeling Mix
(prediluted 1:5) (2 gL), [35S] dATP (0.5 gL, 10 mCi/mL), and Sequenase
Polymerase (2 gL). The reactions were allowed to proceed for 4 minutes at
room temperature. An aliquot (3.5 gL) of the reaction mixture was added
to each of the four termination mixtures containing ddATP, ddTTP,
ddGTP, and ddCTP in a flexible 96-well plate pre-warmed to 37 oC. These
solutions were incubated at 37 OC for 5 minutes before each of the four
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termination reactions were stopped by the addition of Stop Solution (4 [L).
The 96-well plate was immediately placed on ice.
General Procedure for Sequencing Gel Electrophoresis
Sequencing gels (6%) were poured by mixing the appropriate
concentrations of buffer, concentrate, and diluent according to the
manufacturers recommendations. This solution was degassed for 15
minutes and filtered. To this solution was added 10% ammonium
persulfate (800 gtL) and TEMED (35 gL). The gel was poured and allowed to
polymerize for 2 hours. The sequencing gel was pre-run at 75W (1700
Volts) for 45 minutes in filtered TBE (45 mM Tris-borate, 1 mM EDTA)
buffer. The 96-well plate containing the terminated sequencing reactions
was heated at 75 oC for 3 minutes and immediately placed on ice. An
aliquot (2.5 gL) from each termination was loaded into each well. The
sequencing gel was run at 75W (1700 Volts). After running for the
appropriate length of time one of the glass plates was removed and the
plate containing the gel was placed in 15% methanol/5% Acetic acid/80%
ddH20 for 15 minutes. The gel was transferred to drying paper, covered
with saran wrap and dried at 80 OC for 2 hours. The saran wrap was
removed and the gel was placed in a cassette overnight containing film
and an intensifying screen. Film was developed and sequence was read.
Automated Sequencing of the pJG4-5-cDNA containing clones
Automated sequencing was performed by the MIT Biopolymers
Laboratory using the previously mentioned sequencing primer.
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Appendix
Efforts Toward the Total Synthesis of Taxusin
Background
Over the past 10 years the medical community has been incredibly
excited over the prospects of the anticancer chemotherapeutic taxol (1). Taxol
has recently been approved by the FDA for use against drug refractory
ovarian cancer, and has shown tremendous promise in clinical trials against a
variety of other neoplasms (McGuire, W.P., 1989; Rowinsky, E.K. et al., 1990;
Holmes, F.A., 1991; Murphy, W.K. et al., 1992).
O
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Interest in this antitumor agent dates back to the 1960's when the NCI
(National Cancer Institute) discovered that the crude extracts of the Pacific
yew bark, Taxus brevifolia, possessed considerable cytotoxic activity against a
variety of tumor cell lines. The active constituent of this bark, taxol, was
isolated and characterized in 1971 by Wall and his co-workers at the Research
Triangle Institute in North Carolina (Wani, M.C. et al., 1971). Although taxol
showed considerable medicinal promise problems with scarcity, isolation,
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and clinical formulation caused interest in this drug to dwindle until the late
1970's.
In a series of papers presented by Dr. Susan Horwitz, at the Albert
Einstein College of Medicine, the mechanism of taxol's cytotoxicity was
elucidated (Schiff, P.B. et al., 1979; Schiff, P.B. & Horwitz, S.B., 1980). Horwitz
and her colleagues discovered that taxol's antineoplastic activity stemmed
from its ability to act as an antimicrotubule agent. This was quite exciting
since the cell's microtubules are one of the most strategic targets for
antineoplastic agents as evident through the success of the vinca alkaloids,
vinblastine and vincristine, in the eradication of human lymphomas. Unlike
the vinca alkaloids, taxol possessed a totally novel mechanism of action.
Micrutubules are among the most ubiquitous of all cellular
constituents and play a major role in cellular processes ranging from mitosis
to protein trafficking (Dustin, P., 1980). They are long, tubular structures
composed of protein subunits known as tubulin. These tubulin subunits are
heterodimers consisting of 55 kDa a and ~3 tubulin monomers. Microtubules
are not static organelles but are in a constant state of equilibrium with their
tubulin subunits. This equilibrium is carefully controlled throughout the cell
cycle by a variety of second messengers including Ca2+ and GTP (Horwitz,
S.B., 1992). During mitosis signals instruct the tubulin to polymerize and
form the mitotic spindle. This structure is primarily responsible for the
partitioning of the cell's genetic material during anaphase when it is believed
that the microtubules depolymerize and separate the cell's chromosomes.
Any disruption of the normal equilibrium interferes dramatically with cell
replication and growth resulting in cellular death.
It is known that cells treated with either the vinca alkaloids or
colchicine, another antimicrotubule agent, lose their ability to polymerize
143
tubulin dimers and form microtubules (Bershadsky, A.D. & Vasiliev, J.M.,
1988). Therefore, the mitotic spindle is unable to form and separate the
chromosomes during anaphase. Horwitz and her colleagues discovered that
taxol has a radically different effect upon microtubule structure. They
showed that when purified tubulin was treated with only taxol the rate of
tubulin polymerization and microtubule formation was significantly
enhanced. This was quite surprising since such a process usually requires a
number of cofactors such as GTP and Microtubule Associated Proteins
(MAP's). Once polymerized, the scientists were unable to depolymerize the
microtubules even under conditions normally associated with rapid
microtubule depolymerization, CaCl 2 or cold. Taxol treated cells therefore
possessed the ability to form the all important mitotic spindle but were
unable to equipartition the chromosomes during anaphase.
With this renewed excitement over the potential of this
chemotherapeutic agent the problems initially faced regarding scarcity,
isolation, and formulation still needed to be solved.
Taxus brevifolia is a slow growing tree in the pacific northwest which is
the only FDA approved source of taxol at the present time. Taxol is isolated
from the bark of the yew tree and the isolation process results in the death of
the tree. The current demand of taxol is 130 kilograms of drug requiring 2
million pounds of dry yew bark to be harvested. As taxol therapy continues
to expand the demand for taxol will steadily increase. In order to meet this
increasing need a source other than natural isolation from the pacific yew
must be found.
A variety of approaches are underway in order to secure increased
quantities of taxol including growth in cell culture (Christen, A.A. et al.,
1989), biomass from nursery cultivation (Witherup, K.M. et al., 1990), along
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with total and semisynthesis (Swindell, C.S., 1991). Total and semisynthesis
of taxol is an exciting option because in addition to providing the naturally
occurring drug the methodology developed might lead to the creation of
analogs possessing a better toxicity profile along with increased water
solubility.
Semisynthesis of taxol is currently being accomplished through the
synthetic modification of a taxol precursor, 10-deacetyl baccatin-III (2).
HO n ,-1
HO"
Although this molecule lacks taxol's C-13 sidechain it is isolated from a
renewable natural source, the needles of Taxus baccata, in high yields (lg/lkg)
(Chauviere, G. et al., 1981). The C-13 sidechain is absolutely necessary for
biological activity and must be synthetically coupled to 10-deacetyl baccatin
III (2). A number of groups have worked out enantiomeric synthesis of this
side chain along with conditions for its coupling (Denis, J.N. et al., 1988;
Holton, R.A., 1991; Ojima, I. et al., 1991; Denis, J.N. et al., 1991; Deng, L. &
Jacobsen, E.N., 1992).
Over thirty synthetic groups have made contributions to the taxol
literature describing a variety of synthetic strategies. Recently, two research
groups independently reported total syntheses of this complex natural
product (Nicolaou, K.C. et al., 1994; Holton, R.A. et al, 1994).
Synthesis of taxol, and taxol-related compounds, involves a variety of
challenging synthetic problems. First, the highly oxygenated nature of the
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taxane skeleton must be taken into consideration when planning a synthetic
route. Any synthesis must allow for the stereocontrolled introduction of a
number of oxygenated centers about the taxane carbocycle. Second, a route
must be developed which allows for the efficient construction of the
architecturally complex tricyclic carbon skeleton. This skeleton contains an 8-
member B - ring. Such medium sized rings are not easily synthesized by
straight forward annulation strategies i.e. aldol condensations. However,
these rings may be simplified in the retrosynthetic direction through a
connective transform (Corey, E.J. & Cheng, X.-M., 1989). This transform
reconnects 2 carbons of the medium sized ring to afford a bicyclic precursor
which is structurally more complex than the product. However, these
precursors may contain 4- membered bridged and fused ring systems which
are easily generated in the forward direction by a number of powerful ring
forming reactions. Some of the most useful of these reactions involve the
[2+2] cycloadditions of olefins, enones, ketenes, or allenes. These
cycloadditions provide strained products which may be efficiently
fragmented in the forward direction to afford the desired medium sized ring.
Perhaps the most popular of these annulation-fragmentation strategies in the
generation of the taxane B-Ring has been the De Mayo Reaction (Figure
Appendix.1) (De Mayo, P. et al., 1962; Challand, B. et al., 1969). This reaction
was pioneered by De Mayo in the 1960's and involves the photochemical
[2+2] cycloaddition of an olefin and properly functionalized 1,3 diketone
followed by a retroaldol reaction. This sequence affords a polycyclic product
containing an oxygenated medium sized ring. Such a strategy is incredibly
efficient in a taxane synthesis since it not only creates the medium sized B-
ring, but also provides carbonyl functionality useful in the elaboration of this
ring to a fully oxygenated product.
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Figure Appendix.1 The De Mayo Reaction
Connective transforms have been utilized by a number of
groups in their retrosynthetic planning of a taxane syntheses (Figure
Appendix.2).
6
5
C 9-C15
Connective Transform
Transform
Figure Appendix.2 Popular Connective Transforms of the Taxane
Carbocyclic Skeleton
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By far the most popular of these connective transforms has been the C(2)-C(9)
connective transform. This reconnection has been utilized by both Swindell
(Figure Appendix.3) (Swindell, C.S. & Patel, B.P., 1990), and Blechert (Figure
Appendix.4) (Blechert, S. & Klein-Klausing, A., 1991). These groups have
employed photochemical [2+2] enone cyclizations in the formation of fused
cyclobutane precursors which were fragmented to afford the taxane B-ring.
Blechert has been successful in preparing a biologically active taxol analog, 3a
or 3b. This molecule is active in a micrutubule polymerization assay despite
lacking much of the complicated functionality present in taxol.
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Figure Appendix.3 Swindell's synthesis of the taxane skeleton.
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A second connective transform, utilized by Wender, reconnects the
C(2)-C(11) carbons of the taxane backbone (Figure Appendix.5) (Wender, P.A.
& Mucciaro, T.P., 1992). Wender arrives at intermediate 8 in 5 steps from
verbenone (4), the air oxidation product of pinene. The pivitol reaction in this
sequence is the reorganization of the pinene backbone through a
photochemical 1,3 alkyl shift to afford bridged cyclobutane intermediate 6
(Hurst, J.J. & Whitman, G.H., 1967). This compound is subsequently
converted to fragmentation substrate 7 which undergoes base induced
fragmentation to afford tricyclic intermediate 8. This compound might easily
be elaborated into a variety of taxol analogs and potentially into taxol itself.
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Figure Appendix.4 Blechert's synthesis of the taxane skeleton.
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Figure Appendix.5 Wender's synthesis of the taxane skeleton.
A third connective transform has been Winkler's reconnection of C(9)-
C(15) (Figure Appendix.6) (Winkler, J.D. et al., 1989). Winkler arrives at
dioxeneone 10 in 4 steps from enone 9. This intermediate under goes a [2+2]
cycloaddition to afford photoproduct 11 which upon based induced
fragmentation and treatment with diazomethane provides a mixture of
epimeric taxane molecules, 12a and 12b.
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Figure Appendix.6 Winkler's synthesis of the taxane skeleton.
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Our synthetic plan concentrates upon the total synthesis of taxusin (13)
with the hope that the methodology developed might be applied to a
synthesis of taxol (1) along with other medicinally interesting analogs..
Similar to a number of groups pursuing taxane synthesis our synthetic
strategy focuses upon a connective transform. In the retrosynthetic direction
reconnection of the taxane C(3)-C(10) carbons affords a novel fused
cyclobutane intermediate (Figure Appendix.7).
Figure Appendix.7 Taxane Carbocycle C(3)-C(10) Connective Transform.
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This molecule might easily be generated by a [2+2] enone-olefin cyclization
and our retrosynthetic outline is presented in Figure Appendix.8.
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Figure Appendix.8 Our retrosynthetic analysis of the taxane skeleton.
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Results and Discussion
The initial focus of this research project concentrated on the efficient,
enantioselective synthesis of diketone 22. This molecule would serve as a
strategic precursor to a variety of photosubstrates in our convergent synthesis
of taxusin (13). A similar molecule 14 was prepared in the synthesis of
khusimone by Liu (Liu, H.-J. & Chan, W.H., 1979).
CO2CF-
Slight modifications of his synthetic strategy afforded the desired diketone 22
in 7 steps and 29% yield from readily available, inexpensive camphorsulfonic
acid (Figure Appendix.9).
1. NaH 1.05 equiv
Benzene:Hexanes 2:1
'.- 0 °C 25 minutesHO e. , i•
.HO 2. DMF cat.
Oxalyl chloride
0 OC to 25 OC
16 lhIO 10min 81%
Ethyl Grignard
THF:CH 2CI2 2.5:1 .,
Cul cat. O
-15 OC lh 18
85%
Ethylene glycol
TsOH cat. , ,
Reflux 0
Benzene 40 h 0 1
91% 19
RuCl 3 (0.2 eq.)
NalO 4 5.3 (eq.)
CCI4 / H20 / CH3CN
1:1.5:1
0 OC 4 days
0' OR
CH2N2  20 R=
Ether L 21 R=
0 OC
Sodium Methoxide
THF/DMSO
10 0C
_-_ 3 steps 60%
Figure Appendix.9 First seven steps of our synthesis.
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15
KOH 9.1 eq.
200 oC
30 minutes
76%
CI
1717
1(s)-(+)-10 Camphorsulfonic acid (15) was easily converted by alkali
fusion at 200 oC to campholenic acid (16) in 76% yield (Crist, B.V. et al., 1982).
Campholenic acid (16), upon treatment with NaH, oxalyl chloride, and
catalytic DMF at 0 oC afforded acid chloride 17 in 81% yield. Acid chloride 17
was then efficiently converted to ethyl ketone 18 by the dropwise addition of
ethyl grignard at -15 oC in the presence of catalytic Cul (Fujisawa, T. & Sato,
T., 1987). This reaction afforded ethyl ketone 18 in 85% yield which was
converted to ketal 19 by refluxing in benzene with TsOH and excess ethylene
glycol. Catalytic ruthenium tetroxide oxidation of ketal 19 afforded slightly
impure acid 20. This reaction was performed in an CH 3CN/H 20/CC14
solvent system as opposed to simply H 20/CCl4. In this system, developed
by Sharpless (Carlsen, P.H.J. et al., 1981), the CH 3CN serves as a good ligand
for the low valent ruthenium produced during the course of the reaction. In
the absence of CH 3CN the oxidation products, carboxylic acids, coordinate to
the ruthenium forming insoluble masses which remove the catalyst from the
catalytic cycle. Slightly impure acid 20 was esterified with diazomethane at 0
OC to afford methyl ester 21. Methyl ester 21 was then converted to diketone
22 by Diekmann cyclization using sodium methoxide in THF/DMSO.
Diketone was recrystallized from ether/THF to afford pure product (60%
yield from ketal 19).
With large quantities of diketone 22 in hand the next synthetic
challenge was its regioselective conversion to P-substituted enone 23 (Figure
Appendix.10) where X represented a leaving group.
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These molecules would serve as substrates either in addition elimination
reactions or Pd catalyzed coupling reactions to prepare a wide variety of
photosubstrates.
It was reasoned that the sterically demanding geminal methyl center
might discriminate between the reactivities of the two carbonyls. Reaction at
the less sterically demanding carbonyl would provide the desired 03-
substituted enones selectively. The initial enone synthesized was enol
phosphate 24.
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Figure Appendix.10 Desired regioselective conversion of diketone 22.
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Figure Appendix.11 Synthesis of model photosubstrate and
photocyclization.
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This compound was prepared by the addition of NaH to a THF/ether
solution of diketone 22 at 0 oC followed by diethylchlorophosphate at -20 oC.
The reaction afforded a quantitative yield of the 2 possible regioisomers and a
72% yield of the desired isomer 24. The regioisomers were distinguished on
the basis of NMR coupling constants (discussed later). Enol phosphate 24
was converted to photosubstrate 25 by the addition elimination reaction of a
dialkylcuprate formed from 5-methyl 5-hexenyl iodide (Sum, F.-W. & Weiler,
L., 1979). Although the sidechain of this photosubstrate lacked the
functionality necessary for its elaboration into a functionalized taxusin C-ring
it would serve as a model compound to test the viability of the photochemical
[2+2] cyclization.
Photosubstrate 25 was added to the photolysis apparatus and
dissolved in hexanes. The solvent was degassed and the compound subject to
photolysis at -78 oC with a 450 Watt Hanovia lamp through vycor and a
solution filter* ( 38 g CuSO 4, 0.4 g FeSO 4, 5 ml HCI per 1 L H2 0 [10%
transmittance below 330 nm]). The reaction afforded a high yield of a single
product, as a mixture of isomers 26a and 26b. The ratio of isomers
approached 8:1 based on NMR integration of the proton a to the ketone in the
final products. These isomers were unable to be separated and nOE
difference experiments could not be performed in order to determine which
of the isomers was in fact the major isomer.
Previous work conducted by Liu documenting intermolecular
cycloadditions to a related system revealed that the molecule's sole chiral
center afforded a certain degree of facial selectivity (Figure Appendix.12)
(Liu, H.-J. & Chan, W.H., 1979).
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Liu performed the intermolecular cycloaddition of 1,1- diethoxyethene to
enone 14. His results determined the ratio of isomers to be 1.6 : 1 favoring
attack on the face opposite to the methyl ester sidechain.
Based on this precedent we reasoned that our intramolecular
cyclization would also favor addition of the olefin to the side opposite the
ketal containing side chain. This facial selectivity is necessary for the
generation of the proper C(8) stereocenter in taxusin (13). Our model system
therefore appeared to favor production of the desired isomer 26b by this
annulation strategy.
The first complex photosubstrate prepared was dienone 29. The
olefinic sidechain would provide us with the functionality necessary to
elaborate the lower portion of the taxusin C-ring after cyclization. The
sidechain was initially synthesized as vinyl iodide 27 in three steps from
propyne (Figure Appendix.13) (Satoh, Y. et al., 1985). This compound
enabled us to attempt a variety of reactions in order to synthesize dienone 29.
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Figure Appendix.12 Facial selectivity of Liu's photocyclization.
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Initial efforts to add cuprates derived from vinyl iodide 27 to enol
phosphate 24 proved fruitless. It was rationalized that these substrates were
not reactive enough and that enol triflates might potentially increase
reactivity. Enol triflates 28a and 28b were initially synthesized as a 1:1 ratio
of the two regioisomes (Figure Appendix.14). This was accomplished in
nearly quantitative yield by the addition of NaH in THF to diketone 22 at 0 OC
followed by trifluoromethanesulfonicanhydride at -78 oC. The isomers were
separated by flash chromatography and were assigned the proper
regiochemistry based on NMR allylic coupling. The less polar isomer showed
an allylic coupling of 1.5 Hz between one methylene proton, Hb or Hc, and
olefinic proton Ha. The more polar isomer did not show this coupling.
Therefore, it was concluded that the less polar isomer was in fact the desired
product 28b. The reaction was significantly improved by utilizing N-
Phenyltrifluoromethanesulfonimide and warming from -78 oC to 0 oC over a
2 h period. These conditions afforded the desired enol triflate 28b in 74%
yield.
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Figure Appendix.13 Synthesis of side chain for first complex photo-
substrate.
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Figure Appendix.14 Synthesis of two enol triflate regioisomers.
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With enol triflate 28b in hand a variety of cuprate additions were
attempted. Best yields were obtained by the addition of a higher order
cyanocuprate to enol triflate 28b at -78 OC (Figure Appendix.15) (Lipshutz,
B.H., 1983). This reaction afforded between 25-35 % yields of photosubstrate
29. In order to more efficiently synthesize dienone 29 it was decided to
explore the possibility of a Pd(0) catalyzed coupling reaction to attach the
sidechain.
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Figure Appendix.15 Synthesis of first complex photocyclization
substrate and failed photocyclization reaction.
Vinyliodide 27 was converted to a vinyl tin reagent by treatment with
t-BuLi and tributyltinchloride. Palladium catalyzed coupling procedures
were attempted using this newly formed vinyltin reagent and enol triflate 28b
as substrates. A variety of experimental conditions were attempted including
varying temperature, solvent, and Pd catalysts. No reaction conditions
proved to be successful. It was reasoned that the vinyltin was too sterically
congested to undergo the transmetallation step necessary to attach the vinyl
group to the metal (Collman, J.P. et al., 1987).
Although yields from the higher order cyanocuprate addition were
low, enough photosubstrate was obtained to examine the viability of the
cyclization reaction. Photolysis of dienone 29 with a 450 W Hanovia lamp
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through vycor and the previously described solution filter afforded unreacted
starting material and one additional product. This product was formed after
15 minutes of photolysis in approximately a 1:1 ratio with 29 and the ratio did
not change with time. NMR analysis revealed that this new compound was
simply the isomerization product about the y-8 bond of the olefinic sidechain
30 (Figure Appendix.15). This was not a surprising result since it is well
known that acyclic enones relax very efficiently from their singlet excited
state to their ground state by cis-trans isomerization (Horspool, W.M., 1984).
Our substrate was a flexible dienone and showed similar relaxation by
isomerization. Minor attempts were made to remove this double bond prior
to photolysis through its epoxidation but these attempts proved unsuccessful.
At this time an alternative photosubstrate 33 was constructed. This
molecule possessed an olefin 8-E to the carbonyl of the enone which could not
participate in the relaxation of the excited enone. The sidechain was prepared
in 7 steps from 3-methyl 3-butene 1-ol as allylicbromide 31 (Marshell, J.A. et
al., 1967). It was reasoned that the most efficient way of coupling this side
chain to enol triflate 28b would be a Pd(0) catalyzed coupling reaction
(Sheffy, F.K. et al., 1984).
1. MsCI, Et3N
CH2C12, 0 C
2. NaI, Acetone
HO 3. Diethylmalonate
N•T TFT- n OC
1. NaH, DME
Reflux
2. LAH, THF
Reflux Br
3. MsCI, Et3N
)
C•L L,-- - , CO2Et CH2C12, 0 'C
4. LiBr, THF, 23 OC 31
Figure Appendix.16 Synthesis of side chain for second complex photo-
substrate.
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Initial attempts to convert allylic bromide 31 to an allylic tin compound
proved unsuccessful. Therefore, it was decided to convert enol triflate 28b
into vinylstannane 32. This was initially accomplished in low yields by the
addition of tributyltin anion to enol triflate 28b (Still, W.C., 1978). Attempts
to improve these yields proved to be successful by employing the use of
tributyltin cyanocuprate (Seitz, D.E. & Lee, S.-H., 1981). Addition of enol
triflate 28b to this cuprate afforded an 83% yield of the desired product 32. A
variety of Pd species were used as potential catalysts for the coupling of
allylic bromide 31 to vinylstannane 32. Best yields were obtained by using
12% Pd(OAc)2 and 24% PPh3 in THF at 69 OC for 14 h. This reaction afforded
an 87% yield of photosubstrate 33 (Figure Appendix.17).
oo II 31 o
Bu3SnCu(CN)Li Br
THF, -50 0C Pd(OAc) 2, 3 C 3
o 83% s nou THF, 69 OC(bath)
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28b 32 33
Figure Appendix.17 Synthesis of second complex photocyclization
substrate.
Photosubstrate 33 was photolyzed under a variety of conditions
varying temperature, solvent, and filter to determine which conditions would
afford the best ratio of major:minor isomers as products. It was determined
that CH2Cl2 and hexanes afforded approximately a 7:1 ratio of isomers at -78
OC. Reactions in CH 2C12 suffered from increased decomposition. Reactions in
hexanes afforded between 60-70% yield of product as a mixture of isomers
34a and 34b (Figure Appendix.18). Separation of these isomers was
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extremely difficult so it was decided to carry the crude reaction mixture
through to the next step when separation might be easier.
Crude photoproducts 34a and 34b were subject to ozonolysis at -78 oC
to afford 2 predominant products 35a and 35b which were easily separated by
flash chromatography. The overall yield of major isomer for two steps was
58%.
nOE Difference experiments were performed on ketone isomers 35a
and 35b along with the major isomer from the photocyclization step. The
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results of these experiments definitively determined that the major isomer
from the photocyclization was in fact the undesired isomer 34a (Table
Appendix.1-3). This molecule was formed by the addition of the olefin to the
face of photosubstrate 33 which contained the ketal sidechain. The product
therefore possessed the wrong relative stereochemistry between the C(1) and
C(8) carbons of taxusin (13). Additional reactions were conducted at elevated
temperatures (up to 40 oC) and in different solvents (CH 2C12, THF/H 20, 2-
propanol) with the hope that some conditions might be found which favored
the desired products. These efforts proved fruitless and under the best
conditions (40 oC, hexanes) only a 1.5:1 mixture of undesired:desired products
was obtained.
Hb
34a
Table Appendix.1 nOE Results on Major Photocyclization Product.
Positive nOE % nOE
Ha to Hb 3
Ha to Hc 4
Ha to Hd 4
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35a
Table Appendix.2 nOE Results on Major Ketone Isomer
Positive nOE % nOE
Ha to Hb
Ha to Hc
Ha to Hd
I-4
CH3
35b
Table Appendix.3 nOE Results on Minor Ketone Isomer
Positive nOE % nOE
Ha to Hc
Ha to C8 CH3
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Although this was a tremendous setback it was decided to carry out
reactions on the undesired isomer, 35a, with the hope that similar, if not
identical, reactivity would be seen for the desired isomer 35b.
Both tricyclic ketone isomers 35a and 35b were reacted in THF with
potassium tert-butoxide from 25 'C to 60 oC to afford enones 36a and 36b.
Reaction of tricyclic ketone 35a afforded a 66% yield of desired enone 36a
(Figure Appendix.19) whereas only a pure NMR fraction was obtained from
the desired tricyclic ketone 35b (Figure Appendix.20).
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Figure Appendix.19 C(3)-C(10) fragmentation of undesired ketone
isomer.
KOt-Bu THF
23 oC to 65 oC
35b
Figure Appendix.20 C(3)-C(10) fragmentation of desired ketone
isomer.
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The next synthetic step was the introduction of the trans ring fusion
between what would become the B/C rings of taxusin (13). Inspection of the
molecular topology of enone 36a revealed that this molecule possessed an
obvious concave surface. This concavity was present on the face of the
molecule opposite the C(8) methyl group. It was reasoned that external
reagents would add to this molecule with a fair degree of facial selectivity on
the side possessing this C(8) methyl group (convex side). This selectivity
might be utilized to efficiently install the desired trans ring fusion by a two
step allyldiazene rearrangement (Corey, E.J. & Virgil, S.C., 1990). The initial
step involved the formation of triisopropylbenzenesulfonylhydrazone 37
(Figure Appendix.21). This was accomplished in 64% yield by stirring 2,4,6-
triisopropylbenzesulfonyl- hydrazine in a THF solution of enone 36a for 24 h
at 23 oC. The second step involved the reduction of hydrazone 37 with
catecholborane in methylene chloride at -50 oC to afford potential olefin 39
(Figure Appendix.21) (Kabalka, G.W. et. al., 1988). Reduction of hydrazone
37 affords an allyldiazene intermediate 38 which undergoes a stereoselective
[3,3] sigmatropic rearrangement to yield olefin 39. The stereochemistry of the
hydrogen being delivered is therefore determined in the reduction step.
Catecholborane is expected to reduce hydrazone 37 on its convex face
selectively thereby affording the desired ring fusion after rearrangement.
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Total characterization of olefin 39 was not accomplished. However, the
emergence of 2 olefinic hydrogens at 5.52 and 5.35 ppm seems to indicate that
the product is most probably olefin 39.
Conclusion
The original synthetic strategy toward the synthesis of taxusin was
based on the expectation that the enone-olefin cyclization of photosubstrae 33
would favor attack of the olefin on the face of the enone which was opposite
the bulky ketal containing side chain to afford photoproduct 34b. Attack on
this face of the molecule would create the proper C-8 stereocenter found in
taxol and taxusin. Although the desired isomer (34b) is energentically
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Figure Appendix.21 Instalation of trans ring fusion between the B
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favored, it was the undesired isomer (34a) which was the predominant
product. This experimental result implied that the stereochemical outcome of
this enone-olefin cyclization was being determined by factors other than
energy differences in the products and that this particular photocyclization
could not be utilized in the synthesis of taxusin.
A thorough study was conducted by Dr. Paige Mahaney of the Virgil
Lab and it was determined that varying the side chain of the photocyclization
substrate induced an unprecedented reversal of facial selectivity of this
intramolecular cyclization. Dr. Mahaney constructed photosubstrate 39
which when photolyzed afforded only a single photoproduct (40) which
contained the desired stereochemistry at the C-8 postion on the taxane ring
system (Figure Appendix.22). This stereochemical outcome was the result of
the stabilization of the diradical intermediate of the cyclization by the
aromatic ring in photosubstrate 39. A detailed analysis of the stereoelectronic
differences between this photosubstrates 40 and 33 along with efforts toward
the synthesis of taxusin using photoproduct 40 have been reported on
(Mahaney, P.E., 1995).
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Figure Appendix.22 Improved photosubstrate and photocyclization
reaction.
Experimentals and Spectra
General Procedures : Reaction mixtures were stirred using a magnetic
stirring apparatus unless otherwise indicated. All moisture or air sensitive
reactions were carried out under a positive pressure of argon, and were
performed in glassware that was oven and / or flame dried. Solvents and
liquid reagents were transferred via syringe or cannula. Reactions were
monitored by thin layer chromatography as described below. Organic
solvents were removed through concentration using a Buchi rotery
evaporator at 20-40 mmHg.
Materials : Commercial solvents and reagents were used without further
purification with the following exceptions:
Solvents
Benzene was distilled under argon from calcium hydride.
Deuteriochloroform was stored over granular anhydrous potassium
carbonate.
Dichloromethane was distilled under nitrogen from phosphorous
pentoxide.
N,N-Diisopropylamine was distilled under nitrogen from calcium
hydride.
Ethyl ether was distilled under argon from sodium benzophenone
ketyl.
Hexanes was distilled under nitrogen from calcium hydride.
Tetrahydrofuran was distilled under argon from sodium
benzophenone ketyl.
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Triethylamine was distilled under nitrogen from calcium hydride.
Alkyllithium reagents were titrated in tetrahydrofuran or hexane at 0
oC with sec-butanol using 1,10-phenanthroline as an indicator.
Chromatography
Analytical thin-layer chromatography (TLC) was performed on Merck
pre-coated glass-backed silica gel 60 F-254 0.25 mm plates. Visualization of
spots was accomplished by one or more of the following techniques: a.
ultraviolet irradiation, b. exposure to iodine vapor, c. immersion of TLC plate
into an ethanolic solution of 3% p-anisaldehyde containing 0.5% concentrated
sulfuric acid followed by heating.
Column chromatography was performed by using 230-400 mesh
Merck silica gel.
Instrumentation
IR spectra were recorded on a Perkin-Elmer spectrometer equipped
with an internal polystyrene sample as reference.
1H NMR were recorded on either a Bruker 250 MHz spectrometer, a
Varian Unity 300 MHz spectrometer, a Varian XL 300 MHz spectrometer, or a
Varian 500 MHz spectrometer. Chemical shifts were reported as 8 in units of
parts per million (ppm) downfield from tetramethylsilane (8 0.0) using the
residual chloroform signal (8 7.26) as a standard.
13C NMR were recorded on a Varian 300 XL 300 NMR at 75 MHz. The
deuteriochloroform signal (d 77.0) was used as a standard.
High resolution mass spectra (HRMS) were measured on a Finnegan
MATT-8200 spectrometer.
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KOH 9.1 eq.
200 oC
30 minutes
lo 76%A "
C10lH 160 4S CloH1602
M.W. 232.05 M.W. 168.12
R-Campholenic Acid (16)
(1S)-(+)-10-Camphorsulfonic acid (15) (100.0 g, 430.0 mmol) was mixed to
homogeneity with finely ground KOH (219.4 g, 3.9 mol) in a 500 ml roundbottom
flask. The flask was heated in an oil bath to 200 OC while constantly stirring
manually. After 10 min of heating the mixture became brown/black and
solidified into chunks. Heating was continued for an additional 20 min. The
mixture was cooled, poured into a 1L separatory funnel containing 300g of ice,
and extracted at 0 OC with CH 2C12 (2x250 mL). An additional 250g of ice along
with 250 mL of concentrated HC1 was added and the solution was taken to pH 2
at 0 oC. The aqueous phase was extracted with 1:1 ether:methylene chloride
(3x200 mL), dried by filtration through MgSO 4, and concentrated to afford 62
grams of a brown liquid. This liquid was purified by distillation (0.5 mm Hg 88-
91 oC) to afford 54.5 grams of campholenic acid (16) as a clear yellow liquid (76%
). FTIR ( thin film, cm-1) 2956 (broad), 1709, 1435, 1362, 1304, 1221, 1149, 1013,
949, 798, 668; 1H NMR (500 MHz, CDCl3) 8 5.35 (sm, 1H), 2.50 (dd, 1H, J = 4.0,
14.2 Hz), 2.45 (m, 1H), 2.30 (dd, 1H, J = 10.7, 14.2 Hz), 2.25 (m, 1H), 1.95 (m, 1H),
1.60 (smn, 3H), 1.00 (s, 3H), 0.80 (s, 3H); 13C NMR (75 MHz, CDC13) 179.7, 147.8,
121.6, 46.9, 46.2, 35.6, 35.1, 25.6, 19.8, 12.6; HRMS (EI) Calculated for C10H 160 2
(M+): 168.1150. Found: 168.1149.
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HI 3 minutes
1. NaH 1.05 equiv
I-
Bienzene:Hexanes 2:1
0 °C 25 minutes
2. DMF cat.
Oxalvl chlnride
17
1o 0 C to 25 C lh 10min
CloH1602 81% C 10H 15C10
M.W. 168.12 M.W. 186.56
Acid chloride 17
R-Campholenic acid (16) (15.0 g, 89.1 mmol) was placed in a 300 mL
roundbottom flask and pumped under vacuum for 1.5 h. A 2:1 mixture of
hexanes:benzene (60 mL total) was added under argon and the solution was
cooled to 0 oC. NaH (2.25 g, 93.6 mmol) in hexanes (30 mL,10 mL) was added via
cannula over a 25 min period pausing to allow H2 evolution to cease. To this
grey solution was added DMF (5 drops) followed by oxalyl chloride (13.57 g, 107
mmol, 9.33 mL) via syringe over a 20 min period. The solution became clear
yellow in nature and was stirred for 1 h 10 min at 0 oC. The solution was allowed
to warm to 23 OC and stirred for an additional 1 h. The resulting beige/grey
precipitate was concentrated in vacuo to afford a beige paste. The product was
purified by distillation (0.6 mm Hg, 50-53 oC) to afford 13.5 g of acid chloride 17
as a clear, colorless liquid (81%). FTIR ( thin film, cm-1) 3042, 2958, 2866, 1804,
1462, 1436, 1400, 1385, 1363, 1287, 1213, 1171, 1116, 1056, 1015, 995, 964, 854, 799,
756, 704; 1H NMR (500 MHz, CDCl3) 8 5.23 (sm, 1H), 3.00 ( dd, 1H, J = 4.4, 16.1
Hz), 2.83 (dd, 1H, J = 10.7, 16.1 Hz), 2.45 (m, 1H), 2.33 (m, 1H), 1.93 (m, 1H), 1.61
(sm, 3H), 1.02 (s, 3H), 0.80 (s, 3H); 13C NMR (75 MHz, CDCl3) 173.7, 147.6, 121.3,
48.5, 46.9,46.2, 35.1, 25.5, 19.9,12.5.
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Ethyl Grignard
THF:CH2C2 2.5:1
Cul cat.
-15r O 1h 1 1I /
CloH 15CIO 85% C 12H200
M.W. 186.56 M.W. 180.15
Ethyl Ketone 18
The Grignard reagent was prepared fresh by the addition of Mg turnings
to a 250 mL roundbottom flask followed by evacuation and purging with argon.
To this flask was added anhydrous tetrahydrofuran (100 mL) and dibromoethane
(3 drops). The solution was stirred under argon for 15 min at which time freshly
distilled bromoethane(9.78 g, 89.8 mmol, 6.7 ml) was added over a 1.5 h period
via addition funnel. The solution goes from clear colorless to clear grey and
exotherms slightly. The Grignard was titrated using 1,10 phenanthroline as an
indicator and was determined to be 0.845 M.
Acid chloride 17 (13.40 g, 71.8 mmol) was added to a 250 mL roundbottom
flask and pumped under vacuum for 1 h. To this flask was added a 1:1 mixture of
CH 2C12:THF (100 mL). A second flask was charged with Cul (0.686 g, 3.6 mmol)
and pumped under vacuum. THF (100 mL) and CH 2C12 (25 mL) were added
under argon and acid chloride 17 was added via cannula.. The resulting
beige/brown slurry was cooled to -15 oC and the freshly prepared ethyl grignard
reagent (85 mL, 0.845 M, 71.8 mmol) was added via an addition funnel over a 1.5
h period. The reaction mixture became increasingly darker and was allowed to
stir for 1 h at -15 oC before warming to 0 oC for an additional 30 min. The
reaction was quenched with 50 mL of saturated NaHCO 3 and concentrated in
vacuo to remove the THF and CH 2C12. The product was isolated by extraction
with ether, dried by filtration through MgSO 4, and concentrated. Ethyl ketone 18
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was purified by vacuum distillation (0.6 mm Hg 67-70 OC) to afford 10.97 grams
of a clear, colorless liquid (85%). Rf0.78 (1:1 ether/hexanes); FTIR (thin film, cm-
1) 3036, 2954, 1714, 1459, 1412, 1374, 1360, 1285, 1211, 1112, 1015, 854, 797; 1H
NMR (500 MHz, CDCl 3) 8 5.21 (sm, 1H), 2.52-2.32 ( 5H 1 allylic H, 4 H's a to
ketone), 2.24 (m, 1H), 1.79 (m, 1H), 1.61 (sm, 3H), 1.05 (t, 3H, J = 7.3 Hz ), 0.98
(s, 3H), 0.77 (s, 3H); 13C NMR (75 MHz, CDCl3) 211.8, 147.8, 121.7, 46.8, 45.5,
43.4, 36.2, 35.7, 25.6, 19.9, 12.6, 7.8; HRMS (EI) Calculated for C10H200 (M+):
180.1514. Found: 180.1515.
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4 ~Ethylene glycol
TsOH cat.
Reflux
o 18 Benzene 40 h 0 19
C12H 200 C14H2402
M.W. 180.15 M.W. 224.18
Ketal 19
Ethyl ketone 18 (38.60 g, 214 mmol) was added to a 1 L roundbottom flask
equipped with magnetic stir bar, reflux condenser and Dean-Stark trap. The
compound was dissolved in 470 mL of benzene and ethylene glycol (66.43 g, 1.07
mol) was added to the flask. The flask was refluxed for 3 h driving off a quantity
of H20 followed by the addition of p-toluenesulfonicacid(0.5 g, 2.0 mmol). The
reaction was refluxed for 14 h before another quantity of p-toluenesulfonic acid
was added and refluxing was continued for 24 h. The reaction vessel was cooled
and the solution was concentrated in vacuo. The compound was dissolved in
ether, washed with H20 to remove the excess ethylene glycol, and the ether
extracts were dried by filtration through MgSO 4 and concentrated. The product
was purified by vacuum distillation (0.1 mm Hg, 78 OC) to afford 43.67 g of ketal
19 as a clear, colorless liquid (91% yield). Rf 0.69 (25% ethet/hexanes); 1H NMR
(CDCl 3, 250 MHz) 8 5.25 (bs, 1H), 3.91 (m, 4H), 2.35 (m, 1H), 1.50-2.00 (m, 9H),
0.96 (s, 3H), 0.91 (t, 3H, J = 7.5 Hz), 0.73 (s, 1H); 13C NMR (CDC13, 75 MHz) 148.0,
122.5, 112.5, 64.9, 64.5, 47.3, 45.5, 36.7, 30.1, 25.2, 19.4, 12.6, 8.1.
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H3
RuCl3 (0.2 eq.) o
0 NalO4 (5.3 eq.) c
19 o 20
1:1.5:1
C14H2405 0 oC 4 days C14H2405
M.W. 224.18 M.W. 272.16
Acid 20
Ketal 19 (43.67 g, 0.195 mol) was placed in a 2L roundbottom flask
equipped with a mechanical stirrer and dissolved in CCl4 /H 20/CH3CN
(442/666/442 ml). The reaction vessel was cooled to -15 oC and RuCl 3 (0.397 g,
1.52 mmol) was added along with NalO4 (138.93 g, 0.650 mol). The resulting
white precipitate was stirred for 4 days at -15 oC. Over this time period and
additional amount of RuCl 3 (0.397 g, 1.52 mmol) and NalO4 (83.4 g, 0.39 mol)
was added. Saturated NaHCO3 was added to the reaction vessel and the
solution was concentrated in vacuo to remove the organic solvents. The aqueous
phase was extracted with ether (3x) and acidified to pH 5 with 4N HC1. The
product was isolated by extracted with ether, dried by filtration through MgSO4,
and concentrated to afford slightly impure acid 20 (48.3 g) as a clear, colorless oil.
This compound was carried on to the next step. Rf 0.70 (100 % ether), 1H NMR
(250 MHz, CDCl3) 8 3.80-4.05 (m, 4H), 2.60 (aq, 1H, J = 4.7, 5.6, 5.6, 6.1 Hz), 2.54
(dd, 1H, J = 4.7, 16.5 Hz), 2.34 (dd, 1H, J = 6.1, 16.5 Hz), 2.20 (s, 3H), 1.60 (dq, 2H,
J = 7.5 Hz), 1.53 (d, 2H, J = 5.6 Hz), 1.05 (s, 3H), 1.03 (s, 3H), 0.86 (t, 3H, J = 7.5
Hz).
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H3C H3
0 CH 2N2  0
C02H E C02CH,
Ether 0 C
o 20 o 21
C 14H 240 5  C15H2605
M.W. 272.16 M.W. 286.18
Methyl Ester 21
Slightly impure acid 20 (48.3 g) was placed in a 1L roundbottom flask
equipped with a magnetic stir bar and dissolved in ethyl ether (500 mL). The
reaction vessel was cooled to 0 OC and diazomethane was added over a 45 min
period with constant evolution of nitrogen and disappearance of slight yellow
color. When gas evolution ceased and a slight yellow tint remained addition was
ceased and an AcOH solution was added until the yellow color disappeared.
The ether layer was dried by filtration through MgSO 4, and concentrated to
afford slightly impure methyl ester 21 (47.6 g) as an oil. Rf0.62 (25%
ether/hexanes); 1H NMR (250 MHz, CDCl3) 8 3.80-4.05 (m, 4H), 3.66 (s, 3H), 2.62
(aq, 1H, J = 4.7, 5.7, 5.7, 6.1 Hz), 2.48 (dd, 1H, J = 4.7, 16.5 Hz), 2.28 (dd, 1H, J =
6.1, 16.5 Hz), 1.58 (dq, 2H, J = 7.5 Hz), 1.50 (d, 2H, J= 5.6 Hz), 1.01 (s, 6H), 0.85
(3H, J = 7.5 Hz).
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Sodium Methoxi
THF/DMSO
0 0Cto 1O0C 0
0 21
S15H260 5  C14H2204
M.W. 286.18 M.W. 254.15
Diketone 22
A 1L roundbottom flask was pumped under vacuum and filled with
argon. To this flask was added anhydrous tetrahydrofuran (250 mL) and
rmethanol (6.91g, 216 mmol, 8.73 mL). The solution was cooled to 0 oC and NaH
(7.78 g, 324 mmol) in THF (100 mL) was added via cannula over a 1 h period.
The resulting solution was stirred for 1 h at 0 oC at which time methyl ester 21 (
47.6 g, 166 mmol) in THF/DMSO (100 mL/25 mL) was added via cannula. The
reaction was monitored by tlc until all of the starting material was consumed.
Saturated NaHCO 3 was added and the solution was concentrated in vacuo to
remove the THF. The product was isolated by extraction with ether, dried by
filtration through MgSO 4, and concentrated to afford a beige solid. This solid
was recrystallized from ether/THF to afford 29.8 g of diketone 22 as white
crystals (60% from ketal 19). Rf 0.39 (1:1 ether:methylene chloride); FTIR (thin
film, cm -1 ) 2971, 2878, 1600, 1570, 1510, 1475, 1385, 1315, 1290, 1232, 1198, 1170,
1069, 1023, 938, 920, 833; 1H NMR (CDCl3, 500 MHz) 8 5.38 (s, 1H) 3.90 (m, 4H),
3.49 (dd, 1H, J = 1.0, 17.4 Hz) 3.39 (dd, 1H, J = 1.0, 17.4 Hz), 2.98 (ddd, 1H, J = 1.0,
4.6, 17.2 Hz), 2.79 (dd, 1H, J = 4.9, 18.2 Hz), 2.53 (ddd, 1H, J = 1.0, 10.3, 17.2 Hz),
2.32 (dd, 1H, J = 10.5, 18.2 Hz), 2.04 (ddd, 1H, J = 2.0, 4.6, 9.5, 10.3 Hz), 1.89 (dd,
1H, J = 2.0, 14.5 Hz), 1.85 (dd, 1H, J = 1.2, 14.8 Hz), 1.62 (m, 4H (2H + 2H)), 1.50
179
(dd, 1H, J = 9.8, 14.8 Hz), 1.39 (dd, 1H, J = 9.5, 14.5 Hz), 1.24 (s, 3H), 1.15 (s, 3H),
1.11 (s, 3H), 1.00 (s, 3H), 0.89 (t, J = 7.3 Hz) 13C NMR (CDC13, 75 MHz) 208.4,
204.6, 201.5, 184.0, 112.0, 111.5, 102.9, 65.0, 64.6, 55.4, 47.9, 43.5, 42.6, 38.2, 36.1,
35.9, 35.8, 34.9, 30.0, 23.5, 23.0, 19.5, 19.3, 12.5, 8.1; HRMS (EI) Calculated for
C14H220 4 (M+): 254.1518. Found: 254.1517.
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23a
0
1. NaH, THF
0 OC, 1.5 h
2PhN(Tf)0Z 78 OC to 0 OC
2h
Quantitative yield
74%
23b
OTf
C14H2204 O C15H210 6F 3S
M.W. 254.15 o, M.W. 386.12
Enol Triflate 23a and 23b
Diketone 22 (2.00 g, 7.9 mmol) was placed in a 250 ml roundbottom flask
and pumped under vacuum. Anhydrous tetrahydrofuran (100 mL) was added
under argon and the solution was cooled to 0 OC. NaH (0.227 g, 9.4 mmol) was
added in one portion under a stream of argon and the reaction mixture was
allowed to stir for 1.5 h. The resulting cloudy solution was cooled to -78 oC and
N -Phenyltrifluoromethane-sulfonimide (3.34 g, 9.4 mmol) was added in one
portion under a stream of argon. The reaction vessel was allowed to warm
slowly over a 2 h period to 0 oC and the clear colorless solution was quenched
with saturated NaHCO3. The solution was concentrated in vacuo to remove the
THF and the product was isolated by extraction with ether, dried by filtration
through MgSO 4,and concentrated. The reaction affords nearly a quantitative
yield of the two possible regioisomers 23a and 23b which were purified by flash
chromatography (SiO2 20% ether/hexanes) to afford 2.21 g (74%) of the desired
isomer 23b as a slightly yellow oil. Rf0.50 (1:1 ether/hexanes); FTIR (thin film,
cm-1) 2974, 2937, 2883, 2359, 1685, 1659, 1426, 1354, 1334, 1292, 1246, 1215, 1137,
1056, 946, 915, 881, 825, 766; 1H NMR (500 MHz, CDCl 3) 5 5.95 (d, 1H, J = 1.5
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H-z), 3.90 (m, 4H, ketal), 3.00 (dd, 1H, J = 5.3, 19.3 Hz), 2.62 (ddd, 1H, J = 1.5, 8.7,
19.3 Hz), 2.10 (dddd, 1H, J = 2.0, 5.1, 8.7, 9.8 Hz), 1.88 (dd, 1H, J = 2.0, 14.7 Hz),
1.62 (m, 1H), 1.55 (dd, 1H, J = 9.8, 14.7 Hz), 1.16 (s, 1H), 0.99 (s, 1H), 0.90 (t, 3H, J
= 7.3 Hz); 13C NMR (75 MHz, CDCl3) 202.2, 165.1, 120.4, 117.0, 111.6, 65.0, 64.5,
44.8, 38.2, 35.3, 33.0, 30.0, 22.4, 19.1, 8.3; HRMS (EI) Calculated for C15H21F30 6S
(M+): 388.11657 and C15H2 1F30 6S - [CH 2CH 3] (M+) 357.06197. Found: [M-
CH 2CH 3] 357.0619.
Undesired isomer 23a, Rf 0.35 (1:1 ether/hexanes); FTIR (thin film, cm-1)
2879, 2885, 1691, 1634, 14656, 1420, 1371, 1328, 1306, 1247, 1217, 1139, 1070, 1048,
1017, 948, 907, 847, 800, 764, 724, 686, 606; 1H NMR (500 MHz, CDC13) 8 6.01 (s,
1H ), 3.95 (m, 4H, ketal), 2.88 (dd, 1H, J = 3.7, 16.9 Hz), 2.30 (dd, 1H, J = 12.9, 16.9
Hz), 2.15 (dddd, 1H, J = small, 3.5, 9.5, 12.8 Hz), 1.85 (dd, 1H, J = small, 14.1 Hz),
1.65 (m, 2H), 1.50 (dd, 1H, J = 9.5, 14.5 Hz), 1.26 (s, 3H), 1.16 (s, 3H), 0.89 (t, 3H, J
= 7.5 Hz); 13C NMR (75 MHz, CDCl3), 197.1, 173.0, 120.4, 116.2, 111.5, 65.1, 64.7,
40.6, 39.9, 38.3, 36.0, 30.3, 23.3, 18.8, 8.2; HRMS (EI) Calculated for C15H21F30 6S
(M+): 388.11657 and C15H21F30 6S - [CH 2CH 3] (M+): 357.06197. Found: [M-
CH 2CH 3] 357.0621.
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1. Bu 3SnH, LDA
THF, 0 UC, 30 min
2. CuCN, 50 'C
30 min
3.Enol triflate added
OTf to Cuprate
-78 OC to -20 oC
35 min
83%
SnBu 3
C15H 210 6F3S C26H480 3Sn
M.W. 386.12 M.W. 530.28
Vinylstannane 32
Tributyltin hydride (2.31 g, 7.91 mmol, 2.14 mL) was added under argon
to a 250 ml roundbottom flask containing anhydrous tetrahydrofuran and
equipped with magnetic stirbar. The reaction vessel is cooled to 0 oC and LDA
(1M, 8.00 mmol, 8 mL) was added over a 10 min period. The clear colorless
solution became clear yellow and was aged for 30 min at 0 oC. The mixture was
cooled to -50 oC and CuCN (0.636 g, 7.11 mmol) was added in one portion under
a stream of argon. The resulting yellow slurry is aged for 30 min at -50 OC. The
reaction mixture became an orange slurry and then a burnt orange colorless
solution. The reaction vessel is cooled to -78 oC and a solution of enol triflate 23b
(0.970 g, 2.51 mmol) in anhydrous tetrahydrofuran (10 mL) was added to it via
cannula. The reaction vessel was warmed to -20 oC over a 30 min period and
allowed to stir at -20 OC for 5 min before quenching with 50 mL of saturated
NaHCO 3. The resulting dark brown solution was concentrated in vacuo, to
remove the THF. The product was isolated by extraction with ether, dried by
filtration through MgSO 4, and concentrated to afford to afford a clear yellow oil.
This oil was purified by flash chromatography (SiO 2, 15% ether/hexanes) to
afford 1.09 g of vinylstannane 32 (83%) as a clear, colorless oil. Rf 0.66 (1:1
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1. Bu3SnH, LDA
ether:hexanes); FTIR (thin film, cm-1) 2928, 1666, 1582, 1463, 1420, 1379, 1338,
1291, 1265, 1201, 1150, 1071, 948, 876, 823, 772, 691; 1H NMR (500 MHz, CDCl 3) 8
6.13 (dd, 1H, J -= 1.5, 2.4 Hz), 3.90 (m, 4H), 2.88 (ddd, 1H, J = 1.5, 4.5, 19.4 Hz), 2.36
(ddd, 1H, J = 2.4, 9.0, 19.4 Hz), 1.95 (dddd, 1H, J = 2.0, 4.5, 9.0, app. 10 Hz), 1.80
(dd, 1H, J = 2.0, 14.4 Hz), 1.54-1.68 (m, 3H), 1.40-1.54 (m, 6H), 1.24-1.36 (m, 6H),
1.1.4 (s, 3H), 0.86-1.00 (m, 20H) 13C NMR (CDCl3, 75 MHz) 202.0, 171.5, 137.0,
112.2, 65.0, 64.6, 45.1, 40.0, 37.6, 36.0, 30.1, 29.2, 29.1, 27.3, 26.9, 22.6, 19.1, 13.6, 9.3,
8.1; HRMS (EI) Calculated for C26H 480 3Sn (M+): 530.2780 and C26H 480 3Sn-
[CH 2CH 3](M+): 499.22342. Found: [M-CH 2CH 3] 499.2230.
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1. CW"
12% Pd(OAc)2Br 31 24% PPh3
THF, 69 TC (Bath Temp)
SnBu3  18 h
87%
C26H480 3Sn C22H3403
M.W. 530.28 M.W. 346.25
Photosubstrate 33
Vinylstannane 32 (2.90 g, 5.49 mmol) was placed in a 500 mL roundbottom
flask and pumped under vacuum. Anhydrous tetrahydrofuran (200 mL) was
added along with allylic bromide 31 (1.65 g, 8.2 mmol) in THF (100 mL) via
cannula. Pd(OAc)2 (0.100 g, 0.44 mmol) and PPh3 (0.230 g, 0.88 mmol) were
added to the flask under a stream of argon and the resulting slightly yellow
solution was heated to 69 OC (bath temperature) for 15 h. The reaction proceeded
only slightly so additional Pd(OAc)2 (0.062 g, 0.28 mmol) and PPh3 (0.144 g, 0.55
mmol) were added and heating was continued for 3 h. The solution was
concentrated in vacuo to remove the THF and the compound was purified by
flash chromatography (SiO 2, 15% ether/hexanes) to afford 1.71 g (87%) of a
slightly yellow, clear oil. Rf 0.34 (uv) (1:1 ether/hexanes), FTIR (thin film cm-1)
3073, 2968, 2932, 2881, 2726, 2361, 1792, 1666, 1454, 1380, 1335, 1266, 1203, 1164,
1129, 1068, 947, 891, 819, 780, 699, 671, 610; 1H NMR (500 MHz, CDCl3) 8 5.89 (s,
1H), 4.91 (s, 1H), 4.82 (s, 1H), 4.70 (s, 1H), 4.65 (s, 1H), 3.95 (m, 4h), 2.88 (s, 2H),
2.60 (dd, 1H, J = 4.4, 19.1 Hz), 2.18 (dd, 1H), 2.1, (m, 4H), 1.90 (dddd, 1H, J = 1.7,
4.4, 9.8, app. 10.0 Hz), 1.83 (dd, 1H, J = 1.7, 14.5 Hz), 1.70 (s, 3H), 1.60 (m, 2H),
1.45 (dd, 1H, J = 9.8, 14.5 Hz), 1.14 (s, 3H), 0.94 (s, 3H), 0.89 (t, 3H, J = 7.4 Hz); 13C
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NMR (75 MHz, CDC13) 204.5, 160.7, 145.0, 145.0, 125.4, 112.8, 112.1, 110.2, 65.0,
64.5, 44.9, 44.4, 39.2, 36.0, 33.8, 33.7, 30.1, 22.5, 22.4, 19.1, 8.1; HRMS (EI)
Calculated for C22H340 3 (M+) : 346.25080. Found: 346.2509.
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Photoproducts 34a and 34b
Photosubstrate 33 (0.042 g, 1.17 mmol) was dissolved in lmL of ether and
added to the photochemical apparatus equipped with a 450 Watt medium
pressure Canrad-Hanovia immersion lamp, triple-walled pyrex immersion well,
and a solution filter (38 g CuSO4, 0.4 g FeSO 4, 5 mL HC1/ 1L H20 (10 %
transmittance below 330 nm)). The apparatus was pumped under vacuum for 45
minutes and hexanes (300 mL) was added under argon and degassed. The
reaction vessel was cooled to -78 OC subject to photolyzation for 5 h stopping at
stopping at 30min, 1.5 h, 3.0 h., and 5 h. to monitor by TLC. The solution was
concentrated in vacuo and the photoproducts 34a and 34b ( 2:1 mixture of
isomers by NMR) were purified by flash chromatography (SiO 2 15%
ether/hexanes) to afford 29 mg (69%) of a clear colorless oil. The oil was then
rechromatographed in the same solvent system and a sample of the major isomer
was isolated for analysis. Rf0.24 (25% ether/hexanes),; FTIR (thin film, cm- 1)
3069, 2936, 2880, 1698 1649, 1462, 1380, 1360, 1294, 1261, 1202, 1134, 1071, 948, 928,
879, 822, 783, 700; 1H NMR (500 MHz, C6D6) 8 4.8 (s, 1H), 4.85 (s, 1H), 3.5-3.6
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(m, 4H), 2.52 (dd, 1H, J = 5.4, 9.7 Hz), 2.38 (d, 1H, J = 13.7 Hz), 2.26 (d, 1H, J =
13.7 Hz), 2.18 (ddd, 1H, J = 5.9, 5.9, geminal Hz), 2.17 (dd, 1H, 4.9, 11.7 Hz), 2.03
(dd, 1H, J = 10.0, 11.7 Hz), 2.02 (ddd, 1H), 1.89 (dddd, 1H, J = small, small, 10.0,
10.0 Hz), 1.38 (dd, 1H, J = 9.8, 14.7 Hz), 1.32 (ddd, 1H, J = 5.9, 8.3, 12.3 Hz), 1.24
(ddd, 1H, J = 7.3, 7.3, 12.3 Hz), 1.08 (s, 3H), 1.07 (s, 3H), 0.94 (t, 3H, J = 7.3), 0.83
(s, 3H); 13C NMR (75 MHz, C6D6) 218.2, 146.5, 112.8, 110.4, 65.4, 65.0, 48.5, 45.9,
44.5, 43.1, 38.9, 37.9, 37.1, 35.1, 34.5, 32.6, 31.0, 29.1, 25.8, 24.4, 19.7, 8.9; HRMS (EI)
Calculated for C22H340 3 (M+) : 346.25080. Found: 346.2509.
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1 hv
Hexanes -78 OC
Vycor / Solution Filter
2 0
3
CH 3OH/CH 2Cl2
-78 oC
(CH 3)2S
33 58% 2 Steps
C22H340 3  C21H3204
XM W34 6AA25 M.W. 348.23
35b
lvyL. V, .
Tricyclic Ketones 35a and 35b
Photosubstrate 33 (0.229 g, 0.661 mmol) was added to the photolysis
apparatus in a small volume of ether and pumped under vacuum for 45 min.
Hexanes (300 mL) was added under argon, the solvent was degassed, and the
vessel was cooled to -78 oC. The compound was photolyzed for 4 h using a 450
Watt Hanovia lamp through vycor and the previously described solution filter*.
The reaction vessel was warmed to 23 OC and the hexanes was removed in vacuo.
The crude product (0.229 g, 0.661 mmol [6-7:1 ratio of isomers by NMR]) was
dissolved in 40 mL of CH 2C12 /CH 3OH (1:1) and the clear, colorless solution was
stirred at -78 OC for 5 min while bubbling 02 through it.. Ozone was then
generated and bubbled into the solution until the solution was slightly blue. The
excess ozone was removed by bubbling 02 through the solution until it became
clear, colorless. Methylsulfide ( 2 mL) and triethylamine ( 2 mL) were added and
the reaction vessel was allowed to warm to 23 OC and stirred for 12 h before the
addition o saturated NaHCO3 was added. The solution was concentrated in
vacuo to remove the organic solvent. The product was isolated by extraction
with ether, dried by filtration through MgSO 4, and concentrated. The two
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35a
isomers, 35a and 35b, were purified by flash chromatography ( SiO 2, gradient 1:1
to 1.25:1 ether:hexanes). This two step reaction sequence afforded 0.134 g of
major isomer 35a as a yellow, white solid (58% from photosubstrate 33).
Major isomer 35a Rf 0.34 (2:1 ether/hexanes); FTIR (thin film cm- 1) 2966, 2881,
1703(2 overlapping peaks), 1463, 1413, 1381, 1361, 1298, 1256, 1202, 1140, 1111,
1070, 950, 928, 821, 783, 732, 648, 508; 1H NMR ( 500 MHz, C6D6) 8 3.78 (ddd, 1H,
J = 4.6, 7.0, 7.0 Hz), 3.67 (ddd, 1H, J = 6.7, 6.7, 6.7 Hz), 3.53 (ddd, 1H, J = 4.9, 7.0,
7.0 Hz), 3.49 (ddd, 1H, J = 6.8, 6.8, 6.8 Hz), 2.43 (d, 1H, J = 14.7 Hz), 2.32 (d, 1H, J
= 14.7 Hz), 2.28 (dd, 1H, J = 4.4, 9.8 Hz), 2.22 (dd, 1H, J = 4.4, 12.7 Hz), 2.06 (
ddd, 1H, J = 4.9, 6.8, 18.6 Hz), 1.87 (dd, 1H, J = 9.8, 12.2 Hz), d 1.86 (dddd, 1H),
1.77 (ddd, 1H, J = 5.4, 9.3,18.6 Hz), 1.60 (dd, 1H, J = 1.2,14.4 Hz), 1.34 (dd, 1H, J =
10.0, 14.4 Hz), 1.23 (ddd, 1H, J = 4.9, 9.3, 13.7 Hz), 1.16 (ddd, 1H, J = 6.2, 6.2, 13.7
Hz), 1.02 (s, 3H), 0.96 (s, 3H), 0.89 (t, 3H, J = 7.3 Hz), 0.73 (s, 3H); 13C NMR (75
MHz, C6D 6 ) 218.2, 210.8, 112.5, 65.4, 64.8, 49.3, 48.5, 45.5, 44.0, 38.4, 37.5, 36.7,
36.2, 34.4, 34.3, 32.8, 31.1, 25.8, 24.1, 19.2, 9.1; HRMS (EI) Calculated for C21H320 4
(M+) : 348.23006. Found: 348.2299.
Minor isomer 35b Rf 0.29 (2:1 ether/hexanes); 1H NMR (500 MHz, CDCl3)
5 3.9-4.0 (m, 4H), 2.58 (dd, 1H, J = 7.0, 11.3 Hz), 2.48 (d, 1H, J = 15.5 Hz), 2.47
(ddd, 1H, J = 5.8, 11.5, 19.0 Hz), 2.42 (ddd, 1H, J = 4.0, 5.8, 19.0 Hz), 2.38 (d, 1H, J
= 15.5 Hz), 2.29 (dd, 1H, J = 11.3, 12.8 Hz), 2.24 (dd, 1H, J = 4.0, 15.0 Hz), 2.1
(dddd, 1H, J = 1.5, 4.5, 8.8, 13.0 Hz), 1.95 (dd, 1H, J = 7.0, 12.5 Hz), 1.88 (dd, 1H, J
= 1.5, 14.8 Hz), 1.82 (ddd, 1H, J = 5.8, 11.5, 14.0 Hz), 1.79 (ddd, 1H, J = 4.0, 5.8,
14.0 Hz), 1.59-1.70 (m, 2H), 1.56 (s, 3H), 1.38 (dd, 1H, J = 8.8, 14.8 Hz), 1.19 (s,
3H), 1.14 (s, 3H), 1.13 (dd, 1H, J = 13.0 14.8 Hz), 1.4 (t, 1H, J = 7.5 Hz), 0.9 (s, 3H).
190
KOt-Bu
THF
25 oC to 65 oC
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35a
C21H3204 C21H3204
M.W. 348.23 M.W. 348.23
Enone 36a
Tricyclic ketone 35a (0.063 g, 0.181 mmol) was dissolved in THF (3 ml) and
to this clear colorless solution was added solid potassium tert-butoxide (0.20 g,
0.181 mmol). The solution instantly became burnt orange and was stirred at 23 OC
for 3 h. An additional amount of potassium tert - butoxide (0.10 g, 0.091 mmol)
was added, and the solution was heated to 60 OC for 3 h before being quenched
with saturated NaHCO3. The solution was concentrated in vacuo to remove the
THF and the product was obtained by extraction with ether, dried by filtration
through MgSO 4, and concentrated. Enone 36a was purified by flash
chromatography (SiO 2, 1:1 ether/hexanes) to afford 41 mg of product as a white
solid (66% yield). Rf 0.15 (2:1 ether/hexanes); FTIR (thin film, cm- 1) 2968, 2246,
1689, 1661, 1607, 1463, 1392, 1367, 1331, 1283, 1255, 1203, 1145, 1129, 1101, 1066,
994, 949, 921, 899, 873, 849, 819, 772, 732, 647, 557, 519; 1H NMR (500 MHz,
CDCl 3) 8 5.88 (d, 1H, J = 2Hz), 4.0 (M, 4H), 2.94 (ddd, 1H, J = 3.9, 6.8, 13.7 Hz),
2.70 (ddd, 1H, J = 1.8,1.8,13.9), 2.48 (ddd, 1H, J = 5.4, 7.3, 17.3 Hz), 2.40 (ddd, 1H,
J = 5.1, 9.3, 17.3), 2.29 (ddd, 1H, J = 4.4, 11.2, 13.7 Hz), 2.21 (dd, 1H, J = 11.2, 13.7
Hz), 2.18 (ddd, 1H, J = 5.4,9.3, 13.2 Hz), 2.10 (ddd, 1H, J = 3.9, 11.0, 14.4 Hz), 1.98
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(ddd, 1H, J = 4.5, 7.0, 14.5 Hz), 1.83 (tdd, 1H, J = 1.0, 10.5, 10.5 Hz), 1.75 (d, 1H, J =
14.2 Hz), (dq, 1H), 1.56-1.72 9m, 3H), 1.41 (dd, 1H, J = 9.3, 14.6 Hz), 1.23 (s, 3H),
1.16 (s, 3H), 1.05 (s, 3H), 0.91 (t, 3H, 7.3 Hz); 13C NMR (CDC13, 500 MHz) 217.2,
198.4, 170.7, 129.2, 112.2, 64.9, 64.6, 49.8, 46.9, 38.4, 36.5, 36.3, 34.5, 34.2, 33.6, 30.2,
26.3, 25.5, 17.9, 12.5, 8.1; HRMS (EI) Calculated for C2 1 H 3 2 0 4 (M+) : 348.23006.
Found: 348.2299.
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KOt-Bu
THF
25 oC to 65 oC 0
C21H3204 C21H3204
M.W. 348.23 M.W. 348.23
Enone 35b
Tricyclic ketone 34b (0.0124 g, 0.036 mmol) (slight mixture with 34a) was
dissolved in THF (1 ml) and to this clear colorless solution was added potassium
tert-butoxide (0.005 g, 0.045 mmol). The reaction was allowed to stir at 23 OC for
3 h. An additional amount of tert-butoxide (0.003 g, 0.027 mmol) was added and
stirring was continued for 2 h at 65 OC before quenching with saturated NaHCO3.
The THF was removed by rotary evaporation and the product was obtained by
extraction with ether and concentrated. The product was purified by prep plate
chromatography (SiO 2, 100% ether) to afford 1.5 mg of pure enone 36b. Rf0.10
(2:1 ether/hexanes); 1H NMR (CDC13, 500 MHz..
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X) D
2,4,6 triisopropylbenz
sulfonyl hydrazine
0 THF
23 oC 25 h
64%
NNHTris
C21H 320 4  C36H56N20 5S
M.W. 348.23 M.W. 628.92
Trisylhydrazone 37
Enone 36a (0.069 g, 0.198 mmol) was dissolved in anhydrous
tetrahydrofuran (10 mL) and to this solution was added 2,4,6-
triisopropylbenzenesulfonylhydrazine (0.500 g, 0.168 mmol). The reaction was
allowed to stir at 23 OC for 13.5 h before an additional amount of hydrazine (0.035
g, 0.118 mmol; total 0.085 g, 0.288 mmol, 1.5 eq.) was added and stirring was
continued for 11.5 h. The solution was concentrated in vacuo to remove the THF
and the crude mixture was purified by flash chromatography (SiO 2, 1:1
ether/hexanes) to afford 80 mgs (64%) of hydrazone 37 as a mixture of isomers.
Rf 0.19 and 0.14 (1:1 ether/hexanes); 1H NMR (250 MHz, CDCl3) 8 7.14 (s, 2H),
5.90 (s, 1H), 4.23 (m, 2H), 3.90 (m, 4H), 2.90 (m, 1H), 2.80 (m, 1H), 2.55 (d, 1H),
1.9-2.3 (6H), 1.4-1.9 (7H), 0.9-1.4 (24H), 1.1 (s, 3H), 0.95 (s, 3H). 0.85 (t, 3H).
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CH3
Catecholborane
NNHTris CH 2Cl 2
-50 oC
C36H 56N20 5S  C21H3403
M.W. 628.92 M.W. 334.50
Olefin 39
Hydrazone 37 (0.035 g, 0.056 mmol) was added to a round bottom flask
and pumped under vacuum. Methylene chloride (3 ml) was added under argon
and the solution was cooled to -50 oC. Catecholborane (0.0087 g, 0.073 mmol, 8
pgL) was added via syringe and the reaction was allowed to stir at -50 OC for lh
before being warmed to 0 oC for 10 minutes. Tetrabutylammonium acetate
(0.036g, 0.119 mmol) was added at 0 OC and the reaction was allowed to stir for 3
h before being quenched with saturated NaHCO 3. The solution was
concentrated in vacuo and the crude product was isolated by extraction with
ether, dried by filtration through MgSO 4, and concentrated. Olefin 39 was
purified by flash chromatography (SiO 2, 20 % ether/hexanes) to afford 12 mg of
possible product as an oil. Rf 0.64 (2:1 ether:hexanes) 1H NMR (500 MHz, CDC13)
8 5.52 (m, 1H, olefinic H), 5.35 (m, 1H, olefinic H).
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